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V Summary 
Osteoarthritis (OA) is a degenerative joint disease characterised among others by 
the progressive loss of articular cartilage. Lubricin, hyaluronic acid (HA) and surface-
active phospholipids contribute to the boundary lubrication provided by synovial fluid 
(SF). During OA, alterations in the concentrations of lubricin and HA impair the boundary 
lubricating ability of SF and may lead to increased friction and ultimately greater cartilage 
damage. In this line, the main hypothesis of the current study was that OA SF contains 
altered amounts of individual PL species, which might contribute to cartilage destruction 
during OA, and that these alterations are dependent on the stage of the disease.  
Before starting the experiments, approval by the University ethics commission and 
the written informed consent of the patients were obtained. Qualitative and quantitative 
analyses of all phospholipids (PL) species were performed using electrospray ionization 
mass spectrometry (ESI-MS/MS) for human SF from healthy, rheumatoid arthritic (RA) 
and OA knee joints at different stages of the disease. Moreover, healthy and OA canine SF 
were also analysed in order to evaluate whether a canine model of OA reflects composition 
of PL species as found in human. In addition, the protein and mRNA expression pattern of 
surfactant proteins (SP-A, -D) was obtained in joint cells and SF. 
The results of our lipidomic study provide for the first time a detailed overview of 
all PL species being present in human SF. Our analyses of SF indicate differences between 
healthy, OA and RA SF. Interestingly, SF from late stage of OA exhibited significantly 
higher concentrations of most of PL species when compared with healthy SF. More 
importantly, we provide first evidence that significant differences in PL composition exist 
between early and late stage of OA indicating, that PL composition of SF can serve as 
biomarker to distinguish between stages of OA. Moreover, the results obtained from 
human were confirmed by analysis of SF from canine model of OA. Our results also 
indicate a possible pathologic function of PL in the development of OA as based on their 
role in the boundary lubrication of joints as well as their biological activities. In addition, 
we provide several experimental proofs that human SF does not contain SP-A and –D. 
In conclusion, our results support the hypothesis that alterations in composition and 
concentrations of PL species may also contribute to cartilage destruction during OA. 
Moreover, the specific PL pattern reflects stages of the disease. Hence, analysis of the SF 
lipidome can serve as a novel useful tool for diagnosis and prognosis of OA. Our data also 
indicate that surfactant proteins do not play any role in the boundary lubrication of joints.  
Zusammenfassung 
XII 
 
VI Zusammenfassung 
Arthrose, auch Osteoarthritis genannt, ist eine degenerative Gelenkerkrankung, die 
unter anderem durch einen fortschreitenden Verlust des Gelenkknorpels gekennzeichnet 
ist. Lubricin, Hyaluronsäure (HS) und oberflächenaktive Phospholipide (PL) der 
Synovialflüssigkeit (SF) sind an deren Fähigkeit zur Grenzflächenschmierung beteiligt 
Während der Arthrose kommt es zu Veränderungen in den Konzentrationen an Lubricin 
und HS, wodurch die Grenzflächenschmierung der SF beeinträchtigt wird, was zu einer 
erhöhten Reibung und letztlich zu größeren Knorpelschäden führen kann. Im Rahmen der 
vorliegenden Studie sollte daher die Hypothese geprüft werden, dass arthrotische SF 
veränderte Mengen an einzelnen PL-Spezies enthält, die möglicherweise zur 
Knorpelzerstörung während der Arthrose beitragen können und dass diese Veränderungen 
abhängig vom Stadium der Erkrankung sind. 
Vor Beginn der Experimente wurde die Genehmigung durch die Ethikkommission 
der Universität und eine schriftliche Einwilligung der Patienten eingeholt. Qualitative und 
quantitative Analysen der PL-Spezies wurden mit Hilfe der Elektrospray-Ionisations-
Massenspektrometrie (ESI-MS/MS) in humanen SF von gesunden, rheumatoid 
arthritischen und arthrotischen Kniegelenken verschiedener Krankheitsstadien 
durchgeführt. Darüber hinaus wurden gesunde und arthrotische SF von einem 
Hundemodell der Arthrose analysiert um zu beurteilen, ob die SF eine ähnliche 
Zusammensetzung der PL-Spezies aufweist wie humane SF. Zusätzlich wurde das Protein- 
und mRNA-Expressionsmuster der Oberflächenproteine (SP-A und -D) in verschiedenen 
Zellen des Kniegelenks und der SF bestimmt. 
Das Ergebnis unserer Lipidomik-Studie zeigt zum ersten Mal eine detaillierte 
Übersicht über alle PL-Spezies, die in humaner SF vorhanden sind. Unsere Analyse ergab, 
dass es Unterschiede zwischen gesunder, arthrotischer und rheumatoid arthritischer SF 
gibt. Interessanterweise zeigt SF aus dem späten Stadium der Arthrose eine signifikant 
höhere Konzentration der meisten PL-Spezies im Vergleich zur SF gesunder Spender. 
Noch wichtiger ist, dass der erste Nachweis erbracht werden konnte, dass signifikante 
Unterschiede in der PL-Zusammensetzung zwischen frühen und späten Stadien der 
Arthrose bestehen und dass die PL-Zusammensetzung der SF möglicherweise als 
Biomarker genutzt werden kann, um zwischen den einzelnen Stadien der Arthrose 
unterscheiden zu können. Darüber hinaus wurden die Ergebnisse aus der Untersuchung der 
humanen SF durch die Analyse der SF im Hundemodell der Arthrose bestätigt. Unsere 
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Daten deuten außerdem auf eine mögliche Beteiligung der PL in der Pathogenese der 
Arthrose hin, da PL eine Rolle bei der Grenzflächenschmierung der Gelenke spielen und 
sogar biologische Aktivitäten entfalten können. Darüber hinaus können wir mehrere 
experimentelle Beweise erbringen, dass humane SF kein SP-A und -D enthält. 
Abschließend läβt sich sagen, dass unsere Ergebnisse die Hypothese stützen, dass 
Veränderungen in der Zusammensetzung und Konzentration der PL-Spezies zum 
Knorpelabbau während einer Arthrose beitragen können. Zudem reflektiert das spezifische 
PL-Muster der einzelnen Krankheitsstadien das Fortschreiten der Arthrose. Daher kann 
vermutlich eine Bestimmung des Lipidoms, zumindest aber der PL-Zusammensetzung für 
die Diagnose und Prognose der Arthrose genutzt werden. Unsere Daten zeigen auch, dass 
die Oberflächenproteine wie SP-A und -D an der Grenzflächenschmierung der Gelenke 
nicht beteiligt sind. 
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1. Introduction 
1.1 Osteoarthritis (OA) 
Osteoarthritis (OA) is one of the most common forms of joint disorder 
characterised by the progressive loss of articular cartilage. The prevalence of OA is 
worldwide and approximately 5-10 millions of patients in Germany have radiological 
discernible OA alterations of at least one articular joint [1]. In Europe, every 1.5 min. one 
total joint replacement surgery due to OA is reported. In the United States, 500,000 joint 
replacements are performed per year [2-3]. Due to ageing of the population and the 
epidemic of obesity, the prevalence of OA is expected to increase. Current estimates are 
showing that in the United States nearly 27 million people have symptomatic OA and this 
number is expected to increase. Surveys from the World Health Organization assessed that 
symptomatic OA affects worldwide 10% of men and 18% of women aged over 60 years. 
Estimated annual costs of OA in the USA are around 60-89 billion dollars [2, 4].  
1.1.1 Symptoms and risk factors of OA 
The primary clinical symptoms of OA are pain, stiffness and dysfunction of joints. 
This is the main reason why patients are seeking medical help. As the disease progresses 
the pain becomes stronger, begins immediately after using the joint and may also occur 
during rest and night. The pain is often described as deep aching, poorly localised 
discomfort that accompanies for years and can increase with changes in the weather [5]. 
The cause of joint pain in OA is still not fully understood. In most of the patients with 
diagnosed OA movement of the knee joint is limited. Many of them have also crepitus with 
motion and joint effusion. In advanced stages OA can lead to joint deformations and 
subluxations. Twenty five percent of OA patients have limited abilities to perform their 
normal activities of daily living. Patients who suffer from OA have problems with walking, 
climbing stairs and they also complain of early morning stiffness of joints. This can lead to 
impaired performance in the workplace, social isolation and depression [6]. Interestingly, 
some people with radiographic evidence of advanced OA have minimal symptoms, 
whereas people with minimal radiographic changes may have acute pain and severe other 
symptoms [5, 7]. 
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The main risk factor for OA is ageing, nevertheless, other risk factors can be also 
specified like obesity, gender (more women than men suffer from OA), hormonal status of 
women (postmenopausal versus premenopausal), genetic predisposition, joint trauma, 
previous joint injury, abnormal joint shape, muscle weakness and joint laxity [8-14]. 
1.1.2 Diagnosis and therapy 
OA can affect small and large joints, either singly or in combinations. However, the 
most common joints involved are the large weight-bearing joints like the knee and the hip. 
OA is also often diagnosed in the hand, where mainly distal and proximal interphalangeal 
joints and the carpometacarpal joint of the thumb are affected [15]. 
Frequently, the diagnosis of OA is based on the patient’s history and physical 
findings. Therefore, OA is often diagnosed in more advanced stages of the disease. The 
most widely used radiological method for diagnosis of OA is based on the characteristic 
changes of joints visible on plain X-rays. The grading system used both for diagnosis as 
well as clinical studies was first described by Kellgren and Lawrence in 1957 [16]. The so 
called Kellgren/Lawrence (K/L) score (range 0-4) is based on estimating the narrowing of 
joint space and changes in subchondral bone like occurrence of osteophytes and bone 
sclerosis. However, it has been suggested that the described scoring method has some 
limitations especially due to limited sensitivity to discriminate between healthy 
individuals, patients with early phases and late phases of the disease [17]. 
Magnetic resonance imaging (MRI) is supposed to be a better tool to diagnose early 
OA, but still not perfect, since clear quantification of especially small cartilage lesions is 
not possible [18]. Diagnostic strategies other than plain radiography and MRI for instance, 
bone scans, CT scans or even arthroscopic examination of joint surfaces are sometimes 
also applied depending on the diagnostic and/or therapeutic purposes [19]. 
Currently no therapies are available to stop or slow down the progression of OA. 
Therefore, the final therapeutic approach for OA is total joint replacement surgery. The 
main goal of OA treatment is pain relief and improvement of joint function. 
Pharmacological therapies use non-steroidal anti-inflammatory drugs, opioids, 
glucosamine, chondroitin sulfate and intraarticular injection of glucocorticoids or 
hyaluronic acid (HA) [20]. Non-pharmacologic therapies are also applied, such as physical 
therapy, manual therapy, acupuncture, different kinds of orthopaedic devices, education 
and self-management, weight loss, transcutaneous electrostimulation, and thermal 
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modalities [21-23]. Although, the progression of OA often leads to surgery followed by 
rehabilitation, many therapeutical strategies can be helpful to delay the need for joint 
replacement surgery by reducing the pain and inflammation and thus, improve the quality 
of life. 
1.1.3 Pathophysiology of OA 
OA is not a single disease entity but rather a complex disease with different 
underlying pathophysiological mechanisms. It is unlikely that one single factor causes this 
disorder. Historically, OA was considered to be caused only by mechanical factors with 
articular cartilage being the afflicted tissue. Indeed, OA is mostly characterised by a 
progressive and irreparable loss of articular cartilage. However, the present knowledge 
shows that OA affects the whole joint like synovium, subchondral bone and cartilage 
leading to joint degeneration (Figure 1.1). 
In the past, OA was considered as a non-inflammatory disease. However, present 
knowledge indicates that OA is a unique inflammatory disease. OA cartilage does not have 
the characteristic signs of inflammation such as pain, redness, swelling and increased 
temperature since no nerves and blood vessels are present in cartilage. However, several 
studies revealed that many pro-inflammatory mediators are upregulated in OA affected 
chondrocytes similar as in a classic inflammatory cell like macrophages, as it was reviewed 
by Attur et al.  in 2002 [24].  
 
 
 
 
 
 
 
 
 
Figure 1.1. Pathologic alterations in OA. Picture obtained with permission from BMJ [25]. 
Introduction 
4 
 
1.1.3.1   Articular cartilage 
Normal healthy cartilage is an avascular, alymphatic and aneural tissue found at the 
end of articulating bones. It is responsible for providing a load-bearing, low friction 
interface for diarthrodial joints. Histologically, the cartilage tissue is classified into four 
zones: superficial or tangential, middle or transitional, deep or radial and calcified zone, 
where each of those zones is characterised by depth-varying cellular density and 
extracellular matrix properties [26]. The cell density of the superficial zone is high and 
chondrocytes are arranged parallel to the surface of cartilage. Chondrocytes are randomly 
dispersed in the middle zone and a lower cellular density can be observed. In the deep 
zone, chondrocytes have a columnar organisation [27]. It has been demonstrated that a 
tight interaction exists between those zones to regulate cell proliferation and secretion [28]. 
All zones are build by chondrocytes, which are sparsely distributed within the negatively 
charged cartilaginous extracellular matrix [29].  
Proteoglycans (PGs) and collagens, mainly type II, VI, IX and XI are the main solid 
constituents of extracellular matrix, building a stable network within the cartilage. The 
most abundant cartilage PG is aggrecan which can bind to link protein and HA to form 
macromolecules embedded in a collagen net. Each monomer of macromolecule consists of 
core protein to which chains of chondroitin sulfate and keratan sulfate are attached. This 
polysaccharide side chains contribute to the hydrophilic nature of extracellular matrix of 
cartilage [30-32]. 
 The most important process which occurs during initiation and progression of OA 
is an increased activity of proteolytic enzymes degrading the extracellular matrix. In vitro 
and in vivo studies have shown that aggrecanases are the primary enzymes responsible for 
aggrecan degradation of cartilage in the early stage of OA, even before aggrecan and 
collagen are cleaved by matrix metalloproteinases (MMPs). Collagen type II cleavage is 
primarily mediated by MMP-13 after aggrecan is enzymatically degraded by ADAMTS-4 
and -5 (a disintegrin and metalloproteinase with trombospondin motif) and MMPs [33]. 
Activity of MMPs is revealed by generated VDIPEN fragments whereas ADAMTS-4 and -
5 enzymatically produce NITEGE fragments. Both of those fragments can be found in RA 
and OA cartilage and synovial fluid (SF), thus, it is still not fully understood which of 
those enzymes play the major role in aggrecan degradation [34]. Several studies with use 
of ADAMTS-4 and -5 have implicated that they are the major factors responsible for 
cartilage degradation in OA [33, 35]. However, it has also been shown that expression of 
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ADAMTS-4 is induced and directly correlated with the level of cartilage destruction in 
OA, whereas expression of ADAMTS-5 is constitutive and comparable in both, normal 
and OA cartilage [36-37]. Moreover, a study using inhibitors for ADAMSTS-4 and -5 in 
human cartilage explants cultures show reduced production of prostaglandin E2, which is 
known to be involved in PG loss from cartilage [38]. It has been postulated that higher 
levels of PG degradation products such as keratan sulfate and chondroitin sulfate epitopes 
in SF can be an early sign of OA [39-41]. Breakdown products of cartilage catabolism 
have therefore been studied as potential biomarkers for OA [42].  
1.1.3.2   Synovium 
The synovial membrane of healthy joints is only one to three cell layers thick and is 
composed of two cell types loosely embedded in an extracellular matrix: less numbered 
bone marrow-derived macrophage-like (type A) synoviocytes and locally derived, more 
abundant fibroblast-like (type B) synoviocytes (FLS) [43]. Below the synovial membrane 
no basement membrane is present, but the intercellular space contains type IV collagen, 
laminin and nidogen, major components of basement membranes. Such an organisation is 
unique only for the articular joints. The function of the synovial membrane is to provide 
nutrients and oxygen diffused from the blood vessels to avascular cartilage and to remove 
metabolic waste products from cartilage to the lymphatic vessels.  
Several studies using electron microscopic methods provided evidence that FLS 
have lamellar bodies (LBs) [44-45]. This feature is unique and different from other classes 
of fibroblasts [43, 46]. It is known that synovial cells, mainly FLS actively produce HA 
[43, 47] and together with cells from the superficial zone of cartilage produce lubricin [48-
49]. It has been also hypothesised that these cells are also responsible for the production of 
surface active phospholipids (SAPL) [44-45, 50-51] however, no experimental proof has 
been provided until today. 
The following changes in synovium might occur in up to 50% of OA patients and 
can be arthroscopically determined sometimes even in early OA: synovial hyperthrophy, 
synovial hyperplasia, increased number of lining cells, infiltration of the sublining tissue 
with scattered foci of lymphocytes and vascular hyperplasia [52-53].  
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1.1.3.3   Subchondral bone  
The subchondral bone represents a nearly nonporous and poorly vascularised 
subchondral bone plate with an underlying porous trabecular bone containing 
hematopoietic bone marrow and fat [54]. Bone consists of organic components mainly type 
I and III collagens and of non-organic, mineral hydroxylapatite. Because of the presence of 
bone-forming cells namely osteoblasts and bone-resorbing cells named osteoclasts, the 
bone is able to remodel [55].  
In advanced stages of OA the progressive loss of articular cartilage is accompanied 
by the formation of bony structure at the joint margins namely osteophytes. In addition, 
sclerosis of subchondral bone occurs. It has been suggested that osteophytes are the result 
of penetration of blood vessels into cartilage or result from abnormal healing after stress 
fractures [56].  
Regarding the subchondral bone sclerosis, it has been suggested that probably 
excessive load cause microfractures of subchondral trabeculae that heal via callous 
formation and remodelling. Additionally, it is now known that some osteoblasts are 
phenotypically different in OA compared to normal cells. However, they can produce 
increased levels of cytokines and growth factors and play critical role in subchondral bone 
sclerosis [57-58]. 
1.1.3.4   Synovial fluid  
Synovial fluid (SF) is an ultrafiltrate of blood with additives produced by 
surrounding tissues. The volume of SF lies in the range of 0.5-4 ml for healthy knees and 
4.4-21 ml for OA joints [59]. The main functions of SF are lubrication of surfaces like 
articular cartilage, meniscus, tendon, ligaments as well as nutrition, load bearing and shock 
absorption in the joint.  
Normal SF contains molecules postulated to play a key role alone or in combinations in 
boundary lubrication like 
 proteoglycan 4 (PRG4, lubricin, SZP, megakaryocyte stimulating factor, 0.05-
0.35 mg/ml in healthy SF) [60-62]. 
 hyaluronic acid (HA, 1-4 mg/ml in healthy SF, 0.1-1.3 mg/ml in OA SF) [63-
65]. 
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 surface-active phospholipids (SAPL, 0.1- 0.2 mg/ml in healthy SF, 0.2-0.3 
mg/ml in OA SF) [51, 64]. 
Also, SF from rheumatoid arthritic joints contain elevated levels of cell-derived 
microparticles (MPs) mostly from monocytes, granulocytes and lymphocytes [66]. MPs 
represent the heterogeneous population of membrane-bound small vesicles released from 
the cell membranes during cell activation or early apoptosis. In contrast to other cell 
vesicles like exosomes and apoptotic bodies, MPs are bigger and their diameter ranges 
from 200-1000 nm. MPs can vary in size and biochemical composition depending on their 
parental cells. These MPs are thought to have a function in the development of many 
human diseases including rheumatoid arthritis, where they trigger fibroblast-like 
synoviocytes (FLS) to produce cytokines, chemokines and other pro-inflammatory 
mediators [67-69]. Similar, but to a lesser degree, MPs are expected to be present in OA 
and normal SF. 
1.1.4 Animal models of OA 
Because OA is often not diagnosed until alterations in the joints are already 
progressed leading to strong pain and changes in articular cartilage, synovial tissue and SF 
from early stages of OA are not easily available for researchers. Moreover, therapies able 
to stop the progression of OA are thought to be successful only when applied in early 
stages of the disease. For this purpose, over 30 animal models of OA have been developed 
to gain insight into the pathogenesis and to study treatment modalities. However, none of 
these models reproduce the full spectrum of all changes observed in human OA. 
 Two often used models of OA are the anterior cruciate ligament transection 
(ACLT) model, and recently, the canine “groove model of OA”. The transection of the 
anterior ligament leads to a permanent instability within the knee joint of various species 
such as dogs, sheep, guinea pigs and rats. This instability can induce degenerative changes 
in articular cartilage and inflammatory alterations within synovial tissue, representing OA 
[70-71].  
Another animal model of OA is the ‘groove model’ where the articular cartilage of 
femoral condyles is damaged with a Kirchner wire in that several grooves are cut into the 
cartilage. This initiates the development of OA without affecting the subchondral bone and 
is further enhanced by intensified loading of the affected joint [72-75]. Since in the present 
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study the SF from the ‘groove model’ was used, this OA model is described in further 
details in the section 3.1.4.2. 
1.2 Rheumatoid arthritis (RA)  
Rheumatoid arthritis (RA) is another joint disorder affecting a large number of 
patients worldwide. About 1% of the world's population is afflicted by RA, women three 
times more often than men. The onset often starts at the age of 35 to 45 years, but people 
of any age can also be affected [76].  
RA attacks many tissues and organs including synovial joints. Without any 
treatment this disease can slowly destroy whole joints. RA is an aggressive inflammatory 
disease with the synovium being strongly inflamed, hyperplasia of synovial cells, swollen 
joint capsule, and invasion of FLS [77-78]. SF obtained from RA patients is characterised 
by increased number of neutrophiles, granulocytes and macrophages and has a reduced 
viscosity.  
In our study RA has been classified according to the criteria of the American 
College of Rheumatology [79] and SF obtained was used as another control for OA being 
focused on.   
1.3 The boundary lubrication system of articular joints 
Several components of SF have been proposed to contribute to boundary 
lubrication. Schmidt et al. compared experimentally all SF constituents and their 
contribution to the boundary lubrication [80]. Lubricin, HA and SAPL were tested 
individually and in combinations, both at physiological and pathophysiological 
concentrations. The results of this study supported previous data that all components of SF 
significantly contribute alone or in combinations to the boundary lubrication by lowering 
the friction coefficient.   
Until now, HA is considered to be the main SF component responsible for 
lubrication and thereby protecting the surface of articular cartilage. However, the major 
function of HA is not lubrication per se but providing high viscosity of SF. Indeed high 
concentration of HA makes SF very slippery, but doesn’t provide lubricating ability of SF. 
Several studies depleting HA with use of hyaluronidase showed that SF without HA has no 
altered lubricating properties and, furthermore, enzymatic digesting of HA resulted only in 
a lower viscosity of SF [81-82].  
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Similar experiments were performed to support the hypothesis that lubricin and 
SAPL are responsible for boundary lubrication. SAPL were digested with phospholipase 
A2 (PLA2) and lubricin was depleted from SF using trypsin. The results of these studies 
indicated that the major role in lubrication has been assigned with SAPL and lubricin. 
Digestion with both PLA2 and trypsin significantly increased friction and wear of bovine 
cartilage [51, 81, 83]. 
Role, functions and characteristic of all SF components which are thought to 
contribute to boundary lubrication will be described in further details in the next sections.  
1.3.1 Lubricin 
Lubricin is a glycoprotein found only in synovial joints. Lubricin is detected on the 
surface of articular cartilage, synovial membrane, tendons, ligaments and within SF [84]. It 
was first isolated from culture media of superficial slices of bovine articular cartilage [49]. 
Cells responsible for production of this protein are FLS and chondrocytes from the 
superficial zone of cartilage, therefore, lubricin is also called the superficial zone protein 
(SZP) [84-85]. Six homologues due to alternative splicing and post-translational 
modifications of Prg4 gene can be specified: SZP, PRG4, megakaryocyte stimulating 
factor precursor (MSF), camptodactyly-arthropathy-coxa vara-pericarditis syndrome 
(CACP) protein and lubricin [48, 84, 86] 
Lubricin is a large, mucinous glycoprotein encoded by the Prg4 gene [87] with 
observed molecular weight 227.5 kDa. Deglycosylation decrease the apparent molecular 
weight to 120 kDa [84]. Some studies also suggested that in the glycosylated form lubricin 
can have a molecular weight of even 345 kDa [49, 88]. Structurally, lubricin is composed 
of three main domains namely the cysteine-rich, somatomedin B-like N-terminal domain, 
the mucin-like O-linked oligosaccharide-rich repeat domain and a C-terminal domain [89]. 
1.3.1.1   Function of lubricin in OA 
Jay et al. reported that lubricin adsorbs to the articular surfaces of synovial joints 
thereby providing a so called chondroprotection [90]. This hypothesis was intensively 
studied over the last years. It has been shown that Prg4 knockout mice lack cartilage 
surface integrity. Their joints showed a higher friction than joints from wild-type mice and 
they developed histological abnormalities in articular cartilage with an irregular articular 
surface and disruption in the orientation of collagen fibrils [91]. Human CACP syndrome 
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is caused by mutation in Prg4 gene so that no lubricin is expressed. However, SF obtained 
from CACP patients contain normal level of HA indicating that HA is unable to provide 
efficient boundary lubrication while lubricin seems to be a major lubricating component of 
SF [86]. Additionally, several studies using ELISA methods found decreased 
concentrations of lubricin in SF during development of OA in guinea pigs. Teeple et al. 
[92] reported that in the guinea pig model of OA, the lubricin concentration was 73% 
lower in OA knee that in normal knee joints. Observed decrease was from approximately 
70 µg/ml in normal knee joint to 20 µg/ml in OA induced knee. The mechanism 
responsible for reduced level of lubricin still remains unknown, but it was postulated that it 
is due to decreased expression of this protein in FLS and chondrocytes from superficial 
zone cartilage of guinea pig knee [92-93]. 
Recombinant lubricin was proposed to be an efficient substance which might be 
used for intraarticular supplementation in OA treatment. Three animal studies using rats 
showed, that intraarticular injection of 200 or 500 µg/ml lubricin into rat knees may 
prevent cartilage from degradation. Results of the treatment were determined using K/L 
score. Five weeks after lubricin injection, K/L score (range 0-4), significantly decreased 
from 2.0 in PBS treated knees to 1.3 in lubricin treated knees [94-96]. Thus, lubricin seems 
to be a promising new agent to treat OA, however, this needs further confirmation in 
clinical studies.  
1.3.2 Surfactant proteins  
Surfactant protein A (SP-A), B (SP-B), C (SP-C) and D (SP-D) are members of the 
collectin family mostly found in the alveolar space, where they cover surfaces of alveoli 
and reduce surface tension [97]. All four collectins share similar chemical structure and are 
composed out of four regions, an amino terminal region, a collagenous region, an α-helical 
neck peptide and carboxy-terminal C-type carbohydrate recognition region [98]. 
All SPs present in the lung are expressed and secreted by alveolar type II cells and 
Clara cells [99] and each has individual function. SP-A and SP-D are water-soluble and 
hydrophilic, whereas SP-B and SP-C are extremely hydrophobic and strongly interact with 
pulmonary PL. SP-A is believed to be responsible for adsorption, binding and spreading of 
SAPL at alveoli surfaces, enhanced SAPL liposome uptake and inhibiting of SAPL 
secretion by type II cells. Takahashi et al. [100] reported other important functions of SP-A 
and SP-D namely as modulators of innate immunity in the lung [100]. 
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Surfactant proteins have been considered to be present only in the lung. However, 
some investigators believe that these proteins can also be found within other organs where 
PL-rich surfaces are present. Cells which possess LBs for instance, tongue papillae, oral 
epithelium, the gastric and intestimal mucosae, the peritoneum, the pericardium, pleura and 
Eustachian tube are able to secrete those proteins [101-103]. During the past 15 years 
Kankavi provided some evidence that SP-A and SP-D are present in non-lung sites. He 
determined those proteins in human skin, human organ of Corti, human Eustachian tube, 
human and equine SF, human spermatozoa, human kidney and also in vagina, cervix, 
uterus, oviduct and ovaries of mares and prepuce, smegma, testis, prostate and vesicular 
glands of stallion [104-108]. 
There are only a few investigations supporting the hypothesis that SP-A and SP-D 
are present in the synovial joints [101, 109-111]. This hypothesis is based on previous 
observation that FLS similar like epithelial type II cells possesses LBs [44, 51]. Using 
immunoblotting methods, SP-A and SP-D were successfully detected in human and equine 
SF by Kankavi [109-110] and their function was hypothesised to be similar to those in the 
lung. In the lung, surfactant proteins were reported to build together with PL the monolayer 
at the liquid-air surface of alveoli lining. Therefore, the expression of SP-A and SP-D is 
abundant and necessary for normal lung function. Nevertheless, the question whether the 
surfactant system is similar in the joint as it is found in the lung still has to be determined. 
1.3.3 Hyaluronic acid  
High molecular weight HA is one major component of SF found on the surface of 
articular cartilage and in extracellular matrix. Meyer and Palmer [112] reported in 1934 
that they have isolated HA for the first time from bovine vitreous humour. Furthermore, 
Weissman and Meyer [113] determined the HA structure as a long chain of polysaccharide 
with observed molecular weight of 2100 kDa. However, the molecular weight of HA has 
been shown to lie in wide range between 1.6 x 10
6
 and 10.9 x 10
6
 Da [114-115]. This 
polysaccharide is composed out of repeating disaccharide units of D-glucuronic acid and D-
N acetylglucosamine, linked together via alternating β-1,4 and β-1,3 glycosidic bonds 
[113]. HA is synthesised by FLS at the inner layer of the cell membrane by membrane-
spanning hyaluronan synthases (HAS 1-3) [116]. In synovial joints, HA has several 
functional properties with key roles, such as providing hydrodynamic viscous properties of 
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SF, mechano-protection, shock absorption, and being a buffer against fluid loss from 
cartilage during flexion, which prevent cartilage from drying [117]. 
It is well known that during OA influx of water can occur and the volume of SF 
may increase up to 20-fold resulting into a diminished viscoelastic property of SF. In OA 
both the concentration and the molecular weight of HA are decreased. The concentration of 
HA in normal SF varies between 1.45 and 3.12 mg/ml and is decreased in pathological SF 
down to 1.09-1.20 mg/ml [65]. Furthermore, the chain length of HA is enzymatically 
reduced from 7.0 x 10
6
 to 5.0 x 10
6 
Da during OA
 
[114]. Treatment with intra-articular HA 
injection as viscosupplementation for OA shows conflicting clinical results. However, few 
recently published Cochrane reviews support in part the use of HA in the treatment of OA 
[118-119]. Wang et al. [120] reported that human derived FLS treated in vitro with 100 
µg/ml high molecular HA down-regulated gene expression of OA-associated cytokines and 
enzymes, such as IL-6, IL-8, MMP-1, MMP-3 and MMP-13 which all have been shown to 
be involved in OA pathophysiology [120].  
 
1.3.4 Lipids 
 
Lipids are essential cellular and extracellular components which play important 
roles in mammalian cells. Lipids are part of biological membranes such as the cellular 
plasma membrane and the intracellular membranes of organelles like mitochondria, 
endoplasmic reticulum and vacuoles. As second messengers (e.g. diacylglycerols, 
ceramides, eicosanoids, lysolipids) lipids participate in cellular signalling and participate in 
interactions with membrane-associated proteins. Lipids are classified in classes such as 
glycerolipids, glycerophospholipids (phospholipids, PL), sphingolipids and sterol lipids. 
Within the last few years the interest in lipids, their classes, subclasses and individual 
molecular species has been increased constantly. Beside “genomics” and “proteomics”, 
“lipidomics” now also gained increased scientific attention.  
 
1.3.4.1    Phospholipids  
PL are characterised by the presence of glycerol backbone, whereas sphingolipids 
posses a sphingoid base. PL and sphingolipids are a group of molecules which contain a 
large number of molecular species with different length of carbon chains having different 
number of double bounds. It is assumed that 60% of all cellular lipids are PL [121]. 
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Structurally all PL share similar chemical pattern with presence of a polar head attached to 
the glycerol backbone via a phosphodiester bound. Various fatty acids are linked to the 
glycerol backbone at sn-1 and sn-2 position via either two acyl linkages or one acyl and 
one alkyl linkage [121]. Exceptions are lysophospholipids 
(monoacylglycerophospholipids) which have only one fatty acid linked to either sn-1 or sn-
2. According to differences in the head group PL are divided into classes, such as 
phosphatidylcholine (PC), lysophosphatidylcholine (LPC), phosphatidylethanolamine 
(PE), phosphatidylethanolamine-based plasmalogen (PLPE), phosphatidylinositol (PI), 
phosphatidylserine (PS) and phosphatidylglycerol (PG). Each PL class is further divided 
into subclasses according to chain length which are typically 14-22 carbons long and the 
number of double bonds within the fatty acids which are introduced at various positions 
(Figure 1.2). 
Figure 1.2. General chemical structure of glycerophospholipids. 
1.3.4.1.1   Boundary lubrication provided by PL 
As it has been reviewed by Postle [122], PL can be involved in the development of 
many lung diseases like asthma, cystic fibrosis, viral infections and acute respiratory 
distress syndrome, brain diseases like Alzheimer’s disease and Down’s syndrome, heart 
failure, and kidney disorders. Several studies performed by Hills and co-workers indicated 
that PL play also a role in the development of OA [50, 123].  
SAPLs in the lung often named as “surfactants” are produced by alveolar type II 
cells, which are characterised by presence of LBs. Because several studies already showed 
that LBs can be microscopically identified in FLS, it was suggested that those cells in the 
joint are responsible for SAPL synthesis, release and secretion [44-45, 51]. SAPL has also 
been found in many other organs beside the lung such as joints, stomach, Eustachian tube, 
peritoneal cavity and pleural cavity [102, 124-126]. The main component of surfactant 
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found in the lung is the saturated form of PC named di-palmitoyl-phosphatidylcholine 
(DPPC) (PC 16:0/16:0) providing most of the surfactant activities in the lung. Two 
unsaturated PC species are also present in high concentrations in the extrapulmonary sites 
namely palmitoyl-linoleoyl-phosphatidylcholine and palmitoyl-oleoyl-
phosphatidylcholine. Originally, DPPC was believed to be the main PL responsible for 
boundary lubrication, similar as found for the lung. Indeed, it has been demonstrated that 
DPPC is able to reduce friction on the surfaces of articular cartilage. However, it was also 
reported that unsaturated PC species posses better lubrication properties than those of 
DPPC [127]. Some studies using gas chromatography investigated the PL composition of 
articular cartilage surfaces. These studies also support the finding that the most abundant 
species on the surfaces of for instance bovine and human articular cartilage is unsaturated 
PC [128-129]. Chen et al. [130] reported also that PC species play a role in the water 
transport within the articular cartilage. PC molecule can bind to the negatively charged 
surface of cartilage and acts as effective semipermeable membrane which allows for 
transport of water into the cartilage. When the amount of PC lining on the surfaces is 
decreased, increased accumulation of fluid in joint might appear contributing to joint 
effusion [129-130]. 
SAPLs can be reversibly adsorbed onto the surface of articular cartilage, therefore, 
rendering the surface of articular cartilage hydrophobic. SAPLs cover the surface of 
cartilage thereby leading to a microscopically thick hydrophobic bio-film, which is 
believed to contribute to boundary lubrication (Figure 1.3) [131-132].  
 
 
 
 
 
 
Figure 1.3. Scheme of superficial layer of cartilage contains HA and SAPL. Picture obtained with 
permission from Springer [132]. 
 
 
SAPL has been demonstrated to possess the excellent anti-wear properties and to 
act as a cartilage protective agent. In this line, SF was aspirated from sheep knee joints and 
was tested together with PL extracted from SF and synthetic SF in a wear test using a “four 
ball extreme-pressure lubricant machine” [133]. This experiment demonstrated that SF, 
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synthetic SF containing SAPL and HA, and extracted PL reduce kinetic friction as well as 
wear in the wear tests [133].  
 PLs, which can be found within SF and on the surface of articular cartilage, seem to 
be similar to those in the lung (SAPL). However, the question, if the functions of SAPL 
which have been found in the lung can be extrapolated to the joint, still remains to be 
determined. SAPLs, for instance plasmalogens, in the lung were reported to function as a 
scavenger of free radicals [134]. It is not known whether SAPL can play a similar function 
in the joint. However, this would be important to know since several studies already 
implicated that activated oxygen species play a critical role in cartilage destruction and 
chondrocytes apoptosis during OA [135].  
 Little is known about the biosynthesis of PL in the joint and their regulation. 
Several studies indicated that intraarticular injections of glucocorticoids may have a 
prolonged anti-inflammatory effect on OA in humans [136] and horses [123]. Because it is 
already known that glucocorticoids promote the secretion of SAPLs in the lung [137], it 
has been also suggested that in the joint glucocorticoids can also induce SAPLs production 
[123]. This hypothesis would help to explain the long term therapeutic effect of 
corticosteroids which are drugs having a short half-life lying in the range of hours. Hills et 
al. also hypothesised that during the development of OA SAPL are becoming deficient on 
articular surfaces [138]. Using methylprednisdolone acetate (MPA) Hills et al. [123] 
demonstrated, that after intra-articular injection of this corticosteroid, the quantity of 
SAPLs in SF of equine knee joints was elevated. The authors injected 100 mg of MPA in 
2.5 ml of saline into the right knee joints of 5 healthy horses. Two and half ml of saline 
was injected to the left knee joints which served as a control. PL content was determined 
using the phosphate assay, 16 h and 32 h post injection. The phosphate assay oxidise 
phosphorus to phosphate using perchloric acid and then determines the quantity in a 
spectrophotometer after addition of ammonium molybdate as an indicator. This study 
revealed that the amount of PL increased in the treated knee joint from 1.48 to 3.25 mg/ml 
SF, whereas in the control knee it increased only from 2.25 to 2.56 mg/ml SF suggesting 
that intraarticular injection of corticosteroids might promote PL secretion [123]. 
 In the next sections all PL classes which were investigated in this study will be 
introduced in more detail. 
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1.3.4.1.2 Phospholipids containing choline 
Phosphatidylcholine  
Phosphatidylcholine (PC) is a class of PL that incorporates choline as a head group. 
PC is the major PL class within SAPL (Figure 1.4). Two fatty acids are needed to form an 
intact saturated PC or unsaturated PC molecules. DPPC is an example of saturated PC 
which requires two saturated fatty acids, i.e. palmitic acid. Palmitoyl-linoleoyl-
phosphatidylcholine and palmitoyl-oleoyl-phosphatidylcholine are examples of unsaturated 
PC which require one saturated fatty acid namely either palmitic or stearic acid and one 
unsaturated fatty acid either namely linoleic or oleic acid.  
 
 
 
 
 
Figure 1.4. General chemical structure of phosphatidylcholine. R1 and R2–fatty acids. 
PC plays various functions in the human organism for instance, PC is a major 
component of biological membranes and functions as a SAPL in the lung and probably 
also in the joint [129, 139]. It is known that DPPC is more abundant in the lung than the 
unsaturated form of PC and serves as a surfactant in this organ. Chen et al. [129] 
demonstrated that in the joint the unsaturated form of PC is more abundant as compared to 
the saturated form of PC [129]. The study of Eros et al. [140] shows that oral treatment of 
mice with PC exhibit anti-inflammatory properties. In this study, arthritis was induced by 
collagen injection (CIA) in group of 10 mice. The animals received PC-enriched diet either 
prophylactically before induction of CIA or after induction of CIA. The results indicated 
that PC decreased the inflammatory activation of leukocytes and reduced the elevated 
expression of inducible nitric oxide synthase. The study revealed also a decreased degree 
of synovial angiogenesis and less pain, redness and swelling. Taken together, these results 
suggest that PC possess anti-inflammatory properties and may reduce the damages within 
the joint accompanied with the RA disease [140].   
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Lysophosphatidylcholine   
Lysophosphatidylcholine (LPC) is a class of PL which is mainly generated by 
partial hydrolysis of the membrane PC by phospholipase A2 (PLA2). LPC is an exceptional 
PL since it possess only one fatty acid in either sn-1 or sn-2 position (Figure 1.5). LPC is 
the major component of plasma membranes and is recognised as an important cell 
signalling molecule. [141].  
 
 
 
 
Figure 1.5. General chemical structure of lysophosphatidylcholine. R – fatty acid.  
LPC can act as a pro-inflammatory mediator and the PC/LPC ratio in the serum or 
in the SF might be a good diagnostic marker for RA. SF and plasma samples were obtained 
from 9 patients with RA and plasma samples was obtained from 14 patients with RA 
undergoing anti-TNF-α therapy. PC and LPC were determined with MALDI-TOF/MS and 
high resolution 
31
P-NMR with subsequent calculation of the PC/LPC ratio. The PC/LPC 
ratio was expected to be about 20 for healthy individuals and decreased in RA patients to 
9.7±5 prior to therapy. Seven months after therapy the ratio increased 2-fold (19±5) [142].  
1.3.4.1.3 Phosphatidylethanolamine and PE-based plasmalogen 
Phosphatidylethanolamine  
Phosphatidylethanolamine (PE) is the second most abundant component of 
mammalian cell membranes with ethanolamine as a head group (Figure 1.6). 
 
 
 
  
 
Figure 1.6. General chemical structure of phosphatidylethanolamine. R1 and R2-fatty acids. 
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PE together with PS belongs to aminophospholipid group and can be synthesised 
by two independent pathways. In the first pathway the mitochondrial enzyme PS 
decarboxylase converts PS to PE. The second pathway is called the CDP-ethanolamine 
pathway which consists of three steps and which needs ethanolamine from dietary sources. 
This pathway is catalysed by ethanolamine kinase, phosphoethanolamine 
cytidyltransferase and diacylglycerol ethanolaminephosphotransferase  [143].  
PE-based plasmalogen  
 Plasmalogens represent a large group of PL species and make up approximately 
18% of all PL in human body. However, in our study only PE-based plasmalogen (PLPE) 
was measured as one major group of plasmalogens (Figure 1.7). This PL is characterised 
by a vinyl ether linkage at the sn-1 position and an ester linkage at the sn-2 position. 
Plasmalogen can also appear as PC-based, PS-based or PI-based molecules. 
 
 
 
Figure 1.7. General chemical structure of PE-based plasmalogen. R1 and R2-fatty acids. 
 Nagan and Zoeller in their review [144] highlighted the most important functions 
of plasmalogens, such as intracellular signalling, a protective role during oxidant-induced 
stress against reactive oxygen species for instance in the Chinese hamster ovary cells, rat 
neurons and murine macrophage-like cells. A study using plasmalogen-deficient human 
fibroblasts suggested that plasmalogens influence membrane trafficking by promotion the 
fusions of membranes thus, playing a role in endocytosis and secretion [145]. Human 
genetic disorders accompanied by lack of plasmalogen in the tissues, may trigger diseases 
such as, severe mental retardation, hypotonicity, adrenal dysfunction, cataracts, deafness, 
facial dysmorphism, and chondrodysplasia [144]. 
1.3.4.1.4 Phosphatidylserine  
Phosphatidylserine (PS) is quantitatively a minor PL which makes up to 2-10% of 
the total PL. It is primarily localised on the inner leaflet of plasma membranes [146]. PS is 
synthesised by replacement of the head group of existing PL by serine (Figure 1.8). For 
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instance, the choline head group from PC or ethanolamine group from PE can be replaced 
by a serine group. These reactions are catalysed by PS synthase 1 and 2, respectively [147]. 
 
 
Figure 1.8. General 
chemical 
structure of phosphatidylserine. R1 and R2-fatty acids. 
PS was first isolated from bovine brain and it was reported that oral administration 
of bovine cortex-derived PS improves cognitive disorders of patients with senile dementia 
[148]. In another study aged rats were given water with emulsified PS prepared from 
soybean lecithin and L-serine. Average daily intake was 60 mg/kg. Further, memory 
abilities of rats were tested. The results from the Morris water maze test show, that aged-
related memory impairments of rats were improved [149]. Human neural cells from gray 
matter at the surface of cerebral cortex are also enriched with PS as compared to cells from 
other organs. Therefore, PS is considered to play an essential role in the development and 
function of the nervous system [150].  
1.3.4.1.5 Phosphatidylinositol  
Phosphatidylinositol (PI) is a minor component of cell membranes and is 
characterised by the presence of inositol as a head-group. PI can be rapidly phosphorylated 
to form phosphatidylinositol phosphate (PIP), phosphatidylinositol biphosphate (PIP2) and 
phosphatidylinositol triphosphate (PIP3). PIP, PIP2 and PIP3 are collectively called 
phosphoinositides (Figure 1.9).  
Figure 1.9. General chemical structure of (a) phosphatidylinositol and (b) phosphoinositide 
(phosphatidylinositol biphosphate). R1 and R2-fatty acids. 
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It has been shown that monophosphorylated PI is associated with intracellular 
membranes where it can play a role in the constitutive membrane trafficking. Because of 
the negative charge being present on the inositol ring, PI is able to bind to the membrane 
associated proteins and induce protein cycle between organelles from the donor membrane 
to the acceptor membrane. PI is also specifically incorporated in membranes from various 
cell organelles such as the Golgi complex, endosomes, liposomes and vacuoles and may 
play a key role in distinguishing the organelles [151-152]. 
The possible role of PI in the joints is not known, however, in vitro study using 
FLS derived from rabbit knees revealed, that FLS stimulated with 180 µg/ml of 
hydroxyapapite crystals, synthesised respectively released about 2-fold more of PI as 
compared to untreated control [153]. This result suggests that PI can play an important 
function within synovial joints.  
1.3.4.1.6 Phosphatidylglycerol  
Phosphatidylglycerols (PG) possess a glycerol as a head-group (Figure 1.10). Only 
a few molecular species can be determined in human samples. The highest concentration of 
PG in the body can be found in the lung where PG make up to 10% of all SAPLs being 
present in the lung. PG are thought to play an important role in the surfactant system of the 
lung, [154-155] where they interact with SP-B and maintain the alveolar surfactant layer 
[156]. 
 
 
Figure 1.10. General chemical structure of phosphatidylglycerol. R1 and R2-fatty acids. 
1.3.4.1.7   Sphingolipids 
Sphingolipids are found in many living organisms and have been intensively 
investigated over the past years. Sphingolipids are a large group of lipids namely ceramide, 
glycosylceramide, lactosylceramide, sphingomyelin, dihydrosphingomyelin, sphinganine, 
sphinganine-1-phosphate, sphingosylphosphorylcholine, sphingosine and sphingosine-1-
phosphate. The common structural feature of all sphingolipids is the sphingoid base 
composed of a hydrophobic moiety and a hydrophilic head-group [157]. 
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Sphingomyelin (SPM) 
Sphingomyelins (SPM) are amphiphiles consisting of a phosphocholine 
zwitterionic hydrophilic head-group and two saturated hydrocarbon chains which form the 
hydrophobic domain of this molecule (Figure 1.11). In the past, SPMs were considered to 
serve only as a component of the plasma membranes. Currently, SPM have been shown to 
play a more prominent role in cells, for instance, in cellular signal transduction, growth, 
proliferation, differentiation and survival of many cell types e.g. mouse fibroblasts, rat 
brain neurons, mouse epidermal keratinocytes, human neuronal and endothelial cells [158]. 
Figure 1.11. General chemical structure of sphingomyelin. R-fatty acid. 
Gerritsen et al. [159] reported that SPM and sphingomyelinase pathway where 
ceramides (Cer) are produced, may play role in inhibition of cell cycle progression, thus 
inhibit proliferation and also induce apoptosis of cultured human FLS. They also presented 
that treatment with SPM or Cer significantly increased TNF-α production. These results 
indicate that SPM might play a role in development of RA, where apoptosis level is greater 
than in OA and pro-inflammatory cytokines are present in higher concentrations [159].  
Ceramide 
Ceramides (Cer) are composed of sphingosine and fatty acid (Figure 1.12). Cer are 
synthesized by cleavage of phosphorylcholine linkage in SPM, which is catalysed by 
neutral or acid sphingomyelinase. 
Figure 1.12. General chemical structure of ceramide. R-fatty acid. 
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 Cer are found in high concentrations within cell membranes and regulate many 
different cellular processes including, cellular stress response, cell proliferation and 
differentiation, apoptosis and senescence. Interestingly, in vitro studies using cultured 
embryonic rat brain neurons show, that Cer at low concentrations promote survival of 
cells, whereas higher concentrations of Cer induce apoptosis. Some molecular species of 
Cer might act as pro-inflammatory mediators in several human disorder for instance, in 
cystic fibrosis, coronary artery disease, arteriosclerosis, obesity, diabetes and 
cardiovascular diseases [160]. However, glucosylceramides (GluCer) may inhibit 
inflammation. Dinitrofluorobenzene-induced mice with induced allergic contact dermatitis 
in the ears were treated orally with GluCer isolated from maize. Signs of inflammation in 
the ears were decreased by GluCer, which therefore were thought to possess anti-
inflammatory and anti-allergic properties [161]. Another in vitro study using human FLS 
presented, that Cer has influence on proliferation, morphology and apoptosis of FLS. Cells 
were treated with C2-ceramide, a membrane-permeable Cer analogue (N-
acidosphingosine) at concentrations ranging from 6.25 to 50 µM. The results suggest that 
Cer inhibit cell proliferation in a concentration-dependent manner. Moreover, Cer affect 
cell morphology resulting in a rounded body cell and induce apoptosis of FLS [162]. 
In summary, three major components of SF contribute either independently or 
additively to boundary lubrication: lubricin, HA and SAPLs. SAPLs cover the surface of 
articular cartilage thereby leading to a microscopically thick bio-film which prevents the 
cartilage from degradation. Little is known about PL classes and species composition in 
SF, thus their function in synovial joint has still to be elucidated. Certain PL classes may 
act as boundary lubricants, the others can posses different functions. For instance, PC has 
been shown to exhibit anti-inflammatory properties whereas, LPC acts as a pro-
inflammatory mediator. PLPE are considered to have notable antioxidant properties. Cer 
act as pro-inflammatory mediators and, in addition, together with SPM regulate several 
cellular processes such as cell proliferation and differentiation, cellular response for stress 
and apoptosis. Taken together it can be concluded, that lipids are very important targets to 
be studied in order to better understand human biology in health and disease. Thus, 
“lipidomics” is gaining increasing scientific attention. 
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2. Aim of the study 
Boundary lubrication by SF refers to its ability to reduce the friction between 
opposite surfaces of articular cartilage. Lubricin, HA and SAPLs contribute either 
independently or additively to boundary lubrication provided by the SF. Any alterations in 
the concentration or composition of SF constituents may lead to increased friction, hence, 
an increased cartilage damage can occur within articular joints. Previous studies already 
reported about decreased concentrations of HA and lubricin within OA SF. In line of these 
observations, we tested the hypothesis that OA SF also contains altered amounts of 
individual PL species, which might contribute to cartilage destruction during OA, and that 
these alterations are dependent on the stage of the disease. Perspectively, gaining insight 
into the PLs composition and their alterations during development of OA may identify 
novel therapeutic targets. Furthermore, getting access to new diagnostic tools may help to 
diagnose OA in the early stage of the disease and, thus, open a new window to treat OA 
even during its early onset. 
The overall goal of our study was to determine both qualitatively and quantitatively 
the PL composition of human SF as altered by various joint diseases, and to further 
elucidate whether these alterations are also dependent on the stage of OA. 
The specific aims of the present study were 1. to determine whether differences in 
the concentrations of all individual PL species present in human SF are dependent on the 
health status of the joints, 2. to obtain detailed informations about PLs composition of SF 
collected from different stages of human OA, 3. to analyse qualitatively and quantitatively 
all PL species of MPs present in human SF, 4. to evaluate whether a canine model of OA 
reflect the composition of PL species as found in human SF, 5. to determine species 
dependency with respect to the PL composition in SF obtained from humans, dogs and 
horses, and 6. to study mechanical impact on PL composition. 
It has been hypothesised, that FLS might be the source of SAPLs found in SF since 
one electromicroscopical study identified LBs within FLS. In order to proof that FLS can 
indeed synthesise SAPLs, a method for quantitative assessment of PLs present in FLS cell 
culture media should be established. 
Already four studies reported that surfactant proteins might be present in human 
and equine SF. In order to test the hypothesis, that these proteins are indeed present in 
human SF and are also locally synthesised, an additional aim of this study was to obtain 
the protein and mRNA expression pattern of SP-A and -D in different joint tissues and SF. 
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3. Material and Methods 
3.1 Materials 
3.1.1 Technical equipment 
Autoclave, model 3850 EL  Tuttnauer Europe B.V., Breda, The Netherlands 
Automatic pipetting system,  Tecan, Maennedorf, Switzerland                            Pipetting 
Robot Genesis, RSP 150 
Balance, model 770-12   Kern & Sohn GmbH, Balingen-Frommern, Germany 
Balance, model EG2200-2NM  Kern & Sohn GmbH, Balingen-Frommern, Germany 
Biological Safety Cabinet, Microflow
®
 Thermo Scientific Inc., Rockford, IL, USA 
Cell culture incubator, model 3039 Forma Scientific Inc., Marietta, OH, USA 
Cell culture incubator, Cellstar
®
 Nunc GmbH, Wiesbaden, Germany 
Centrifuge, model 5403   Eppendorf AG, Hamburg, Germany 
Drying oven, model 700  Memmert GmbH&Co. KG, Schwabach, Germany 
Electrophoresis chamber vertical, Bio-Rad Laboratories GmbH, Munich, Germany               
Mini PROTEAN
®
 Tetracell 
Electrophoresis chamber horizontal, Bio-Rad Laboratories GmbH, Munich, Germany         
Wide Min-SUB
®
 Cell GT 
ELISA-Reader, Multiscan Plus MK11 Titertek Instruments, Huntsville, AL, USA 
ELISA-Reader, Sunrise™  Tecan, Crailsheim, Germany 
Freezer -20°C, model KGE 34422 Bosch GmbH, Gerlingen-Schillerhoehe, Germany 
Freezer -86°C, model HFU 486 Top Thermo Electron GmbH, Langenselbold, Germany 
Gel iX Imager INTAS
® 
   Intas Science GmbH, Goettingen, Germany 
Horizontal shaker, Polymax 1040 Heidolph Instruments GmbH&Co.KG,                          
Schwabach, Germany  
Light microscope, Axiovert
®
 40 CFL Carl Zeiss, Goettingen, Germany 
Liquid handling roboter system  HamiltonRobotics, Bonaduz, Switzerland             
MicroStarlet
®
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Magnetic stirrer, model MR 3002 Scientific Industries Inc., Bohemia, NY, USA  
Mass Spectrometer,   Micromass, Manchester,  United Kingdom              Quattro 
Ultima Triple™ Quadrupole 
Mass Spectrometer,   Bruker Daltonics, Bremen, Germany                       
Ultraflex I MALDI TOF/TOF 
Microcentrifuge, model 5415D Eppendorf AG, Hamburg, Germany 
Microplate shaker, model LD-45 Kisker Biotech GmbH&Co.KG, Steinfurt, Germany 
Multichannel pipette 8-, 12-channels Eppendorf AG, Hamburg, Germany 
Multipette
® 
plus Eppendorf AG, Hamburg, Germany 
PCR-Mastercycler
®
, Personal Eppendorf AG, Hamburg, Germany 
pH-meter digital, handylab 1 SI Analytics GmbH, Mainz, Germany 
Pipetboy, Easypet
®
 Eppendorf AG, Hamburg, Germany
  
Pipette, single channel:   Eppendorf AG, Hamburg, Germany                                
0.5-10 µl, 10-100 µl, 100-10000 µl
 
 
Pipette, single channel  Eppendorf AG, Hamburg, Germany 
Power Supply, PowerPac™ HC Bio-Rad Laboratories GmbH, Munich, Germany 
Pump, model 16612 Sartorius, Goettingen, Germany 
Refrigerator +4 °C, model KGU66920 Bosch GmbH, Gerlingen-Schillerhoehe, Germany 
Thermomixer, Comfort Eppendorf AG, Hamburg, Germany 
Semi-Dry Transfer cell,          Bio-Rad Laboratories GmbH, Munich, Germany           
Trans-blot
®
SD 
Spot Cutter, ExQuest
®
 Bio-Rad Laboratories GmbH, Munich, Germany 
Universal centrifuge, model 320R Hettich GmbH&Co. KG, Tufflingen, Germany 
UV-visible spectrophotometer,  Shimadzu Corporation, Duisburg, Germany                    
UV-1601 
Vacuum concentrator, Christ RVC Wolf Laboratories Limited, York, United Kingdom 
Vortex mixer, Vortex-Genie
®
2  Scientific Industries Inc., Bohemia, NY, USA 
Water bath, AQUAline AL5  DJB Labcare Ltd, Buckinghamshire, UK 
Material and Methods 
26 
 
X-ray cassette, Hypercasette™   GE Healthcare Europe GmbH, Freiburg, Germany 
RPN11642 
3.1.2 Consumables 
Cartridges, Bond Elut
®
-NH2  Agilent Technologies Inc., Santa Clara, CA, USA 
Cell culture flask T-75   Greiner bio-one GmbH, Frickenhausen, Germany 
Cell strainer, nylon 70 μm, sterile Becton Dickinson GmbH, Heidelberg, Germany 
Combitips plus
®
: 5 ml, 10 ml  Eppendorf AG, Hamburg, Germany 
Conical tubes: 15 ml, 50 ml  Becton Dickinson GmbH, Heidelberg, Germany 
Filter Tip FT: 10 μl, 100 μl, 1000 μl Nerbe plus GmbH, Winsen, Germany 
Gel blotting paper, extra thick,         Bio-Rad Laboratories GmbH, Munich, Germany                                                                                                      
18.5 x 19 cm, Protein
®
 II xi Size                                                                                                 
Neubauer chamber   LO-Laboroptik GmbH, Bad Homburg, Germany 
Needles 18G, 23G   Becton Dickinson GmbH, Heidelberg, Germany 
PCR tubes: 0.2 ml   Nerbe plus GmbH, Winsen, Germany 
Petri dish 94 x 16 mm   Greiner bio-one GmbH, Frickenhausen, Germany 
Pipette tip:                                               Sarstedt AG & Co., Nuembrecht, Germany                       
10 µl, 100 µl, 300 µl, 1000 µl 
Plastic tubes: 5 ml   Sarstedt AG & Co., Nuembrecht, Germany 
8-port manifold , autoclavable  Fisher Scientific GmbH, Schwerte, Germany               
(#704526) 
PVDF Membrane, ImmunBlot™ Bio-Rad Laboratories GmbH, Munich, Germany 
Radiographic film, Hyperfilm™ ECL GE Healthcare Europe GmbH, Freiburg, Germany          
18x24 cm 
Reaction tubes: 1.5 ml, 2 ml  Sarstedt AG & Co., Nuembrecht, Germany 
Serological pipette:                              Becton Dickinson GmbH, Heidelberg, Germany       
2 ml, 5 ml, 10 ml, 25 ml 
Sterile scalpel Nr. 21   Feather Safety Razor Co. Ltd., Osaka, Japan 
Sterile syringe: 2 ml, 5 ml, 10ml B. Braun Melsungen AG, Melsungen, Germany 
Syringe-driven filter units: 1.2 µm Whatman Inc. Clifton, NJ, USA 
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Syringe-driven filter units:  Sartorius AG, Goettingen, Germany        
1.2 µm, 5 µm 
Syringe filter 0.22 μm, Millex®GP Millipore GmbH, Schwalbach/Ts., Germany 
Syringe for infusion: 50 ml  Dispomed Witt OHG, Gelnhausen, Germany 
Tissue culture plates, rectangular Nalge Nunc Int., Roskilde, Denmark                                  
4-well (#176597)                                                                          
Tissue culture plates 6-well, Nunclon™ Nalge Nunc Int., Roskilde, Denmark 
96-well ELISA plates, MICROLON
®
 Greiner bio-one GmbH, Frickenhausen, Germany 
3.1.3 Reagents 
Acetic acid, puriss p.a.   Sigma-Aldrich GmbH, Taufkirchen, Germany (#A6283) 
Acrylamide : bisacrylamide (37.5:1) Carl Roth GmbH, Karlsruhe, Germany  (#3029.2)        
solution, Rotiphorese
®
 Gel 30  
Agarose, analytical grade  Promega Corp., Madison, WI, USA (#3121) 
Albumine, bovine serum  Invitrogen GmbH, Karlsruhe, Germany (#55213) 
Ammonium acetate, ≥98%  Sigma-Aldrich GmbH, Taufkirchen, Germany (#A7330) 
Ammonium peroxodisulfate,   Sigma-Aldrich GmbH, Taufkirchen, Germany (#09913)     
(APS) ≥ 98%   
Aqua B. Braun     B. Braun Melsungen AG, Melsungen, Germany              
(sterile water for irrigation)  (#75/12604052/0503) 
β-Mercaptoethanol, >99%  Sigma-Aldrich GmbH, Taufkirchen, Germany (#63689) 
BD Matrigel™    BD Biosciences, Bedford, MA, USA (#356230) 
Bromophenol blue   Sigma-Aldrich GmbH, Taufkirchen, Germany (#B-8026) 
Chloroform, ≥99.8%   Merck KGaA, Darmstadt, Germany (#1.02444.1000) 
Complete™ Protease Inhibitor, tablets Roche Diagnostic GmbH, Mannheim, Germany 
(#04693116001) 
Coomassie Brillant Blue R-250  Bio-Rad Laboratories GmbH, Munich, Germany 
Destaining solution   (#161-0438) 
Coomassie Brillant Blue R-250  Bio-Rad Laboratories GmbH, Munich, Germany     
Staining solution   (#161-0436) 
DEPC water    Carl Roth GmbH, Karlsruhe, Germany (#T143) 
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Dexamethasone , ≥97%    Sigma-Aldrich GmbH, Taufkirchen, Germany (#D4902) 
Diethylether, ≥99.5% Sigma-Aldrich GmbH, Taufkirchen, Germany (#309966) 
Dimethyl sulphoxide (DMSO), sterile Sigma-Aldrich GmbH, Taufkirchen, Germany (#2650) 
Dispase II  PAN Biotech GmbH, Aidenbach, Germany (#P10032100) 
D-MEM medium PAN Biotech GmbH, Aidenbach, Germany (#P04-01550) 
D-MEM medium w/o Phenol Red PAN Biotech GmbH, Aidenbach, Germany (#P04-01515) 
DNA Ladder (100 bp)  Promega Corporation, Madison, WI, USA (#G210A) 
Dulbecco’s phosphate buffered saline PAA Laboratories GmbH, Pasching, Austria (#H15-002)  
(PBS) 1x 
Dulbecco’s phosphate buffered saline Bio-Rad Laboratories GmbH, Munich, Germany              
(PBS) 10x    (#161-0780) 
Ethanol absolut , ACS   J. T. Baker, Deventer, The Netherlands (#UN1170) 
Ethylendinitrilo-N, N, N’, N’, -  Sigma-Aldrich GmbH, Taufkirchen, Germany (#E5513)         
tetra-acetic-acid (EDTA), >99%    
Foetal calf serum (FCS)  Sigma-Aldrich GmbH, Taufkirchen, Germany (#F7524) 
Formic acid 0.1% in water,  Carl Roth GmbH, Karlsruhe, Germany (#CP03.1)            
LP-MS grade 
Gentamycin sulfate   Calbiochem, Merck KGaA, Darmstadt, Germany 
(#345814) 
Glycerol, ≥99.5% p.a. Carl Roth GmbH, Karlsruhe, Germany (#3783.1) 
Glycine, ≥99% p.a. Carl Roth GmbH, Karlsruhe, Germany (#3908.2) 
Goat polyclonal anti-human SP-C Santa Cruz Biotechnology Inc., Heidelberg, Germany 
(#SC-13979)  
Hexane, ≥99% p.a.  Sigma-Aldrich GmbH, Taufkirchen, Germany (#34859) 
HRP-conjugated  rabbit polyclonal   Dako Deutschland GmbH, Hamburg, Germany (#P0160)        
anti-goat IgG      
HRP-conjugated  rabbit polyclonal   Dako Deutschland GmbH, Hamburg, Germany (#P0160)        
anti-mouse IgG      
HRP-conjugated swine polyclonal   Dako Deutschland GmbH, Hamburg, Germany (#P0160)        
anti-rabbit IgG      
Hyaluronidase from bovine testes Sigma-Aldrich GmbH, Taufkirchen, Germany #(3506) 
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Hydrochloric acid, ≥37% purum p.a. Sigma-Aldrich GmbH, Taufkirchen, Germany (#84422) 
2-(4-2-hydroxyethyl)-piperazinyl- PAA Laboratories GmbH, Pasching, Austria (#S11-001) 1-
ethansulfonate (HEPES),                                                      
1M solution  
ITS™+Premix    BD Biosciences, Bedford, MA, USA (#354352) 
Methanol, min. 99.9%   Sigma-Aldrich GmbH, Taufkirchen, Germany (#34860) 
MMLV Reverse Transcriptase  Promega Corp., Madison, WI, USA (#M3681) 
Mouse monoclonal anti-human SP-A     Abcam plc, Cambridge, United Kingdom (#ab51891)  
Mouse monoclonal anti-human SP A Dako Deutschland GmbH, Hamburg, Germany (#PE-10)          
Mouse monoclonal anti-human SP-D     Abcam plc, Cambridge, United Kingdom (#ab51891)      
N,N,N’,N’-tetramethyl-ethane-  Carl Roth GmbH, Karlsruhe, Germany (#2367.3)                           
1,2-diamine (TEMED), 99% p.a.  
Neomycin sulfate   Calbiochem, Merck KGaA, Darmstadt, Germany (#4801) 
Non-fat Milk, blotting grade  Carl Roth GmbH, Karlsruhe, Germany (#T145.3) 
Oligo(dt)15 Primer   Promega Corp., Madison, WI, USA (#C1101) 
PCR Nucleotide Mix   Promega Corp., Madison, WI, USA (#C1141) 
Penicillin-streptomycin (100x),  PAA Laboratories GmbH, Pasching, Austria (#P11-010) 
solution, penicillin 1000 U/ml,                                                                                                   
streptomycin 10 mg/ml 
PeqGOLD TriFast™ Peqlab Biotechnologie GmbH, Erlangen, Germany           
(#12-6834-00) 
Phenol Red Sigma-Aldrich GmbH, Taufkirchen, Germany (#P3532) 
Phosphoric acid, 85% puriss p.a. Sigma-Aldrich GmbH, Taufkirchen, Germany (#30417) 
Precision Plus Protein™ Standards   Bio-Rad Laboratories GmbH, Munich, Germany  
(#161-0374) 
2-Propanol, UV/IR grade Carl Roth GmbH, Karlsruhe, Germany (#T910.1) 
Quinacrine dihydrochloride, min. 90% Sigma-Aldrich GmbH, Taufkirchen, Germany (#Q3251) 
Rabbit polyclonal anti-human SP-A Millipore GmbH, Schwalbach/TS, Germany (#ab3420)  
Rabbit polyclonal anti-human SP-B  Millipore GmbH, Schwalbach/TS, Germany (#07-614) 
RNase Away
®
,
 
Surface Decontaminant Molecular BioProduct Inc., San Diego, CA, USA (#7000) 
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RNase-free water Promega Corp., Madison, WI, USA (#P119C) 
RNase Inhibitor, RNasin
®
 Promega Corp., Madison, WI, USA (#N251B) 
Sacharose, ≥99.5% p.a. Carl Roth GmbH, Karlsruhe, Germany (#4621.1) 
Sodium chloride, ≥99.5% p.a. Carl Roth GmbH, Karlsruhe, Germany (#3957.1) 
Sodium chloride, 0.9% solution  B. Braun Melsungen AG, Melsungen, Germany 
(#2350748) 
Sodium dodecyl sulfate (SDS), ≥99% Carl Roth GmbH, Karlsruhe, Germany (#2326.1) 
Surfactant protein–A forward primer biomers.net GmbH, Ulm, Germany (#00121699-1) 
Surfactant protein-A reverse primer biomers.net GmbH, Ulm, Germany (#00121699-2) 
Surfactant protein-D forward primer biomers.net GmbH, Ulm, Germany (#00099655-1) 
Surfactant protein-D reverse primer biomers.net GmbH, Ulm, Germany (#00099655-2) 
Trifluoroacetic acid, 25% Life Technologies GmbH, Darmstadt, Germany            
(#400003)  
Tris, Pufferan
®
, ≥99% Carl Roth GmbH, Karlsruhe, Germany (#5429.3) 
Trisodium citrate, ≥99.5% Sigma-Aldrich GmbH, Taufkirchen, Germany (#71402) 
Trypan blue Merck KGaA, Darmstadt, Germany (#1.11732.0025) 
Trypsin/EDTA 0.5%/0.2% in PBS (10x)PAA Laboratories GmbH, Pasching, Austria (#L11-003) 
Tween
®
20 Carl Roth GmbH, Karlsruhe, Germany (#9127.1) 
X-ray developer concentrate  Adefo-Chemie GmbH, Dietzenbach, Germany 
(#00036/04036)  
X-ray fixer concentrate  Adefo-Chemie GmbH, Dietzenbach, Germany 
(#00036/07036)  
3.1.4 Reagent kits 
Albumin Removal Kit SwellGel
®
Blue Thermo Scientific Inc., Rockford, IL, USA (#89845) 
β2-Microglobulin ELISA kit MP Biomedicals LLC, Orangeburg, NY, USA        
(#07BC-1061) 
Bio-Rad Protein Assay Bio-Rad Laboratories GmbH, Munich, Germany         
(#500-0201) 
DNase I Kit Fermentas GmbH, St-Leon-Rot, Germany (#EN0521) 
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ECL Plus Western Blotting  GE Healthcare Europe GmbH, Freiburg, Germany 
Detection System   (#RPN2132) 
GelRed Prestaining Kit   Biotium Inc., Hayward, CA, USA (#31010) 
GoTaq
®
Flexi DNA Polymerase  Promega Corp., Madison, WI, USA (#M8301) 
PCR Mycoplasma Test Kit II PromoKine, PromoCell GmbH, Heidelberg, Germany 
(#PK-CA20-700-10) 
PeqGOLD Total RNA Kit Peqlab Biotechnologie GmbH, Erlangen, Germany      
(#12-6834-00) 
Quanti Chrom™ Urea Assay Kit   BioAssay Systems, Hayward, CA, USA (#DIUR-500) 
RNAqueous™ Ambion Inc., Austin, TX, USA (#1911) 
3.1.5 Analysis Software 
Compas 1.1 software package  Bruker Daltonics, Bremen, Germany 
ELISA reader software, Magellan™ Tecan, Crailsheim, Germany  
Graph Pad Prism 5.2 Graph Pad Inc., San Diego, USA 
Excel Macros    Dr. G. Liebisch, Regensburg, Germany 
Intas
®
 GDS    Intas Science GmbH, Goettingen, Germany 
LabImage 1D L340 4.1    Intas Science GmbH, Goettingen, Germany 
Mascot     MatrixScience, London, United Kingdom 
MassLynx software   Macromass, Manchester, United Kingdom  
R version 2.14.0   www.r-project.org 
3.1.6 Buffers and solutions 
10% APS solution  
1 g of APS was dissolved in 10 ml aqua B. Braun. 
 
Blocking solution pH 7.5  
Component   Total volume 200 ml  Final concentration  
non-fat dry milk    10 g    5% (w/v) 
1x Tris Buffer Saline/Tween
®
20 up to 200 ml 
The pH was adjusted to 7.5 with HCl 
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Culture medium-complete DME-M 
Component   Total volume 200 ml  Final concentration  
FCS (heat-inactivated)   20 ml    10% (v/v) 
HEPES     2 ml    10 mM 
Penicillin-streptomycin   2 ml    10 U/ml penicillin  
         0.1 mg/ml streptomycin 
D-MEM medium   176 ml     
 
Culture medium – Starvation medium 
Component   Total volume 200 ml  Final concentration  
FCS (heat-inactivated)   4 ml    2% (v/v) 
HEPES     2 ml    10 mM 
Penicillin-streptomycin   2 ml    10 U/ml penicillin  
         0.1 mg/ml streptomycin 
D-MEM medium   192 ml     
 
FCS  heat-inactivated 
500 ml of frozen FCS was kept overnight at 4ºC. Subsequently, completely thawed FCS was 
incubated in water bath at 56ºC. When fluid temperature was approximately 56ºC, FCS was heat-
inactivated for following 30 min.   
 
Protease- Phospholipase Inhibitor Coktail (PPI) 
Component   Total volume 5 ml  Final concentration  
Quinacrine dihydrochloride  24 mg    10 mM 
Neomycin sulfate   23 mg    5 mM 
Gentamycin sulfate   28 mg    10 mM 
Aqua B. Braun     5 ml 
Complete™Protease Inhibitor  1 tablet 
 
Resolving gel solution (1.125 M Tris-HCl) pH 8.8 
Component   Total volume 200 ml  Final concentration  
Tris     27.26 g    1.125 M 
Sacharose     60 g    30% (w/v) 
Aqua B. Braun     up to 200 ml 
The pH was adjusted to 8.8 with HCl. 
 
 
Material and Methods 
33 
 
2x SDS-loading buffer pH 6.8  
Component   Total volume 100 ml  Final concentration  
Glycerol    50 ml    50% (v/v) 
SDS      10 g    10% (w/v) 
β-Mercaptoethanol   1 ml    10% (v/v) 
Bromophenol blue   10 mg    0.01% (w/v) 
125 mM Tris-HCl, pH 6.8   up to 100 ml 
The pH was adjusted to 6.8 with HCl. 
 
10x SDS-running buffer pH 8.3  
Component   Total volume 1 l  Final concentration  
Tris     30.3 g    250 mM 
Glycine     144.1 g    1.92 M 
SDS      10 g    0.1% (w/v) 
Aqua B. Braun     up to 1 l 
The pH was adjusted to 8.3 with HCl. 
 
1x SDS-running buffer pH 8.3  
10x SDS-running buffer was diluted 1:10 in aqua B. Braun.  
The pH was adjusted to 8.3 with HCl. 
 
10% SDS stock solution 
10 g SDS were dissolved in 100 ml aqua B. Braun. 
Stacking gel solution pH 6.8  
Component   Total volume 200 ml  Final concentration  
Tris     15.14 g    625 mM 
Aqua B. Braun     up to 200 ml 
The pH was adjusted to 6.8 with HCl. 
 
10x Tris Buffer Saline/Tween
®
20 (TBS/T) pH 7.5  
Component   Total volume 2 l  Final concentration  
Tris     121.14 g   500 mM 
NaCl     58.44 g    500 mM 
Tween
®
20    20 g    0.01% (w/v) 
Aqua B. Braun     up to 2 l  
The pH was adjusted to 7.5 with HCl. 
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1x Tris Buffer Saline/Tween
®
20 (TBS/T) pH 7.5  
10x TBS/T was diluted 1:10 in aqua B.Braun. 
The pH was adjusted to 7.5 with HCl. 
 
Transfer buffer pH 8.0  
Component   Total volume 1 l  Final concentration  
Tris    2.42 g     20 mM 
Glycine    11.26 g     150 mM 
Methanol   200 ml     20% (v/v) 
Aqua B. Braun    up to 1 l 
The pH was adjusted to 8.0 with HCl. 
3.1.7 Synovial fluid 
3.1.7.1 Human synovial fluid 
Synovial fluid (SF) was collected in order to investigate the levels of the boundary 
lubricants PL and surfactant proteins. SF was obtained from the knee joints of 16 cadavers, 
23 RA patients and of 85 OA patients (Table 2.1). OA joints were classified into subgroups 
of early and late stages of OA according to Kellgren/Lawrence (K/L) grades of 
radiographic severity (range 0-4) and according to the macroscopical appearance of 
cartilage surfaces as determined by the Outerbridge score [16, 19]. Only patients fulfilling 
the inclusion criteria and those without the exclusion criteria were included in the study 
(Table 2.2 and 2.3). SF was collected by direct aspiration during arthroscopy or total knee 
replacement surgery. RA SF was obtained by Dr. med. U. Käßer (Rheumatologische 
Schwerpunktpraxis, Internistisches Praxiszentrum am Balserischen Stift, Giessen, 
Germany) and prepared as described in section 3.2.1 within 30 min from aspiration. 
Cadaveric SF was collected by the Institute of Forensic Medicine, Giessen, Germany. 
Samples were aspirated from knee joints within several hours until 5 days after death. 
Subsequently, SF was stored at 4ºC for not longer than 24 h and further prepared as 
described in section 3.2.1. All investigations were approved by the local ethics commission 
(AZ: 62/06 from 18.05.06 with amendment from 16.02.09).  
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Diagnosis n Gender ♂/♀ 
Age [years]  
min-max             
mean ± SD 
BMI [kg/m
2
]          
min-max          
mean ± SD 
Human cadavers with 
healthy joints 
15 14/1 
17-34              
23.8 ± 4.9 
18.6-38.3          
24.4 ± 4.8 
RA 20 5/15 
43-86            
61.04 ± 14.03 
20.7-43.4        
29.4 ± 6.3 
OA early stage 29 18/11 
18-75              
41.8 ± 17.2 
16.9-37.3        
25.9 ± 4.4 
OA late stage 26 11/15 
44-85               
69.6 ± 9.9 
19.2-37.4        
28.7 ± 4.4 
Table 2.1. Characterization of patients included into the study. 
 
 
Human cadavers 
OA 
early stage 
OA 
late stage 
RA 
men, women men, women men, women men, women 
age < 35 age < 85 age < 85 age < 90 
BMI < 40 BMI < 40 BMI < 40 BMI < 45 
sudden death all CRP- levels all CRP- levels all CRP- levels 
- 
Kellgren-Lawrence 
score ≤ 2 
Kellgren-Lawrence 
score > 2 
ACR criteria 
healthy knee joints OA OA RA 
Table 2.2. Inclusion criteria.  
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Human cadavers OA RA 
joint related joint related joint related 
knee joint surgery  
knee joint surgery              
within last 6 months            
(e.g. arthroscopy) 
knee joint surgery              
within last 6 months             
(e.g. arthroscopy) 
any knee joint damage due to 
e.g. OA, RA, gout, trauma  
other surgeries                  
within last 3 months 
other surgeries                   
within last 3 months 
- 
fracture of joints               
within last 24 months 
fracture of joints               
within last 24 months 
- 
inflammatory arthritides in 
other joints (like rheumatoid 
arthritis, psoriasis arthritis, 
spondylitis ankylosans), 
tendinitis 
- 
- 
collagenosis in other joints  
(like lupus erythematodes, 
skleroderma) 
- 
- joint infection joint infection 
- 
any joint diseases like gout,                           
trauma within last 3 months 
any joint diseases like gout, 
trauma within last 3 months 
Other diseases Other diseases Other diseases 
osteoporosis 
severe liver disease             
(GPT or GOT > 100 U/L) 
severe liver disease            
(GPT or GOT > 100 U/L) 
osteopenia  
severe kidney disease  
(creatinine > 1,5 mg/dl) 
severe kidney disease   
(creatinine > 1,5 mg/dl) 
tumor/cancer (near joint) Diabetes mellitus Diabetes mellitus 
chronic disease                   
resulting in death  
tumor/cancer (near joint) tumor/cancer (near joint) 
HIV-infection 
thyroid gland diseases              
(hypothyroidism, 
hyperthyroidism, euthyroidism) 
thyroid gland diseases              
(hypothyroidism, 
hyperthyroidism, euthyroidism) 
- HIV-infection HIV-infection 
Drugs Drugs Drugs 
intraarticular drugs drug abuser drug abuser 
- 
Hyaluronat                       
(within last 6 months) 
Hyaluronat                        
(within last 6 months) 
- 
immunosuppressive drugs 
(within last 6 months) 
- 
- 
corticosteroids (within last 6 
months) 
corticosteroids                 
(within last 6 months) 
Table 2.3. Exclusion criteria.  
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3.1.7.2 Canine synovial fluid  
 Healthy SF obtained from human cadavers was aspirated from knee joints within 
several hours until even 5 days after death. During this time degradation processes might 
occur. Thus, we also obtained normal healthy SF aspirated directly after death, however 
this time from dogs using SF from the canine groove model of OA. Additionally, canine 
SF obtained from distraction experiments were analysed in order to test whether 
mechanical loading has an influence on PL composition in SF. The canine groove model 
and distraction experiment was accomplished by Prof. Dr. F. Lafeber and S. Mastbergen, 
PhD (Department of Rheumatology & Clinical Immunology, University Medical Center 
Utrecht, The Netherlands). Mixed breed canines (n=21 females, mean age 1.8 ± 0.5 years, 
weighing 17.5 ± 1.3 kg) were obtained from the animal laboratory of Utrecht University, 
The Netherlands. The study was approved by the Utrecht University Medical Ethical 
Committee for animal studies. 
OA was induced in the right knee joint of all 20 dogs according to the method 
described elsewhere [72-74]. Under general anaesthesia, surgery was performed through a 
2-2.5 cm medial incision close to the ligamentum patellae. In utmost flexion, 
approximately ten longitudinal and diagonal grooves were made on the parts of the femoral 
condyles using a 1.5 mm diameter Kirschner-wire. 
Joint distraction was performed using the right knee joint of 9 dogs. Ten weeks 
after OA induction, the external fixation frame was placed with three bone pins drilled into 
the femur and the tibia. Distraction of the joints was carried out using the screw threaded 
connecting rods. In order to control for the influence of the frame alone on the dogs 
loading behaviour of joints, additional 5 dogs received only a frame without distraction of 
the knee joint. After five days of recovery, all dogs were allowed to use the patio. After 8 
weeks, distraction of joints was terminated. The severity of OA was evaluated 45 weeks 
after induction of OA in all animals. 
At the end of the experiment all dogs were sacrificed with an intravenous injection 
of pentobarbital Euthesate
®
. Both hind limbs were amputated and processed within 2 h. SF 
was obtained by direct aspiration from both knee joints and prepared as described in 
section 3.2.1. Subsequently the samples were frozen at -80°C, shipped on dry ice to our 
laboratory where they were stored frozen at -86°C until further analysis. 
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3.1.7.3 Equine synovial fluid  
In order to obtain healthy SF and to compare PL composition in different species, 
SF was aspirated from 14 horses by direct aspiration from knee joint after euthanasia 
(mean age ± SD: 12.7 ± 4.7; mean weight ± SD: 518.6 ± 81.7 kg, 6 female and 8 male). 
Only SF from horses with healthy knee joints and no arthritic disease history were used. 
Equine SF sampling was performed by Dr. med. vet. Martina Sperling (Veterinary Clinic 
for Horses, Justus-Liebig-University of Giessen, Germany). SF was stored at 4ºC and 
prepared as described in section 3.2.1 within a time period not longer than 12 h after 
aspiration. 
 
3.1.8 Human cells and tissues 
3.1.8.1 Human fibroblast-like synoviocytes 
 Human fibroblast-like synoviocytes (FLS) were isolated and cultured in order to 
investigate 1. whether synthesis and/or secretion of PL can be measured also in vitro and 2. 
whether FLS express the sp-a and sp-d genes. FLS were isolated from synovial membranes 
obtained from 9 OA patients (3 male, 6 female; age 57-77 years, mean age ± SD: 68.1 ± 
7.3) undergoing total knee replacement surgery, as described in section 3.2.7.1. All 
investigations were approved by the local ethics commission (AZ: 106/03 from 08.01.04 
with amendment from 21.07.09) and written informed consent was obtained from all 
patients. 
3.1.8.2 Human tissues 
 Human synovial membranes and cartilage specimens were obtained from 3 OA 
patients (4 female, 2 male; age 61-76, mean age ± SD: 69 ± 7.5) undergoing total knee 
replacement surgery in order to test the hypothesis that sp-a and sp-d genes are expressed 
in those tissues. All investigations were approved by the local ethics commission (AZ: 
106/03 from 08.01.04 with amendment from 21.07.09) and written informed consent was 
obtained from all patients. 
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3.2 Methods 
3.2.1 Sampling of synovial fluid  
 Aspirated SF samples were macroscopically analyzed according to colour, turbidity 
and contamination. Samples contaminated with blood and characterised by high turbidity 
were discarded. Samples with a volume lower than 2 ml were diluted by the addition of 2 
ml sterile 0.9 % NaCl-solution. Samples were incubated for 30 min at 37°C, followed by 
filtration through 1.2 µm filter. Light microscopical analysis were performed using a 
Neubauer chamber to verify that 10 µl SF samples were free from cells and cellular debris. 
SF samples containing cells were filtrated again as described above. Subsequently, 10% 
(v/v) of PPI was added, samples were aliquoted, frozen at -86°C and stored for a maximum 
duration of 2 years for further analysis.   
3.2.2 Isolation of microparticles  
Microparticles (MP) were isolated in order to determine PL composition of MPs 
present in SF which was further compared with PL from MP-free SF supernatant. MPs 
from SF and cell culture media were isolated according to Berckmans et al. with slight 
modifications [67]. Briefly, 250 μl aliquots of SF and cell culture media were centrifuged 
for 45 min at 16.100 x g and 20°C to pellet the MPs. Supernatant (225 μl) was discarded or 
stored frozen at -86°C for further analysis. 25 μl of pellet was resuspended in 225 μl PBS 
(pH 7.4) containing 10.9 mM trisodium citrate and centrifuged again as described above. 
Supernatant (225 μl) was again removed and MPs were resuspended in 25 μl of 
PBS/citrate buffer resulting in a final volume of 50 μl. Isolated MPs were stored frozen at -
86°C until analyzed.  
3.2.3 Extraction of lipids  
 Lipids were extracted from SF and cell culture media in order to relatively and 
absolutely quantify PL using electrospray ionization tandem mass spectrometry (ESI-
MS/MS). Extraction of PL was performed according to the method of Bligh and Dyer 
[163] in the presence of non-naturally occurring lipid species which served as internal 
standards. The following lipid species were added as internal standards: PC 14:0/14:0, PC 
22:0/22:0, PE 14:0/14:0, PE 20:0/20:0, PS 14:0/14:0, PS 20:0/20:0, PG 14:0/14:0, PG 
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20:0/20:0, PI 16:0/16:0, PI 17:0/17:0, LPC 13:0, LPC 16:0, Cer 14:0, Cer 17:0, D7-FC, CE 
17:0 and CE 22:0 [164-166]. 50 μl of cell- and cell debris-free SF, cell-, cell debris- and 
MPs-free SF or isolated MPs were diluted with 750 μl of water, whereas 800 μl of cell 
culture media being cell-, cell debris- and MPs-free were used as starting material. PLs 
were isolated by adding 3 ml of methanol/chloroform (2:1, v/v) followed by 1 h incubation 
at RT. Separation of phases was performed by adding 1 ml of chloroform and 1 ml of 
water. Subsequently, samples were centrifuged at 2.500 x g for 10 min at RT. The 
chloroform phases containing PLs were collected using an automatic pipetting system and 
were dried in vacuum centrifuge for 1 h. Dried samples were then dissolved in 1 ml 
methanol/chloroform (3:1, v/v) containing 10 mM ammonium acetate.  
3.2.4 Solid phase extraction 
Solid phase extraction (SPE) was performed to separate PL fractions from 
chloroform phase containing the lipids and to eliminate contaminations. 4 ml of cell-, cell 
debris- and MPs-free cell culture media were taken as starting material. Lipid extraction 
was performed as described in the previous section. The SPE method was adapted from 
Kim and Salem [167]. Briefly, extracted lipids were dissolved in 400 µl of chloroform. 
Subsequently, the total volume of chloroform was loaded onto equilibrated Bond Elut
®
-
NH2-columns. Thereafter, four elution steps were applied under vacuum using 4 ml of the 
following elution solutions:  
1. Chloroform : 2-propanol (2:1) mixture – elutes neutral lipids  
2. Diethylether containing 2% acetic acid - elutes free fatty acids  
3. Methanol - elutes neutral PL 
4. Hexane : 2-propanol : ethanol : 0.1 M ammonium acetate in water : formic acid 
(420:350:100:50:0.5) containing 5% phosphoric acid – elutes acidic PL 
Additionally, the acidic PL fraction was dried under nitrogen for 10 min to 
evaporate hexane, dissolved in 1 ml of water and was subsequently extracted three times 
using 1 ml of chloroform.  
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3.2.5 Phospholipid mass spectrometry  
 PL species were quantified by ESI-MS/MS using the mass spectrometer Quattro 
Ultima™ Triple Quadropole and an analytical setup and strategy described by Liebisch et 
al. [164, 166, 168]. A precursor ion scan of m/z 184 specific for phosphocholine-
containing lipids was used for phosphatidylcholine (PC), sphingomyelin (SPM) [166] and 
lysophosphatidylcholine (LPC) [164]. Neutral loss fragments were used for 
phosphatidylethanolamine 141 (PE) and phosphatidylserine (PS) 185 [169]. PE-based 
plasmalogen was analyzed according to method described elsewhere [170]. Ammonium-
adduct ions of phosphatidylglycerol (PG) and phosphatidylinositol (PI) were determined 
by neutral loss scans of m/z 189 and 277, respectively [171]. Ceramides (Cer) were 
measured as a product ion of m/z 264 [165]. Quantification was performed by calibration 
lines generated by addition of non-naturally occurring lipid species served as internal 
standards. Internal standards from the same lipid class were used to quantity all lipid 
classes. However, for SPM determination the PC internal standard was used, whereas the 
PE internal standards were taken as PE-based plasmalogens internal standards. Free 
cholesterol (FC) and cholesteryl ester (CE) were quantified using a fragment ion of m/z  
369. Correction of isotopic overlap of lipid species was performed by Excel Macros for all 
lipid classes according to the method described elsewhere [166]. PL quantification by ESI-
MS/MS was performed in Laboratory of Prof. Dr. med. G. Schmitz by Dr. rer. nat. G. 
Liebisch (Institute for Clinical Chemistry and Laboratory Medicine, University Hospital of 
Regensburg, Germany). 
3.2.6 ESI-MS/MS data correction 
 The quantitative values of all PL species were corrected for dilution of SF due to 
possible effusion induced by inflammation. For this purpose the concentrations of β-2-
microglobulin and urea were determined in SF samples in order to calculate a dilution 
factor for SF. 
3.2.6.1 Enzyme-linked immunosorbent assay for β-2-microglobulin 
 β2-microglobulin (β2-MG) levels in SF samples were measured using a 
commercially available enzyme-linked immunosorbent assay (ELISA) kit according to the 
instructions provided by the manufacturer. Briefly, 5 μl of standards, controls and samples 
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were pipetted into the wells of a 96-well microtiter plate coated with anti-β2-MG antibody, 
diluted with sample diluents and incubated for 30 min at 37°C, which was followed by five 
washing steps. After 30 min of incubation with enzyme conjugate reagent and repetitive 
washing, substrate solution was added to each well. After incubation for 20 min in the 
dark, the reaction was stopped by adding 100 µl of 1 N HCl. The optical density was 
measured at 450 nm using a microplate ELISA reader. The unknown samples values were 
calculated from the standard curve. The detection limit for β2-MG was 0.1 μg/ml. 
3.2.6.2 Urea determination 
 Urea concentrations in SF and serum samples were measured using commercially 
available QuantiChrom™ Urea Assay Kit. Determination was performed according to the 
manufacturer’s instructions. In brief, 5 μl of standards and samples were pipetted into the 
wells of a 96-well microtiter plate and 200 μl of chromogenic substrate was added. The 
assay detects urea directly by using o-phthalaldehyde that specifically binds urea and forms 
a coloured complex with primaquine diphosphate. After 20 min incubation at RT the 
optical density was measured at 520 nm using a microplate ELISA reader. The unknown 
urea concentrations of samples were calculated from the standard curve. The detection 
limit for urea was 0.08 mg/dl (13 μM).  
3.2.7 Culture of human fibroblast-like synoviocytes 
In order to investigate whether FLS synthesize and/or secrete PL, cells were 
isolated from synovial membrane and cultured under various cell culture conditions. 
3.2.7.1 Isolation of fibroblast-like synoviocytes 
 Isolation of FLS was performed according to the method previously described 
[172]. Briefly, synovial membrane was rinsed with sterile phosphate-buffered saline (PBS) 
and, using sterile technique, tissue containing blood vessels and fat were removed. Excised 
synovium was chopped with a surgical scalpel in < 1 mm
3
 pieces. The minced pieces were 
digested for 1 h at RT in PBS containing 1% dispase II. The cell suspension was filtered 
through a 70 μm-mesh cell strainer to obtain single cell suspension. Subsequently cells 
were collected by centrifugation at 300 x g for 10 min and plated into cell culture T-75 
flasks. FLS were cultured with 15 ml Dulbecco’s modified Eagle’s medium (DMEM) 
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supplemented with 10% FCS (heat inactivated), 1% penicillin/streptomycin and 1% 2-(-4-
2-hydroxyethyl)-piperazinyl-1-ethansulfonate (HEPES) in a humidified atmosphere of 5% 
CO2 at 37°C. To ensure the purity of isolated FLS, cells were morphologically 
characterised by light microscopy and verified by positive staining for fibroblast-specific 
antibody SM1214PS using fluorescence-activated cell sorting (FACS). Cells were 
harvested using EDTA/Trypsin and passaged into new T-75 flasks when attaining 80-90% 
confluency. All experiments were carried out with FLS from passage 3-6 to ensure stable 
phenotype and genotype of cultured FLS [172]. 
3.2.7.2 Effect of various cell culture conditions 
 In order to optimize cell culture conditions for synthesis and/or release of PL by 
FLS several different cell culture conditions were applied. Before each experiment cell 
culture media were tested for mycoplasma contamination using the PCR Mycoplasma Test 
Kit. Furthermore, cells were trypsinized, counted in a Neubauer chamber and the 
percentage of viable cells was calculated using the trypan blue method. Subsequently, cells 
were plated onto 6-well tissue culture dishes at a density of 80.000
 
cells/well. After cells 
reached 90% confluency, medium was exchanged and cells were starved in serum-free 
medium for 16 h. Subsequently medium was exchanged and cells were cultured for 24 h. 
In order to optimize synthesis and/or release of PL by FLS, the following cell culture 
conditions were investigated:  
1. Serum-free D-MEM medium supplemented with 1% penicillin/streptomycin and 
1% HEPES. 
2. Serum-free D-MEM medium supplemented with 1% ITS™+Premix, 1% 
penicillin/streptomycin and 1% HEPES. 
3. Serum-free D-MEM medium supplemented with 1% penicillin/streptomycin, 1% 
HEPES and dexamethasone of different concentrations (10
-9
 mol/ml – 10-3 mol/ml). 
4. Serum-free D-MEM medium supplemented with 1% penicillin/streptomycin, 1% 
HEPES. FLS were cultured in 6-well plates coated with 50µl/cm
2
 BD Matrigel™ 
Basement Membrane Matrix Growth Factor Reduced. 
5. Serum-free D-MEM medium supplemented with 1% penicillin/streptomycin, 1% 
HEPES. FLS were cultured in 4-well plates under shear stress conditions on 
horizontal shaker (5 rpm). 
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3.2.7.3 Preparation of cell culture media for MS analysis 
 After a culture period of 24 h, cell culture media from each well were collected and 
filtrated through a 0.22 µm syringe filters to obtain cell-free samples. After addition of 
10% (v/v) of PPI, samples were centrifuged for 45 min at 16.100 x g at RT in order to 
pellet MPs. Cell-, cell debris- and MPs-free supernatant were aliquoted, and stored frozen 
at -86°C until further analysis as described in sections 3.2.3 and 3.2.4. 
3.2.8 SF preparation for gel electrophoresis 
3.2.8.1 Hyaluronidase treatment 
 SF contains high concentrations of HA which can disturb analysis of surfactant 
proteins. In order to digest HA and to reduce the viscosity of SF samples, samples were 
incubated with 320 U/ml of hyaluronidase in a thermomixer for 1 h at 37ºC [109]. 
3.2.8.2 Albumin depletion 
 SF contains high concentrations of albumins which can disturb surfactant protein 
detection. In order to remove albumins from SF samples, SwellGel
®
 Blue Albumin 
Removal Kit was used according to the instructions provided by the manufacturer. Briefly, 
100 μl of SF was loaded onto hydrated SwellGel® Blue Disc. After 2 min incubation at RT, 
discs were centrifuged at 12.000 x g and then samples were re-applied onto a SwellGel
®
 
Blue Disc to repeat described procedure. In order to release unbound proteins other than 
albumins, 50 μl of washing buffer containing 25 mM Tris and 75 mM NaCl, pH 7.5, was 
loaded onto the SwellGel
®
 Blue Disc followed by 1 min centrifugation step at 12.000 x g. 
Samples free from albumins were collected for further analysis.  
3.2.8.3 Protein quantification 
 The concentrations of proteins in SF was first determined in order to calculate the 
volume of sample and thus the quantity of protein needed to perform a sodium dodecyl 
sulfate-polyacrylamide (SDS-PAGE) electrophoresis for separating of proteins according 
to their molecular weight. The concentrations of proteins in each sample are needed in 
order to load the same amount of proteins per lane as described in section 3.2.9. The 
concentrations of proteins in SF were spectrophotometrically determined using the 
Bradford dye reagent [173]. The protein assay is based on the colour change of Coomassie 
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Brilliant Blue G-250 dye after binding to proteins. The dye binds non-covalently primarily 
to basic and aromatic amino acids residues. 10 µl of sample was mixed with 200 µl of dye 
reagent and transferred to a 96-well plate. Bovine serum albumin (BSA) was used as the 
protein standard in a concentration range of 0.1-1 µg/μl. Standards were mixed with the 
dye reagent in the same ratio as the samples of unknown concentrations. The reaction 
mixtures were incubated for 15 min at RT. The absorbance of the samples was measured at 
570 nm. The unknown amount of samples protein was calculated from the standard curve.  
3.2.9 Separation of proteins with gel electrophoresis 
 In order to separate proteins according to their size SDS-PAGE electrophoresis was 
performed. SF, HA-free SF and albumin-free SF samples were reduced by adding 10% β-
mercaptoethanol and denatured by heating at 95°C for 10 min in 2x Sodium dodecyl 
sulfate (SDS)-loading buffer. 50 μg of proteins was loaded onto the gel as described 
elsewhere [174]. Precision Plus Protein™ Standards was used as a molecular weight 
marker with range of 10-250 kDa. Separation of proteins was performed in the gel 
consisting of 5% stacking gel and 10% or 15% resolving gel (Table 2.4). Electrophoresis 
was carried out in 1x SDS-running buffer with constant 100 V until the bromophenol blue 
reached the bottom of the resolving gel. 
Component Stacking gel 5% 
Resolving gel 
10% 
Resolving gel 
15% 
Aqua B. Braun  6.46 ml - 3.21 ml - 6,46 ml - 
acrylamide:bisacrylamide 
Rotiphorese
®
 Gel 30 
1.33 ml 5% 3.3 ml 10% 1.33 ml 15% 
10% SDS 100 μl 0.1 % 100 μl 0.1 % 100 μl 0.1 % 
Resolving gel solution, pH 8.8    - - 3.33 ml - 3.33 ml - 
Stacking gel solution, pH 6.8 2 ml - - - - - 
10% APS 100 μl 0.1 % 50 μl 0.05% 50 μl 0.05% 
TEMED 10 μl 0.01 % 10 μl 0.01 % 10 μl 0.01 % 
       Table 2.4. 10 ml SDS-gel mixtures [175]. 
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3.2.10 Western blot 
Using specific antibodies Western blot were obtained in order to proof whether SP-
A and SP-D proteins are present in SF. 
3.2.10.1 Protein blotting 
Proteins separated on SDS-PAGE were transferred to polyvinylidene fluoride 
(PVDF) membrane using the semi-dry transfer technique according to the instructions 
provided by manufacturer. The PVDF membrane was activated by dipping in methanol 
before used. Electro blotting was performed using a semi-dry system and a transfer buffer 
pH 8.0 at a constant current of 2 mA/cm
2
 for 90 min.  
3.2.10.2 Protein detection  
 The membranes were blocked in blocking solution pH 7.5 at RT for 1 h followed 
by incubation with the primary antibody at 4°C overnight. Primary antibody concentrations 
varied depending on the antibody used in the experiment (Table 2.5). Membranes were 
washed three times for 10 min using 1 x TBS/T pH 7.5. Membranes were incubated with 
the respective horseradish peroxidase-labeled secondary antibody for 2 h at RT (Table 2.6), 
and then washed again four times for 15 min with 1 x TBS/T. Proteins were detected using 
Enhanced Chemiluminescence (ECL) Plus Kit
®
 followed by exposure of the membrane to 
an ECL film lying in the X-ray cassette. Bands were then visualized by dipping the ECL 
film into the X-ray developer and fixation solution.  
 
Target Host Dilution Description Company 
Surfactant protein A (SP-A) Mouse 1:500 monoclonal Dako 
Surfactant protein A (SP-A) Rabbit 1:20000 polyclonal Chemicon 
Surfactant protein A (SP-A) Mouse 1:2000 monoclonal Abcam 
Surfactant protein B (SP-B) Rabbit 1:500 polyclonal Millipore 
Surfactant protein C (SP-C) Goat 1:2500 polyclonal Nycomed 
Surfactant protein D (SP-D) Mouse 1:1000 monoclonal Abcam 
      Table 2.5. Primary antibodies used in the study. 
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Antibody Host Dilution Company 
HRP-conjugated                   
anti-mouse IgG 
Rabbit 1:2000 Dako 
HRP-conjugated                     
anti-rabbit IgG 
Swine 1:2000 Dako 
HRP-conjugated                  
anti-goat IgG 
Rabbit 1:2000 Dako 
      Table 2.6. Secondary antibodies used in the study. 
3.2.11 Two-dimensional gel electrophoresis 
 To investigate whether protein bands obtained by Western blots are indeed the 
proteins of interest, 2-D gel electrophoresis was performed to separate proteins according 
to size and isoelectric point (PI). 400 μg protein from SF were applied on immobilized pH 
gradient (IPG) strips and isoelectric focusing was performed with 32.05 kVh followed by 
equilibration. For the second dimension IPG strips were placed on top of 12.5% SDS-
PAGE gel and electrophoresis was carried out with the following program: 15 min at 15 
mA/gel followed by 5 h at 110 mA at 25°C. Gels were stained with Coomassie brilliant 
blue R-250. 2-D gel electrophoresis was done in the laboratory of Prof. Dr. rer. nat. G. 
Lochnit (Protein Analytics, Department of Biochemistry, Justus-Liebig-University of 
Giessen, Germany). 
3.2.12 Protein identification (MALDI-TOF)  
 The two 2-D gel electrophoreses with the same sample were run in parallel. 
Subsequently, one gel was blotted and Western blot was performed in order to visualise 
spots detected by specific antibodies. Simultaneously, the second gel was stained with 
Coomassie blue. The gels were compared and spots detected by the antibodies were 
localised on the Coomassie blue stained gel and excited with the ExQuest
®
 spot cutter. 
Further, proteins within the spots were digested with trypsin on a liquid handling automatic 
system. In order to identify proteins present in excised spots, Matrix-Assisted Laser 
Desorption Ionization Time-Of-Flight Mass Spectrometry (MALDI-TOF-MS) of the in-gel 
tryptic digests was applied. MALDI-TOF-MS was performed on an Ultraflex™ I 
TOF/TOF mass spectrometer with a nitrogen laser. The instrument was operated in the 
positive-ion (reflectron) mode using 2.5-dihydroxybenzoic acid and methylendiphosphonic 
acid as a matrix (5 mg/ml each in 0.1% trifluoroacetic acid). Sum spectra consisting of 
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200-400 single spectra were acquired. For data processing and instrument control the 
Compass 1.1 software package was used. Proteins were identified by peptide mass 
fingerprint search using the MASCOT search machine and human IPI database 
(International Protein Index, version 3.61). All 2-D gels, in-gel digestions and mass 
spectrometric analyses were performed by Prof. Dr. rer. nat. G. Lochnit (Protein Analytics, 
Department of Biochemistry, Justus Lieblig University of Giessen, Germany). 
3.2.13 RNA isolation 
 Total RNA was isolated from synovial membranes, cartilage, FLS and cells present 
in SF to perform reverse transcription and PCR reactions in order to investigate whether 
sp-a and sp-d genes are expressed at least on the mRNA level. 
3.2.13.1 RNA isolation from synovial tissue and cells 
 Total RNA was isolated from both synovial membrane and cells according to the 
manufacturer’s instruction provided with peqGOLD TriFast™. For tissue extraction, 100 
mg of synovial membrane was used. FLS were extracted by addition of 1 ml of TriFast™ 
reagent per 10 cm
2
 area of culture dish where cells reached 90% confluency. The number 
of cells used to isolate RNA was approximately 800.000/T75 flask. After 5 min of 
incubation on ice, samples were collected into 1.5 ml tubes. Subsequently, 0.2 ml 
chloroform was added to the samples, mixed, kept for 10 min at RT and were then 
centrifuged with 12.000 x g for 30 min at 4°C. The aqueous phase was transferred to a 
fresh tube, mixed with 0.5 ml of 2-propanol, incubated for 15 min on ice and again 
centrifuged with 12.000 x g for 10 min at 4°C. The supernatant was removed, the 
precipitated pellet containing RNA was washed with 500 µl of 75% ice-cold ethanol and 
centrifuged again with 7.500 x g for 8 min at 4°C. Washing and centrifugation steps were 
repeated twice. Obtained RNA pellet was resuspended in RNase-free water. DNA 
contaminations were removed using DNase I Kit. Concentration and purity of obtained 
RNA was determined spectrophotometrically at 260 nm and 280 nm wavelengths and the 
260/280 ratio was calculated. Samples containing pure RNA with a 260/280 ratio between 
1.8 and 2.0 were used for further analysis. 
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3.2.13.2 RNA isolation from cartilage 
 Several different RNA isolation methods were used to obtain the highest amount 
and quality of cartilage RNA. Isolation of total RNA from 100 mg pulverized cartilage was 
performed according to the manufacturer’s instructions provided with peqGOLD 
TriFast™, peqGOLD Total RNA Kit or RNAqueous™ Ambion Midi Kit. RNA was 
resuspended or eluted with RNase-free water, respectively. DNA contaminations were 
removed using DNase I Kit. Concentration and purity of obtained RNA was determined 
spectrophotometrically at 260 nm and 280 nm wavelength and the 260/280 ratio was 
calculated. Samples containing pure RNA with a 260/280 ratio between 1.8 and 2.0 were 
used for further analysis. 
3.2.14 Reverse transcription reaction 
 In order to perform a reverse transcription polymerase chain reaction (RT-PCR) 1 
µg isolated RNA was used and RNase-free water was added resulting in a final volume of 
16.12 µl [176]. The RNA was heated in a thermomixer at 70°C for 5 min, immediately 
transferred onto ice, and then pre-mixed RT-PCR components (Table 2.7) were added. The 
total reaction volume was 25 μl. 
To synthesize complementary DNA (cDNA), the reaction mixture was incubated in 
a PCR thermocycler at 40°C for 10 min, then at 43°C for 50 min and further heated to 
94°C for 5 min to inactivate the enzyme. The obtained 25 µl of cDNA was then either used 
for PCR or stored frozen at -20°C until used. 
 
RT-PCR components Volume Final concentration 
5 x Reaction buffer 
 
5 µl 1x 
10 mM dNTP mix 1.25 µl 0.5 mM 
Oligo(dt)15 
Primer (500 μg/ml) 
1 µl 0.02 μg/μl 
RNase inhibitor (20 U/µl) 0.63 µl 0.504 U/μl 
M-MLV reverse 
transcriptase (50 U/µl) 
1 µl 2 U/μl 
RNase-free water up to 25 µl  
           Table 2.7. The RT-PCR mixture. 
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3.2.15 Semi-quantitative polymerase chain reaction  
 A semi-quantitative polymerase chain reaction (PCR) was performed according to 
the manufacturer’s instructions provided with the GoTaq® Flexi DNA Polymerase Kit. The 
PCR reaction was prepared as described in table 2.8. 
PCR components Volume Final concentration 
5 x Reaction buffer 
(free MgCl2) 
10 µl 1x 
25 mM MgCl2 3 µl 1.5 mM 
10 mM dNTP mix 1 µl 0.2 mM 
100 μM forward primer 2 µl 4 μM 
100 μM reverse primer 2 µl 4 μM 
Taq DNA Polymerase  
(5 U/µl) 
0.25 µl 0.025 U/μl 
cDNA template 2 µl  
RNase-free water up to 50 µl  
           Table 2.8. The PCR mixture. 
 
The PCR components were mixed on ice and transferred to a PCR-thermocycler.  
Using the following program the cDNA was amplified:  
 
PCR step Time Temperature 
First denaturation 2 min 95°C 
Annealing 0.5 min 55-58°C* 
Elongation 0.5 min 72°C 
Second denaturation 1 min 95°C 
Final extension 5 min 72°C 
           Table 2.9. The PCR cycle program.  
* Annealing temperature varied depending on the primers used and was provided by the 
manufacturer (Table 2.10). 
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 The PCR steps were repeated 30-33 cycles depending on the amplified sequence to 
obtain appropriate amount of product. The number of cycles was suggested by the 
manufacturer who provided the primers. Amplicons were stored either at -20°C or 
immediately separated according to amplicon size by the agarose gel electrophoresis and 
visualized using GelRed
™
 Prestaining Kit as described in section 3.2.16.  
GeneBank™ 
Accesion (NCBI) 
Forward Primer 
(5’-3’) 
Reverse Primer 
(5’-3’) 
Annealing 
temperature 
[°C] 
Amplicon 
size (bp) 
NM_005411        
SP-A 
ATCTAGATGAGGA
GCTCCAAG 
CCTCAGTCAGGCCT
ACATAGG 
56 270 
NM_003019         
SP-D 
CCACAGAACAATG
CCCAGTG 
TTGCCCTGAGGTCC
TATGTTC 
55 321 
NM_002046 
GAPDH 
CCTCAAGATCATCA
GCAATGCCTCCT 
GGTCATGAGTCCTT
CCACGATACCAA 
58 355 
Table 2.10. Primers used to determine the expression of sp-a and sp-d genes [175]. 
3.2.16 DNA agarose gel electrophoresis 
 Agarose gel electrophoresis was performed in order to separate and visualise DNA 
amplicon obtained by PCR according to size and to visualize possible primer dimers. The 
experiments were performed in order to detect whether the bp size of bands for sp-a and 
sp-d genes are appropriate and thus, whether those genes are expressed in analyzed cells 
and tissues. 1% agarose gels were used. Agarose was mixed with 1x GelRed™ running 
buffer. The DNA samples were mixed with 6x GelRed™ loading buffer containing DNA 
intercalating fluorescent dye GelRed™, that enables visualization of the DNA fragments 
under ultraviolet light. Electrophoresis was performed in horizontal electrophoresis 
chamber at 75 V in 1x GelRed™ running buffer for 1 h. The size of amplified DNA was 
determined by a 100 bp DNA molecular size marker (range 100-1000 bp).  
 
 
 
 
 
Material and Methods 
52 
 
3.2.17 Statistical analysis of data 
 The non-parametric tests were chosen, since a non-Gaussian distribution of all data 
presented here was assumed. Statistical significant differences of PL concentrations were 
determined using the Kruskal-Wallis test. In order to determine statistical significance 
without possible type I error, adjustment for multiple testing in the series of Kruskal-Wallis 
tests was done by applaying the false discovery rate (FDR) being 10%. Kruskal-Wallis 
tests subsequently combined with the FDR were performed using the online available 
statistical software R version 2.14.0 (www.r-project.org). 
The results obtained with the Kruskal-Wallis tests adjusted with FDR were further 
analysed using the paired Wilcoxon signed-rank test to determine statistical significant 
differences in median of PL species concentrations between all investigated groups 
(human: healthy SF vs. OA early SF vs. OA late SF vs. RA SF; dogs: healthy SF vs. OA 
SF; distraction experiment: OA group vs. frame group vs. distraction group; species 
dependency: human SF vs. canine SF vs. equine SF). P-value of less than 0.05 was 
considered statistically significant with: * 0.01<p≤0.05; ** 0.001<p≤0.01; *** p<0.001. 
The paired Wilcoxon signed-rank test was performed using the statistical software R. 
Spearmanꞌs correlation and linear regression were used to determine the coefficient 
of determination (R
2
). R
2 
was calculated in order to correlate (a) the volume of SF with 
concentrations of β-MG, (b) the concentrations of urea in SF with those in serum and, (c) 
the concentrations of PL classes with the time period post-mortem. Spearmanꞌs correlation 
and linear regression were performed using the commercially available software Prism 5.2 
(GraphPad Inc., San Diego, USA).  
Data are presented as a mean ± SD for bars graphs. The notched boxplots show 
whiskers extending to the minimum and maximum values with circles indicating outliners 
and 95% confidence intervals for the median. Presented bars graphs were produced using 
Prism 5.2 software. Moreover, all PL species were analysed individually and graphed as 
notched boxplots (presented notched boxplots are shown as an example). The notched 
boxplots were generated with statistical software R. 
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4. Results 
4.1 Estimation of undiluted SF volume  
In order to eliminate unknown dilution of SF that might occur during effusion 
induced by inflammation and to normalise quantitative data obtained from ESI-MS/MS, 
we were searching for a method to correct our results. For this purpose two independent 
methods were tested. First using β2-MG concentrations in SF samples and second using 
urea concentrations in SF and serum samples obtained from the same patient. 
4.1.1 ELISA for β2-microglobulins 
 Β2-microglobulins (β2-MG) concentrations were determined in 68 OA SF samples 
using a commercially available ELISA kit. To test whether there is a correlation between 
β2-MG level and volume of aspirated SF, β2-MG concentrations were plotted against the 
corresponding volume of SF. We found no correlation between β2-MG level and total 
volume of SF (Figure 4.1). Concentrations of β2-MG were in the range of 0.05 and 5.3 
µg/ml and those values were independent from the respective total volume of SF. 9 
different SF samples had a volume of 12 ml, however, concentrations of β2-MG varied in 
those samples between 0.4-4.45 µg/ml. This result suggests that the concentration of β2-
MG is not a suitable factor to correct for any dilution of SF.  
 
. 
 
 
 
 
Figure 4.1. Correlation between β2-MG concentrations and corresponding total volume of 
SF. Variable volumes of SF were obtained from 68 OA patients. Β2-MG concentrations were 
measured using a commercially available ELISA kit. R
2
: a linear regression analysis was 
performed to determine the coefficient of determination. Β2-MG: β2-microglobulins.   
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4.1.2 Urea concentration in serum and SF 
Since several studies already [177-179] suggested that the use of urea 
concentrations is an appropriate method to compensate for variations of SF due to effusion, 
levels of urea in SF and serum samples were determined using a commercially available 
QuantiChrom™ Urea Assay Kit. This assay detects urea directly by using o-
phthalaldehyde that specifically binds urea and forms a coloured complex with primaquine 
diphosphate. Optical density was measured at 520 nm using a microplate ELISA reader. 
Subsequently, urea concentrations in SF were plotted against the corresponding urea 
concentrations in serum according to the method described by Kraus et al. [177] 
Correlation was subsequently calculated between the concentrations of urea in SF 
and those in serum obtained from the same patient (Figure 4.2). In our samples more urea 
was found in the serum samples compared to SF samples. The dilution factors for all OA 
and RA SF samples were calculated following previously reported protocols, also applied 
by Kraus et al. to correct dilution of SF [177-178]. The formula to calculate the dilution 
factor was as follow: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Correlation between SF and serum urea concentrations. Urea concentrations were 
determined in 39 SF samples from early stage of OA with a total volume not being higher than 2.5 
ml, which is assumed to be normal, and in 39 serum samples obtained from the same patients. Urea 
concentrations were determined using commercial available QuantiChrom™ Urea Assay Kit. R2: a 
linear regression analysis was performed to determine the coefficient of determination. 
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Our results are similar to the data reported [177-178], therefore in the present study 
quantitative values of PL obtained from ESI-MS/MS analysis could be normalised using 
the urea method. 
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Figure 4.3. Comparison of the concentrations of PL classes between non-corrected and corrected 
values. The different PL classes were quantified by ESI-MS/MS for 9 healthy SF, 19 OA SF from 
early stage, 14 OA SF from late stage and 18 RA SF. Presented PLs are phosphatidylcholine (PC), 
lysophosphatidylcholine (LPC), phosphatidylethanolamine (PE), PE-based plasmalogen (PLPE), 
sphingomyelin (SPM) and ceramides (Cer). Data are presented as mean ± SD of concentrations of PL 
classes [nmol/ml].  “Non-corrected”-values before correction. “Corrected”-values after correction for 
possible dilution using the dilution factor (DF) obtained by the determination of the urea 
concentrations. OA-osteoarthritis, RA-rheumatoid arthritis. 
 
The quantitative values of all PL classes and individual species obtained from ESI-
MS/MS were normalised using the calculated dilution factor derived from concentrations 
of urea in SF and serum. As Figure 4.3 presents, concentrations of PL classes in SF from 
late stage of OA are higher after normalisation due to possible dilution using the dilution 
factor obtained by the determination of the urea concentrations as compared to the non-
corrected values. However, analysis of PL species in individual patients revealed that in 
certain cases the determined concentrations were several fold higher after correction, and 
in other cases we did not observe any differences between corrected and non-corrected 
values.  
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4.2 Analysis of PL composition of human SF 
The composition of PL species in human SF and their role in the development of 
diarthrodial joint diseases are currently largely unknown. There are only several studies 
which focused on this aspect and not much is known about composition and the 
physiological and pathophysiological role of PL in the normal and OA joints.  
4.2.1 Phospholipid content in healthy SF from human cadavers 
Healthy, normal SF was obtained from 15 human cadavers with healthy joints. 
Samples were aspirated from knee joints within several hours until 5 days after death. In 
order to confirm that PL composition in SF is stable until 5 days after death, concentrations 
of all PL classes were plotted against this time period. Figure 4.4 demonstrates that 
concentrations of PL classes remained unchanged. The correlation coefficient of all 
investigated PL classes indicates that PLs are stable until 5 days post-mortem. In addition, 
similar analysis was performed for the main individual PL species (e.g. PC 34:2, PC 38:4, 
LPC 16:0, LPC 18:2, PE 36:2, SPM 16:0, SPM 24:1, Cer 24:0). As expected, no changes 
were identified (data not shown).  
4.2.2 Composition of PL in microparticles present in human SF 
Extracellular membrane vesicles with diameter of 200-1000 nm, in literature also 
often called MPs, are present in SF and contain cell membranes composed out of PLs. In 
order to distinguish between PLs, which are a part of MPs and free, extracellular PLs, MPs 
were isolated from 10 healthy SF, 19 OA SF from early stage, 14 OA SF from late stage 
and 18 RA SF. Subsequently, ESI-MS/MS analysis was performed for cell- and cell 
debris-free SF, cell-, cell debris- and MPs-free SF and isolated MPs. As presented in Table 
4.1, no statistical significant difference could be identified between cell- and cell debris-
free SF (total SF) and cell-, cell debris- and MPs-free SF (supernatant) for all groups of 
interest. MPs contain PLs, however, the determined concentrations were low. This is also 
reflected for all PL classes with the exception of PS where the highest concentration was 
detected in MPs (Table 4.2). Based on these data, our further analyses were performed 
using cell-, cell debris- and MPs-free SF (further named “SF”) to determine only the 
extracellular PLs which may serve as boundary lubricants.   
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Figure 4.4. Correlation between the concentrations of PL classes and time period post-
mortem. The different PL classes were quantified in 10 SF samples obtained from human cadavers 
by ESI-MS/MS. Panel A shows phosphatidylcholine (PC), sphingomyelin (SPM) and 
lysophosphatidylcholine (LPC), and panel B shows phosphatidylethanolamine (PE), PE-based 
plasmalogen (PLPE), phosphatidylserine (PS), phosphatidylglycerol (PG), and ceramide (Cer). R
2
: 
a linear regression analysis was performed to determine the coefficient of determination. 
 
 
 
 
 PC SPM LPC 
R
2
 0.25 0.39 0.0021 
 PE PLPE PS PG Cer 
R
2
 0.044 0.0049 0.23 0.0064 0.045 
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Table 4.1. Total PL content in SF fractions as dependent on the health status of joints. 
  
Total SF [nmol/ml] 
 
Supernatant  [nmol/ml] 
 
MPs [nmol/ml] 
 
Healthy 273.0 (142.6-569.2) 213.4 (102.5-354.7) 126.5 (45.8-226.5) 
OA-early stage 597.4 (174.2-1214.8) 556.5 (65.3-1505.3) 294.8 (54.2-730.5) 
OA-late stage 1029.9 (375.4-2270.3) 1072.3 (336.8-2612.0) 429.2 (54.5-1147.5) 
RA 639.3 (247.8-1006.7) 731.0 (307.7-1178.2) 577.0 (165.2-1397.8) 
The total PL content was determined by ESI-MS/MS in 9 healthy SF, 19 OA SF from early stage, 
14 OA SF from late stage and 18 RA SF. All values were corrected for possible dilution using the 
dilution factor (DF) obtained by determination of the urea concentrations. Data are presented as 
mean concentrations, range of data in parentheses. MPs-microparticles, OA-osteoarthritis, RA-
rheumatoid arthritis. 
 
4.2.3 Composition of PL classes in human SF 
To investigate potential changes in the concentrations of PL classes in SF, lipids 
were isolated from 10 healthy SF, 19 OA SF from early stage, 14 OA SF from late stage 
and 18 RA SF. Subsequently, ESI-MS/MS analysis was performed for cell-, cell debris- 
and MPs-free SF. Analysed PL classes were as followed: PC, LPC, PE, PLPE, PI, PG, PS, 
SPM and Cer. All the data presented in this study represent one experiment. However, the 
reproducibility of the data was tested by a second independent analysis using a different 
batch of samples, performed at a different time point with newly calibrated instrument 
settings and other preparation of internal standards. Statistical analysis of the second 
analysis is summarised in Table 6.2. A lower number of statistical significant differences 
were found in the second analysis as compared to first one, however, the trends of changes 
were in both analyses mostly the same indicating good reproducibility. 
The composition of PL classes showed low variations between different groups of 
patients and a characteristic pattern was observed for all SF samples (Figure 4.5 B). As 
expected, PC was the most abundant PL present, accounting for to 65% of all PLs present. 
The concentration of PC lied in the range of 135.3 nmol/ml for healthy SF and 735.5 
nmol/ml for late stage of OA. However, PG and PS were detected in very low 
concentrations. Moreover, PC, PE, PLPE, SPM and Cer were increased in SF from late 
stage of OA as compared to healthy SF (Figure 4.5 A). Determined concentrations in SF 
from late stage of OA were increased 543.5 ± 346.5% for PC, 289.1 ± 194.3% for PE, 
337.3 ± 241.4% for PLPE, 447.3 ± 274.5 for SPM, and 376.2 ± 279.7% for Cer as 
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compared to healthy SF (=100%). Remarkably, PS is the only PL class with a higher 
proportion in healthy SF and SF from early stage of OA as compared to SF from late stage 
OA and RA (Figure 4.5 B).   
In addition, the ratios of PL classes were calculated. As illustrated in Figure 4.6 and 
Table 6.1, PC/LPC ratio as well as SPM/Cer ratio did not differ between the groups with 
different health status of the joints. Interestingly, PC/PS ratio and PE/PS ratio appear on 
the highest level in SF from early stage of OA as compared to all others investigated 
groups. 
4.2.4 Composition of PL species in human SF 
The decision to determine all individual PL species present in SF, and subsequently 
to address questions concerning metabolism and possible functions of individual PL 
species in health and OA, was based on the fact, that there is no detailed study showing PL 
species composition of human SF until now. It is known, that functions and properties of 
PL species also depend on the chain length and number of double bounds present in FA. 
Therefore, a method using ESI-MS/MS was applied, since this technology enables the 
quantitative determination of all PL species being present in human SF.  
PC, PE, PG, PI and PS classes contain two FA. It is important to note, that mass 
spectrometry analysis used allows only to determinate the sum of carbon atoms and double 
bonds present in both FA. Thus, for instance a PE 38:4 may represent different 
combinations of FA such as 18:0/20:4, 16:0/22:4, etc.  
All the PL species were analysed individually and graphed as notched boxplots 
which show 95% confidence intervals for the median as presented in Figure 4.7. However, 
presentation of all determined PL species would be beyond the allowed volume of this 
thesis, thus only randomly chosen species of PC are presented individually as notched 
boxplots in order to illustrate statistical method applied. Statistical significant changes of 
all individual PL species found between all investigated groups are summarised in Table 
4.4.   
As shown in Figure 4.8 and Table 4.3, PC in SF was present mostly in highly 
polyunsaturated form of PC characterised by the presence of three of more double bounds. 
Unsaturated DPPC, the most abundant compound of the surfactant system in the lung (PC 
32:0), was present in very low concentration in OA (3% of all PC). Moreover, healthy SF 
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contains higher percentage of saturated PC, however, statistical analysis revealed no 
significant differences between SF from joints with different health status (Table 4.3). 
 
Table 4.2. PL classes in SF fractions as dependent on the health status of joints. 
Healthy (n=9) 
Fraction PC 
[nmol/ml] 
LPC 
[nmol/ml] 
PE 
[nmol/ml] 
PLPE 
[nmol/ml] 
PS 
[nmol/ml] 
PG 
[nmol/ml] 
SPM 
[nmol/ml] 
Cer 
[nmol/ml] 
Total SF 168.1 26.0 5.5 11.1 1.9 1.3 56.9 2.1 
Supernatant 135.3 22.2 4.5 8.6 0.4 2.4 39.2 1.9 
MPs 62.2 9.7 8.8 14.0 7.1 2.4 19.8 2.6 
OA early (n=19) 
Fraction PC 
[nmol/ml] 
LPC 
[nmol/ml] 
PE 
[nmol/ml] 
PLPE 
[nmol/ml] 
PS 
[nmol/ml] 
PG 
[nmol/ml] 
SPM 
[nmol/ml] 
Cer 
[nmol/ml] 
Total SF 393.5 64.0 8.0 16.3 0.6 1.0 104.9 4.0 
Supernatant 371.6 62.0 7.5 14.6 0.07 0.9 90.9 3.5 
MPs 186.5 36.2 6.9 12.2 0.5 1.8 46.6 2.9 
OA late (n=14) 
Fraction PC 
[nmol/ml] 
LPC 
[nmol/ml] 
PE 
[nmol/ml] 
PLPE 
[nmol/ml] 
PS 
[nmol/ml] 
PG 
[nmol/ml] 
SPM 
[nmol/ml] 
Cer 
[nmol/ml] 
Total SF 695.9 97.7 13.6 29.9 1.6 3.8 176.3 7.8 
Supernatant 735.5 106.1 13.1 29.1 0.3 1.8 175.4 7.1 
MPs 272.6 48.6 11.6 21.6 1.3 3.2 66.8 4.5 
RA (n=18) 
Fraction PC 
[nmol/ml] 
LPC 
[nmol/ml] 
PE 
[nmol/ml] 
PLPE 
[nmol/ml] 
PS 
[nmol/ml] 
PG 
[nmol/ml] 
SPM 
[nmol/ml] 
Cer 
[nmol/ml] 
Total SF 415.6 34.1 8.3 14.7 3.0 0.3 109.5 13.7 
Supernatant 526.8 45.2 9.1 16.3 1.4 0.3 126.4 5.3 
MPs 354.1 28.8 14.4 45.7 31.5 1.3 92.8 8.3 
The different PL classes were quantified by ESI-MS/MS for 9 healthy SF, 19 OA SF from early 
stage, 14 OA SF from late stage and 18 RA SF. Presented PLs are phosphatidylcholine (PC), 
lysophosphatidylcholine (LPC), phosphatidylethanolamine (PE), PE-based plasmalogen (PLPE), 
phosphatidylserine (PS), phosphatidylglycerol (PG), sphingomyelin (SPM) and ceramides (Cer). 
Data are presented as mean of concentrations [nmol/ml]. All values were corrected for possible 
dilution using the dilution factor (DF) obtained by the determination of the urea concentrations. 
MPs-microparticles, OA-osteoarthritis, RA-rheumatoid arthritis. 
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Figure 4.5. Synovial fluid PL classes composition. The different PLs were quantified by ESI-
MS/MS. The data shown represent (A) the quantitative values corrected for possible dilution using 
the dilution factor (DF) obtained by the determination of the urea concentrations and (B) the 
percentages of the respective PL class of all analysed PLs (=100%). Presented PLs are 
phosphatidylcholine (PC), lysophosphatidylcholine (LPC), phosphatidylethanolamine (PE), PE-
based plasmalogens (PLPE), phosphatidylserine (PS), phosphatidylglycerol (PG),  sphingomyelin 
(SPM), and ceramide (Cer). Values represent mean ± SD of concentrations of PL classes. OA-
osteoarthritis, RA-rheumatoid arthritis. 
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Figure 4.6. Ratios of PL classes in all four groups of patients. The different PL classes were 
quantified by ESI-MS/MS for 9 healthy SF, 19 OA SF from early stage, 14 OA SF from late stage 
and 18 RA SF. The quantitative values of PL classes presented in Figure 4.5 B were used to 
calculate ratios. The notched boxplots show 95% confidence intervals for the median. Circles 
indicate outliners. Statistical analysis is summarised in Table 6.1. PC-phosphatidylcholine, LPC-
lysophosphatidylcholine, PE-phosphatidylethanolamine, PS-phosphatidylserine, PLPE-
phosphatidylethanolamine-based plasmalogen, SPM-sphingomyelin, Cer-ceramides, OA-
osteoarthritis, RA-rheumatoid arthritis.  
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The main LPC species present was LPC 16:0 with a concentration range lying 
between 9.2 nmol/ml and 29.2 nmol/ml. According to the carbon number, the most 
abundant group present was the FA chain with 18 C-atoms covers 40.4-55.1% of total 
LPC. Most of the LPC species were detected in higher concentrations in arthritic SF when 
compared to healthy SF (Figure 4.9 B). For instance, concentrations of the main LPC 
species increased up to 290.1 ± 153.1% in early OA, 545.1 ± 301.5% in late OA and 297.1 
± 143.4% in RA SF for LPC 16:0, 407.5 ± 277.5% in early OA, 713.4 ± 420.4% in late OA 
and 419.8 ± 256.9% in RA SF for LPC 18:0, 228.7 ± 113.6% in early OA, 374.5 ± 201.2% 
in late OA and 217.8 ± 104.5% in RA SF for LPC 18:1, 246.2 ± 132.7% in early OA, 
337.6 ± 204.7% in late OA and 204.9 ± 104.3% in RA SF for LPC 18:2, and 204.1 ± 
111.2% in early OA, 294.4 ± 146.2 in late OA and 181.7 ± 89.8% in RA SF for LPC 20:4, 
when compared to healthy SF (=100%). 
Similarly to PC, PE species were present mostly in polyunsaturated form (Figure 
4.10, Table 4.3). Interestingly, ether-phosphatidylethanolamine (PE O 40:3) was decreased 
to 60.8 ± 5.1% in RA SF as compared to SF from late stage of OA (=100%).  
As Figure 4.11 demonstrates, 39 individual PLPE species were detected. The species 
were further divided into three groups according to the number of C-atoms and double 
bounds of the first FA. Similar distribution, dependent on the composition of the second 
FA was observed in all three groups of PLPE species (Table 4.3). Moreover, detected 
concentrations of those species were similar in all groups and also dependent from the 
composition of the second FA. 
PI 38:4 was the dominant PI species determined in all analysed samples covers 49.4 
± 5.3 % of total PI. Almost all of the PI species were present in increased concentrations in 
both OA SF groups as compared to other healthy SF (Figure 4.12 A). Observed increases 
in the concentrations were as follow, 186.2 ± 65.9 % in early OA and 211.6 ± 117% in late 
OA SF for PI 36:4, 204 ± 80.5 % in early OA and 229.7 ± 102% in late OA for PI 38:3,  
205.4 ± 76.1 % in early OA and 243.7 ± 115% in late OA SF for PI 38:4, and 168.1 ± 61.2 
% in early OA and 182.3 ± 116%  in late OA SF for PI 38:5, when compared to healthy SF 
(=100%).  
As expected, there was a significant increase of most of Cer species in OA late and 
RA SF including Cer 16:0, Cer 22:0, Cer 23:0, Cer 24:1 and GluCer 24:1 (Figure 4.12 B). 
Determined concentrations increased up to 296.7 ± 187.6 % in late OA and 197.8 ± 
136.6% in RA SF for Cer 16:0, 395.5 ± 332.8 % in late OA and 246.2 ± 128.4% in RA SF 
for Cer 22:0,  390.6 ± 341.5 % in late OA and 246.4 ± 133.7% in RA SF for Cer 23:0, 
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322.2 ± 219.1 % in late OA and 210.2 ± 95% in RA SF for Cer 24:1, and 329.8 ± 224.4 % 
in late OA and 213.4 ± 130.6% in RA SF for GluCer 24:1,when compared to healthy SF 
(=100%). 
Table 4.3. Distribution of saturated and unsaturated PL species according to FA saturation 
status in a chosen PL class. 
Phosphatidylcholine (PC) Healthy OA-early OA-late RA 
Saturated 6.3 ± 5.1% 4.4 ± 0.9% 3.6 ± 1.2% 3.1 ± 1.2% 
Unsaturated 86.0 ± 5.6% 88.9 ± 1.8% 90.1 ± 1.8% 90.7 ± 2.2% 
Ratio (Saturated/Unsaturated) 0.078 ± 0.074 0.049 ± 0.011 0.040 ± 0.014 0.035 ± 0.014 
Lysophosphatidylcholine (LPC) Healthy OA-early OA-late RA 
Saturated 55.5 ± 2.7% 60.8 ± 5.3% 67.1 ± 3.2% 72.0 ± 4.0% 
Unsaturated 44.5 ± 2.7% 39.2 ± 5.3% 32.9 ± 3.2 % 28.0 ± 4.0 % 
Saturated/Unsaturated 1.3 ± 0.1 1.6 ± 0.4 2.1 ± 0.3 2.6 ± 0.5 
Phosphatidylethanolamine (PE) Healthy OA-early OA-late RA 
Saturated 2.5 ± 0.9% 2.2 ± 1.5% 1.2 ± 0.5% 0.7 ± 0.2% 
Unsaturated 97.5 ± 0.9% 97.8 ± 1.5% 98.8 ± 0.5% 99.3 ± 0.2% 
Saturated/Unsaturated 0.026 ± 0.010 0.022 ± 0.016 0.012 ± 0.005 0.007 ± 0.002 
PE-based plasmalogen (PLPE) Healthy OA-early OA-late RA 
16:0 40.6 ± 2.5% 39.7 ± 2.0% 39.7 ± 1.6% 38.9 ± 2.2% 
18:1 30.3 ± 2.3% 26.6 ± 3.0% 25.0 ± 2.3% 22.0 ± 2.7% 
18:0 29.1 ± 2.5% 33.7 ± 2.7% 35.3 ± 2.4% 39.1 ± 3.2% 
Sphingomyelin (SPM) Healthy OA-early OA-late RA 
Saturated 61.3 ± 1.9% 62.8 ± 1.5% 63.4 ± 1.5% 63.2 ± 2.5% 
Unsaturated 38.7 ± 1.9% 37.2 ± 1.5% 36.6 ± 1.5% 36.8 ± 2.5% 
Saturated/Unsaturated 2.0 ± 0.5 1.9 ± 0.4 1.8 ± 0.3 1.9 ± 0.5 
Ceramide (Cer) Healthy OA-early OA-late RA 
Saturated 70.2 ± 4.2% 74.0 ± 3.0% 74.6 ± 3.0% 74.9 ± 4.0% 
Unsaturated 29.8 ± 4.2% 26.0 ± 3.0% 25.4 ± 3.0% 25.1 ± 4.0% 
Saturated/Unsaturated 2.4 ± 0.5 2.9 ± 0.5 3.0 ± 0.5 3.1 ± 0.7 
PC species were analysed by ESI-MS/MS in 9 healthy SF, 19 OA SF from early stage, 14 OA SF 
from late stage and 18 RA SF. The values represent the percentage of PL species with the 
respective FA saturation status of total PL class (=100%) and calculated ratios of total saturated PL 
and unsaturated PL. Data represent mean ± SD of percentage or ratio. PC-phosphatidylcholine, 
LPC-lysophosphatidylcholine, PE-phosphatidylethanolamine, PLPE-phosphatidylethanolamine-
based plasmalogen, SPM-sphingomyelin, Cer-ceramide, OA-osteoarthritis, RA-rheumatoid 
arthritis. 
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Figure 4.7. Notched boxplots for randomly chosen PC species. PC species were analysed in 9 
healthy SF, 19 SF from early stage of OA, 14 SF from late stage of OA and 18 RA SF. The notched 
boxplots show 95% confidence intervals for the median. Circles indicate outliners. Statistical 
analysis is summarised in table 4.4. Additional data are also presented in Figure 4.8. OA-
osteoarthritis, PC-phosphatidylcholine, RA-rheumatoid arthritis. 
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Figure 4.8. Phosphatidylcholine species composition of SF as dependent on the health status 
of joints. The different PL species were quantified by ESI-MS/MS. All values were corrected for 
possible dilution using the dilution factor (DF) obtained by the determination of the urea 
concentrations. Values are expressed as mean ± SD of concentrations of PC species. PL species 
showing any significant differences between groups are marked with red boxes. Statistical analysis 
is summarised in table 4.4. OA-osteoarthritis, PC-phosphatidylcholine, RA-rheumatoid arthritis. 
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Figure 4.9. A. Ether-phosphatidylcholine and B. Lysophosphatidylcholine species 
composition of SF as dependent on the health status of joints. The different PL species were 
quantified by ESI-MS/MS. All values were corrected for possible dilution using the dilution factor 
obtained by the determination of the urea concentrations. Values represent mean ± SD of 
concentrations of PL species. PL species showing any significant differences between groups are 
marked with red boxes. Statistical analysis is summarised in table 4.4. LPC-
lysophosphatidylcholine, OA-osteoarthritis, PC O-ether phosphatidylcholine, RA-rheumatoid 
arthritis. 
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Figure 4.10. Phosphatidylethanolamine species composition of SF as dependent on the health 
status of joints. The different PL species were quantified by ESI-MS/MS. All values were 
corrected for possible dilution using the dilution factor (DF) obtained by the determination of the 
urea concentrations. Values represent mean ± SD of concentrations of PE species. PL species 
showing any significant differences between groups are marked with red boxes. Statistical analysis 
is summarised in table 4.4. OA-osteoarthritis, PE-phosphatidylethanolamine, RA-rheumatoid 
arthritis. 
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Figure 4.11. Phosphatidylethanolamine-based plasmalogens species composition of SF as 
dependent on the health status of joints. The different PL species were quantified by ESI-
MS/MS. All values were corrected for possible dilution using the dilution factor (DF) obtained by 
the determination of the urea concentrations. Values represent mean ± SD of concentrations of 
PLPE species. PL species showing any significant differences between groups are marked with red 
boxes. Statistical analysis is summarised in table 4.4. OA-osteoarthritis, PLPE-
phosphatidylethanolamine-based plasmalogen, RA-rheumatoid arthritis. 
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Compared to other PL classes, only three PG and two PS species could be detected. 
The values of the PG and PS species were close to the detection limit, thus, no individual 
species composition are presented on any graphs.  
Similarly to the LPC class, saturated species characterised by 16 C-atoms in FA 
were the dominant species found in the SPM class accounting for 50.2 ± 3.4 % of total 
SPM (Figure 4.13). In addition, the SPM species had increased concentrations in SF from 
early and late stage of OA and in RA SF as compared to healthy SF. Observed increases in 
the concentrations of the main SPM species were as follow, 216 ± 144.4% in early OA, 
405 ± 241.3% in late OA and 256.6 ± 102% in RA SF for SPM 16:0, 250 ± 189.3% in 
early OA, 527.5 ± 385.3% in late OA and 336.5 ± 183.5% in RA SF for SPM 18:0, 275.7 ± 
208.1% in early OA, 555.6 ± 356.3% in late OA and 344.8 ± 164.2% in RA SF for SPM 
22:1, 329.5 ± 287.2% in early OA, 600.9 ± 406% in late OA and 395.4 ± 230.7% in RA SF 
for SPM 24:0, 227.1 ± 162.4% in early OA, 430.6 ± 262.1% in late OA and 278.9 ± 139% 
in RA SF for SPM 24:1, and 199.2 ± 125.2% in early OA, 378.5 ± 232.1 in late OA and 
237.9 ± 97.9% in RA SF for SPM 24:2, when compared to healthy SF (=100%). Opposite 
to PC species, a higher percentage of saturated SPM species was found in SF from all 
investigated groups (Table 4.3). 
Additionally, the relative contribution of PL species with various length of the FA 
chains to the total amount of respective PL class was calculated. As evident from Table 4.5 
and Table 6.3, due to the development of OA and RA the FA chains are getting elongated 
in PC, PE, PLPE and PI. In healthy SF, a higher percentage of FA with shorter chains was 
observed (≤34) whereas, in OA ad RA SF a higher percentage of FA with longer chains 
was observed (>34).  
To summarise, our result clearly show that there are significant differences between 
healthy and arthritic SF. Interestingly, SF from late stage of OA exhibited significantly 
higher concentrations of most of the depicted lipid species when compared with healthy SF 
and SF from early stage of OA. More importantly, significant differences in PL 
composition were also observed between early and late stage of OA (Table 4.4). 
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Figure 4.12. A. Phosphatidylinositol and B. Ceramide species composition of SF as dependent 
on the health status of joints. The different PL species were quantified by ESI-MS/MS. All values 
were corrected for possible dilution using the dilution factor (DF) obtained by the determination of 
the urea concentrations. Values represent mean ± SD of concentrations of PL specie. PL species 
showing any significant differences between groups are marked with red boxes. Statistical analysis 
is summarised in table 4.4. Cer-ceramide, GluCer-glucosylceramide, OA-osteoarthritis, PI-
phosphatidylinositol, RA-rheumatoid arthritis. 
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Figure 4.13. Sphingomyelin species composition of SF as dependent on the health status of 
joints. The different PL species were quantified by ESI-MS/MS. All values were corrected for 
possible dilution using the correction factor obtained by the determination of urea concentrations. 
Values represent mean ± SD of concentrations of SPM species. PL species showing any significant 
differences between groups are marked with red boxes. Statistical analysis is summarised in table 
4.4. OA-osteoarthritis, RA-rheumatoid arthritis, SPM-sphingomyelin. 
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Table 4.4. Summary of statistically significant changes of the concentrations of individual PL 
species as dependent on the health status of joints.  
PL - specie 
OA early 
vs. Healthy 
OA late vs. 
Healthy 
RA vs. 
Healthy 
OA early 
vs. OA late 
OA early 
vs. RA 
OA late vs. 
RA 
Phosphatidylcholine (PC) 
    
  
PCO 30:0 NS ***↓  ** ↓  ** ↑  * ↑ NS 
PC 32:0 NS   **↑   ** ↑ NS NS NS 
PCO 32:0   * ↑ ***↑ ***↑ NS  * ↓ NS 
PC 32:1 NS   ** ↑   ** ↑ NS NS NS 
PCO 32:1 NS ***↑   ** ↑ NS NS NS 
PC 32:2 NS ***↑ ***↑ NS NS NS 
PC 34:0  **↑ ***↑ ***↑  *↓  * ↓ NS 
PCO 34:0   * ↑ ***↑ ***↑ NS  * ↓ NS 
PC 34:1   * ↑ ***↑ ***↑  *↓  *↓ NS 
PCO 34:1 *↑ ***↑ ***↑ *↓ *↓ NS 
PC 34:2 **↑ ***↑ ***↑ **↓ **↓ NS 
PCO 34:2 *↑ ***↑ ***↑ *↓ NS NS 
PC 34:3 *↑ ***↑ ***↑ *↓ *↓ NS 
PC 36:0 **↑ ***↑ ***↑ **↓ NS NS 
PC 36:1 **↑ ***↑ ***↑ *↓ NS NS 
PCO 36:1 **↑ ***↑ ***↑ **↓ **↓ NS 
PC 36:2 **↑ ***↑ ***↑ **↓ **↓ NS 
PCO 36:2 **↑ ***↑ ***↑ **↓ **↓ NS 
PC 36:3 **↑ ***↑ ***↑ **↓ *↓ NS 
PC 36:4 **↑ ***↑ ***↑ **↓ *↓ NS 
PCO 36:4 **↑ ***↑ ***↑ **↓ *↓ NS 
PC 36:5 **↑ ***↑ ***↑ *↓ NS NS 
PCO 36:5 **↑ ***↑ ***↑ *↓ NS NS 
PC 38:1 **↑ ***↑ ***↑ **↓ *↓ NS 
PC 38:2 **↑ ***↑ ***↑ **↓ **↓ NS 
PC 38:3 **↑ ***↑ ***↑ **↓ NS NS 
PC 38:4 **↑ ***↑ ***↑ **↓ NS NS 
PC 38:5 **↑ ***↑ ***↑ *↓ NS NS 
PC 38:6 **↑ ***↑ ***↑ **↓ *↓ NS 
PC 40:4 **↑ ***↑ ***↑ *↓ NS NS 
PC 40:5 **↑ ***↑ ***↑ **↓ NS *↑ 
PC 40:6 **↑ ***↑ ***↑ **↓ *↓ NS 
Lysophosphatidylcholine 
(LPC)     
  
LPC 15:0 ***↑ ***↑ **↑ *↓ NS **↑ 
LPC 16:0 ***↑ ***↑ *↑ **↓ NS ***↑ 
LPC 16:1 **↑ ***↑ NS *↓ *↑ ***↑ 
LPC 18:0 ***↑ ***↑ ***↑ **↓ NS **↑ 
LPC 18:1 **↑ ***↑ NS *↓ NS ***↑ 
LPC 18:2 **↑ ***↑ NS NS **↑ ***↑ 
LPC 18:3 **↑ **↑ NS NS ***↑ ***↑ 
LPC 20:0 ***↑ ***↑ **↑ NS NS **↑ 
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Table 4.4. Continuation.  
PL - specie 
OA early 
vs. Healthy 
OA late vs. 
Healthy 
RA vs. 
Healthy 
OA early 
vs. OA late 
OA early 
vs. RA 
OA late vs. 
RA 
Lysophosphatidylcholine 
(LPC)     
  
LPC 20:3 **↑ ***↑ NS NS *↑ **↑ 
LPC 20:4 *↑ ***↑ NS NS *↑ ***↑ 
LPC 20:5 **↑ **↑ NS NS *↑ **↑ 
LPC 22:0 NS NS NS NS *↑ **↑ 
LPC 22:4 NS NS NS NS **↑ ***↑ 
LPC 22:5 **↑ **↑ NS NS **↑ **↑ 
LPC 22:6 **↑ ***↑ NS NS *↑ ***↑ 
Phosphatidylethanolamine 
(PE)     
  
PE 32:2 NS NS **↓ NS **↑ *↑ 
PE 34:0 NS NS NS NS NS NS 
PE 34:1 NS **↑ ***↑ *↓ **↓ NS 
PE 34:2 *↑ ***↑ ***↑ *↓ *↓ NS 
PE 36:1 NS ***↑ ***↑ *↓ ***↓ NS 
PE 36:2 **↑ ***↑ ***↑ *↓ **↓ NS 
PE 36:3 **↑ ***↑ ***↑ NS NS NS 
PE 36:4 *↑ ***↑ ***↑ **↓ *↓ NS 
PE 36:5 NS *↑ *↑ NS NS NS 
PE 38:1 *↑ ***↑ **↑ *↓ NS NS 
PE 38:3 *↑ ***↑ ***↑ *↓ *↓ NS 
PE 38:4 *↑ ***↑ ***↑ **↓ **↓ NS 
PE 38:5 *↑ ***↑ ***↑ *↓ *↓ NS 
PE 38:6 *↑ ***↑ ***↑ *↓ **↓ NS 
PE O 38:7 NS **↑ **↑ *↓ NS NS 
PE O 40:3 NS NS ***↓ NS ***↑ **↑ 
PE 40:5 **↑ ***↑ ***↑ *↓ NS NS 
PE 40:6 *↑ ***↑ ***↑ *↓ **↓ NS 
PE 42:5 NS NS NS NS *↑ NS 
PE 42:7 NS NS ***↓ NS ***↑ *↑ 
PE-based plasmalogen 
(PLPE)     
  
PLPE 16:0/16:0 NS NS **↓ NS ***↑ **↑ 
PLPE 16:0/16:1 NS NS ***↓ NS ***↑ ***↑ 
PLPE 16:0/18:0 NS NS ***↓ NS ***↑ **↑ 
PLPE 16:0/18:1 NS **↑ *↑ NS NS NS 
PLPE 16:0/18:2 NS **↑ *↑ *↓ NS NS 
PLPE 16:0/18:3 NS NS **↓ NS ***↑ **↑ 
PLPE 16:0/20:3 NS **↑ NS NS NS *↑ 
PLPE 16:0/20:4 *↑ ***↑ ***↑ **↓ NS NS 
PLPE 16:0/20:5 NS **↑ NS *↓ NS ** 
PLPE 16:0/22:3 NS NS **↓ NS ***↑ ***↑ 
PLPE 16:0/22:5 *↑ ***↑ **↑ *↓ NS NS 
PLPE 16:0/22:6 ***↑ ***↑ ***↑ **↓ NS *↑ 
PLPE 18:0/16:0 NS NS *↓ NS *↑ ***↑ 
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Table 4.4. Continuation.  
PL - specie 
OA early 
vs. Healthy 
OA late vs. 
Healthy 
RA vs. 
Healthy 
OA early 
vs. OA late 
OA early 
vs. RA 
OA late vs. 
RA 
PE-based plasmalogen 
(PLPE)     
  
PLPE 18:0/16:1 NS NS **↓ NS **↑ **↑ 
PLPE 18:0/18:0 NS NS ***↓ NS ***↑ *↑ 
PLPE 18:0/18:1 NS **↑ **↑ *↓ *↓ NS 
PLPE 18:0/18:2 *↑ ***↑ ***↑ *↓ NS NS 
PLPE 18:0/18:3 NS NS **↓ NS **↑ *↑ 
PLPE 18:0/20:3 NS **↑ NS *↓ NS *↑ 
PLPE 18:0/20:4 **↑ ***↑ ***↑ **↓ *↓ NS 
PLPE 18:0/20:5 *↑ ***↑ **↑ *↓ NS *↑ 
PLPE 18:0/22:3 NS NS ***↓ NS **↑ *↑ 
PLPE 18:0/22:5 **↑ ***↑ **↑ *↓ NS NS 
PLPE 18:0/22:6 ***↑ ***↑ ***↑ ***↓ *↓ *↑ 
PLPE 18:1/16:0 NS NS NS NS **↑ **↑ 
PLPE 18:1/16:1 NS NS ***↓ NS ***↑ **↑ 
PLPE 18:1/18:0 NS NS ***↓ NS ***↑ **↑ 
PLPE 18:1/18:1 NS *↑ NS NS NS NS 
PLPE 18:1/18:2 NS **↑ NS *↓ NS NS 
PLPE 18:1/18:3 NS NS ***↓ NS ***↑ **↑ 
PLPE 18:1/20:3 NS NS NS NS NS *↑ 
PLPE 18:1/20:4 *↑ ***↑ ***↑ **↓ NS NS 
PLPE 18:1/20:5 NS *↑ NS NS NS *↑ 
PLPE 18:1/22:3 NS NS ***↓ NS ***↑ **↑ 
PLPE 18:1/22:4 NS NS *↓ NS *↑ **↑ 
PLPE 18:1/22:5 NS NS NS NS NS *↑ 
PLPE 18:1/22:6 *↑ ***↑ **↑ *↓ NS **↑ 
Phosphatidylglycerol (PG) 
    
  
PG 32:0 NS NS ***↑ NS ***↑ **↑ 
PG 34:1 NS NS **↑ NS *↓ ***↓ 
PG 36:2 NS NS NS NS *↓ *↓ 
Phosphatidylserine (PS) 
    
  
PS 36:1 *↑ NS *↑ *↓ ***↓ ***↓ 
PS 36:2 NS NS NS NS *↓ *↓ 
Sphingomyelin (SPM) 
    
  
SPM 14:0 *↑ ***↑ ***↑ **↓ *↓ NS 
SPM 15:0 **↑ ***↑ ***↑ **↓ *↓ NS 
SPM 16:0 *↑ ***↑ ***↑ **↓ NS NS 
SPM dih 16:0 *↑ ***↑ ***↑ **↓ *↓ NS 
SPM –OH 16:0 *↑ ***↑ ***↑ **↓ NS **↑ 
SPM 16:1 *↑ ***↑ ***↑ **↓ NS NS 
SPM –OH 16:1 *↑ ***↑ ***↑ **↓ *↓ NS 
SPM 18:0 *↑ ***↑ ***↑ **↓ **↓ NS 
SPM dih 18:0 NS **↑ ***↑ *↓ *↓ NS 
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Table 4.4. Continuation.  
PL - specie 
OA early 
vs. Healthy 
OA late vs. 
Healthy 
RA vs. 
Healthy 
OA early 
vs. OA late 
OA early 
vs. RA 
OA late vs. 
RA 
Sphingomyelin (SPM) 
    
  
SPM 18:1 **↑ ***↑ ***↑ **↓ *↓ NS 
SPM 20:0 *↑ ***↑ ***↑ **↓ NS NS 
SPM 20:1 *↑ ***↑ ***↑ **↓ *↓ NS 
SPM 22:0 **↑ ***↑ ***↑ **↓ *↓ NS 
SPM 22:1 **↑ ***↑ ***↑ **↓ *↓ NS 
SPM 22:2 NS **↑ ***↑ *↓ *↓ NS 
SPM 24:0 **↑ ***↑ ***↑ *↓ *↓ NS 
SPM 24:1 *↑ ***↑ ***↑ *↓ *↓ NS 
SPM 24:2 *↑ ***↑ ***↑ **↓ NS NS 
SPM 24:3 NS *↑ *↑ NS NS NS 
Ceramide (Cer) 
    
  
Cer 16:0 NS ***↑ ***↑ **↓ *↓ NS 
GluCer 16:0 NS ***↑ ***↑ **↓ **↓ NS 
Cer 22:0 NS ***↑ ***↑ **↓ **↓ NS 
Cer 23:0 NS ***↑ ***↑ *↓ *↓ NS 
Cer 24:0 **↑ ***↑ ***↑ **↓ **↓ NS 
Cer 24:1 NS ***↑ ***↑ **↓ *↓ NS 
GluCer 24:1 NS ***↑ ***↑ **↓ *↓ NS 
Statistical analysis was performed by the non-parametric Kruskal-Wallis test followed by the false 
discovery rate (FDR) correction. Subsequently, paired Wilcoxon signed-rank test was applied to 
identify significant changes between each group. P-values of less than 0.05 were considered 
statistically significant with: *0.01<p≤0.05; **0.001<p≤0.01; ***p<0.001; NS-not significant. 
↑:increase ↓:decrease. Chosen individual PL species are presented in Figures 4.8-4.13. PC-
phosphatidylcholine, PC O-ether phosphatidylcholine, LPC-lysophosphatidylcholine, PE- 
phosphatidylethanolamine, PLPE-phosphatidylethanolamine-based plasmalogen, PG-
phosphatidylglycerol, PI-phosphatidylinositol, PS-phosphatidylserine, SPM-sphingomyelin, Cer-
ceramide, GluCer-glucosylceramide, OA-osteoarthritis, , RA-rheumatoid arthritis. 
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Table 4.5. FA chain length according to the number of C-atoms in a chosen PL class. 
PC 30 32 34 36 38 40 ≤ 34 > 34 ≤ 36 > 36 
Healthy 1.4% 8.8% 39.4% 33.3% 15.0% 2.2% 49.6% 50.5% 82.9% 17.2% 
OA-early 0.7% 5.1% 36.4% 36.6% 18.5% 2.7% 42.2% 57.8% 78.8% 21.2% 
OA-late 0.6% 4.2% 36.1% 37.0% 19.2% 2.9% 40.9% 59.1% 77.9% 22.1% 
RA 0.4% 3.9% 38.3% 37.0% 17.7% 2.7% 42.6% 57.4% 79.6% 20.4% 
PC-O 30 32 34 36 38 40 ≤ 34 > 34 ≤ 36 > 36 
Healthy 3.1% 14.2% 34.6% 48.1% / / 51.9% 48.1% 100% / 
OA-early 1.9% 11.4% 30.6% 56.1% / / 43.5% 56.1% 99.6% / 
OA-late 1.4% 10.4% 29.7% 58.4% / / 41.5% 58.4% 99.9% / 
RA 0.9% 11.5% 30.6% 57.1% / / 43.0% 57.1% 100.1
% 
/ 
PC+PC-O 30 32 34 36 38 40 ≤ 34 > 34 ≤ 36 > 36 
Healthy 1.5% 9.2% 39.0% 34.5% 13.8% 2.0% 45.2% 50.3% 84.2% 15.8% 
OA-early 0.8% 5.5% 36.1% 37.8% 17.4% 2.5% 42.4% 57.7% 80.2% 19.9% 
OA-late 0.6% 4.6% 35.7% 38.3% 18.0% 2.8% 40.9% 59.1% 79.2% 20.8% 
RA 0.5% 4.5% 37.8% 38.3% 16.5% 2.5% 42.8% 57.3% 81.2% 19.0% 
PE 30 32 34 36 38 40 ≤ 34 > 34 ≤ 36 > 36 
Healthy / 2.2% 6.3% 12.7% 28.7% 50.1% 8.5% 91.5% 21.2% 78.8% 
OA-early / 1.4% 6.7% 16.0% 35.6% 40.2% 8.1% 91.8% 24.1% 75.8% 
OA-late / 2.7% 7.9% 16.0% 38.6% 34.8% 10.6% 89.4% 26.6% 73.4% 
RA / 0.8% 8.8% 24.2% 43.6% 22.7% 9.6% 90.5% 3.8% 66.3% 
PLPE 30 32 34 36 38 40 ≤ 34 > 34 ≤ 36 > 36 
Healthy / 3.5% 15.7% 33.6% 33.9% 13.5% 19.2% 81.0% 21.2% 47.4% 
OA-early / 2.2% 12.5% 30.1% 41.9% 13.3% 14.7% 85.2% 24.1% 55.1% 
OA-late / 1.9% 11.3% 31.4% 42.6% 12.8% 13.2% 86.8% 26.6% 55.4% 
RA / 0.8% 11.1% 32.4% 43.5% 12.3% 11.9% 
% 
88.2% 33.8% 55.8% 
PI 30 32 34 36 38 40 ≤ 34 > 34 ≤ 36 > 36 
Healthy / 5.4% 11.3% 31.0% 52.3% 5.4% 11.3% 88.7% 42.3% 57.7% 
OA-early / 5.8% 7.8% 25.0% 61.4% 5.8% 7.8% 92.2% 32.8% 67.2% 
OA-late / 5.3% 8.2% 23.0% 63.5% 5.3% 8.2% 91.8% 31.2% 68.6% 
RA / 4.7% 9.0% 25.2% 61.1% 4.7% 9.0% 91.0% 34.2% 65.8% 
PC species were analysed by ESI-MS/MS in 9 healthy SF, 19 OA SF from early stage, 14 OA SF 
from late stage and 18 RA SF. The values represent the percentage of PL species with the 
respective FA chain length of total PL class (=100%). Statistical analysis is presented in table 6.3. 
OA-osteoarthritis, PC-phosphatidylcholine, PC O-ether phosphatidylcholine, PE-
phosphatidylethanolamine, PLPE-phosphatidylethanolamine-based plasmalogen, PI-
phosphatidylinositol, RA-rheumatoid arthritis. 
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4.3 Phospholipid composition of healthy and OA canine SF 
In order to confirm whether a canine OA-model represent our finding from human  
SF, lipids were isolated from canine SF obtained from 7 healthy and 7 contralateral OA-
induced knee joints.  
Similarly to human SF, PC is the most abundant PL class present in canine SF, 
accounting for to 77% of all PLs present (Figure 4.14). In contrast to the data obtained 
from human samples, ESI-MS/MS analysis of canine SF revealed no significant 
differences between surgically induced OA-like knee joints and contralateral healthy 
control joints. However, the observed slight differences in the canine model of OA are 
similar with respect to their trends to those obtained from humans SF, where most of PL 
classes were present in higher concentrations in OA SF when compared to healthy SF 
(Figure 4.14). Data from individual PL species are not shown.  
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Figure 4.14. PL classes in healthy and contralateral canine OA SF. The different PL classes 
were quantified by ESI-MS/MS. The displayed values were corrected for possible dilution using 
the dilution factor (DF) obtained by the determination of the urea concentrations. SF was obtained 
from healthy, control knee (blue bars) and contralateral knee with induced OA (red bars). Values 
represent mean ± SD from 6 dogs. Shown PLs are phosphatidylcholine (PC), 
lysophosphatidylcholine (LPC), phosphatidylethanolamine (PE), phosphatidylethanolamine-based 
plasmalogen (PLPE), phosphatidylserine (PS), phosphatidylglycerol (PG), sphingomyelin (SPM), 
and ceramide (Cer). OA-osteoarthritis. 
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4.4 Effect of joint distraction on composition of PL in SF 
According to the data published elsewhere, joint distraction used to treat human OA 
may be of long-term clinical benefits with respect to both, symptoms and structure 
modification [180]. Therefore, induction of OA was performed in the group of 9 dogs 
followed by joint distraction. The effect of joint distraction on PL composition was 
evaluated by determining potential changes between OA induced knee joint and OA 
induced knee followed by joint distraction.  
As shown in Figure 4.15, the concentrations of PE and PLPE were significantly 
elevated (161.8 ± 87.5 % for PE and 168.6 ± 90.5 % for PLPE) in distracted joints 
compared to untreated OA joints (=100%). Other PL classes remained within the control 
level since the delta between treated and control knee joints was near 0.  
 
Figure 4.15. Effect of joint distraction on PL composition of OA SF. The different PL classes 
were quantified by ESI-MS/MS in SF obtained from healthy, control knee (n=21), OA knee 
without treatment (OA group; n=7), OA framed knee (frame group; n=5) and OA distracted knee 
(distraction group; n=9). Quantitative PL values were corrected for possible dilution using the 
dilution factor (DF) obtained by the determination of the urea concentrations. The displayed values 
are shown as delta between treated and healthy, control knee joints of the same dog. The notched 
boxplots show 95% confidence intervals for the median. Circles indicate outliners. Statistical 
analysis was performed by the non-parametric Kruskal-Wallis test followed by the false discovery 
rate (FDR) correction. Subsequently, paired Wilcoxon signed-rank test was applied to identify 
significant changes between each groups. P-values of less than 0.05 were considered statistically 
significant. PC-phosphatidylcholine, LPC-lysophosphatidylcholine, SPM-sphingomyelin, PE-
phosphatidylethanolamine, PLPE-phosphatidylethanolamine-based plasmalogen, Cer-ceramide, 
OA-osteoarthritis.  
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4.5 Composition of PL in various mammalian species 
In order to elucidate potential differences between various mammalian species and 
to answer the question whether PL composition of healthy SF is species-dependent, lipids 
were extracted from 9 human SF, 21 canine SF and from 14 equine SF and ESI-MS/MS 
analysis was performed. All subjects were characterised by the lack of arthritic disease 
history in the knee of interest. Almost all of PL species present in human SF were also 
detected in canine and equine SF (data not shown). The relative distribution show 
approximately equal levels of PL classes in all investigated groups (Figure 4.16). However, 
quantitative data revealed significant changes between several PL classes (Figure 4.17 and 
Table 6.4). Interestingly, the PC levels did not differ between humans, dogs and horses.  
Additionally, human, dogs and horses present similar PL species with the exception 
of LPC where only 4 species were determined in equine SF. In contrast, human and canine 
SF possess 15 different LPC species (data not shown). Moreover, decreased concentrations 
of LPC, PE, PLPE and Cer were found in equine SF as compared to human and canine SF 
(Figure 4.17). 
 
Figure 4.16. Relative distribution of PL classes in SF of various mammalian species. The 
different PL classes were quantified by ESI-MS/MS in healthy human SF (n=9; blue bars), healthy 
canine SF (n=20; red bars) and healthy equine SF (n=14; yellow bars). The displayed values are 
shown as a percentage of the respective PL class of all analysed PL (=100%) and are expressed as 
mean ± SD. Cer-ceramide, LPC-lysophosphatidylcholine, PC-phosphatidylcholine, PE- 
phosphatidylethanolamine, PG-phosphatidylglycerol, PL-phospholipids, PLPE-
phosphatidylethanolamine-based plasmalogen, PS-phosphatidylserine, SPM-sphingomyelin. 
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The concentrations determined for equine SF were decreased down to 3 ± 1.7%  for LPC, 
26.6 ± 16.5% for PE, 43.5 ± 18.9 % for PLPE and 22.1 ± 7.7% for Cer when compared to 
human SF (=100%), and 8 ± 4.4% for LPC, 20.4 ± 9.2% for PE, 29 ± 12.6 % for PLPE and 
27 ± 9.4% for Cer when compared to canine SF (=100%). It is also worth to note, that PL 
composition is comparable in human and canine SF.  
 
 
Figure 4.17. PL classes in SF of various mammalian species. The different PL classes were 
quantified by ESI-MS/MS in healthy human SF (n=9), healthy canine SF (n=20) and healthy 
equine SF (n=14). The notched boxplots show 95% confidence interval for the median. Circles 
indicate outliners. Statistical analysis is presented in table 6.4. PC-phosphatidylcholine, PC O-ether 
phosphatidylcholine LPC-lysophosphatidylcholine, PE-phosphatidylethanolamine, PLPE-
phosphatidylethanolamine-based plasmalogen,  PG-phosphatidylglycerol, PS-phosphatidylserine, 
SPM-sphingomyelin, Cer-ceramide. 
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4.6 Fibroblast-like synoviocytes cell culture 
4.6.1 Optimisation of FLS culture conditions 
To optimise FLS culture conditions in order to measure synthesis and/or release of 
PLs, the different cell culture conditions were studied. FLS were cultured with 15 ml D-
MEM medium supplemented with 10% FCS, 1% penicillin/streptomycin and 1% HEPES. 
Subsequently, cells were plated onto 4- or 6-well plates at a density 80.000
 
cells/well. After 
cells reached 90% confluency, medium was exchanged and cells were starved in serum-
free medium for 16 h. Further, medium was exchanged and cells were cultured for 24 h in 
serum-free medium at conditions as follow: 
1. Supplemented with 1% of ITS™. 
2. Supplemented with 10-5 mol/ml dexamethasone  
3. FLS were cultured in 6-well plates coated with 50µl/cm2 BD Matrigel™ 
Basement Membrane Matrix Growth Factor Reduced.  
4. FLS were cultured in 4-well plates under shear stress conditions on horizontal 
shaker (5 rpm). 
Dexamethasone has been previously described as a drug which may be able to 
induce PLs synthesis in equine knee joint [123]. Therefore, the effect of dexamethasone on 
the PLs synthesis and/or release by FLS was also investigated. However, only culture on 
Matrigel™ Basement Membrane which enabled a 3-dimension culture of FLS (Figure 
4.18) slightly increased the total PL concentration as compared to blank medium from 0.68 
± 0.062 to 1.5 ± 0.12 nmol/ml/2x10
5
cells (Figure 4.19). These preliminary data indicate 
that PLs were synthesised and/or released by FLS. However, all obtained values from all 
analysed sampled were near the limit of quantification.  
 
 
 
 
 
 
 
 
 
Figure 4.18 Effect of three-dimensional FLS culture on cell morphology. A–FLS 
growing in monolayer, B-FLS growing in 3-D culture. FLS cells were cultured in 6-well 
plates coated with 50 µl/cm
2
 BD Matrigel™ Basement Membrane Matrix Growth Factor 
Reduced for 24 h. Cell morphology was examined using light microscopy (magnifications 
50x). FLS-fibroblast-like synoviocytes. 
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Figure 4.19. Concentrations of total PL in nutrient media from FLS culture. The presented 
results were obtained after 24 h using cells from different cell cultures. PL were quantified by ESI-
MS/MS and normalised to number of cells investigated (200.000). Each dot represents individual 
wells with different cell preparations. PL-phospholipids, ITS™+Premix-Insulin-Transferrin-
Selenium, Dex.-Dexamethasone. 
4.6.2 Development of a method for PL detection in cell culture media 
The results of our preliminary experiments indicate that FLS synthesise and/or 
release PL. Nonetheless, the concentrations of all PL classes were very low. Our next aim 
was to prove, that the ESI/MS-MS method was suitable to determine PL quantitatively in 
FLS culture media. In order to concentrate and purify PLs present in media sample, SPE 
was performed as outlined in Material & Methods section.  
The data obtained of SPE purification, indicated a 2-4-folds increase in each PL 
class analysed in lipid extracts acquired after SPE, compared to lipid extracts from 
standard Bligh & Dyer method (Figure 4.20 A). 
To further analyse PL composition of each obtained SPE fraction and to address the 
question, whether SPE is a suitable method to purify PLs present in media samples, all four 
fractions were analysed separately by ESI/MS-MS. Accordingly to a previously published 
protocol [167], PLs should be present in fraction 3 containing neutral PLs and in fraction 4 
containing acidic PLs. As expected, fraction 3 and 4 contained the highest amount of 
detected PL (Figure 4.20 B). However, in fraction 1, which according to literature contains 
neutral lipids [167], a high amount of Cer was detected. In fraction 2, which contains free 
FA, no detectable amounts of PLs were found.  
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Figure 4.20. Purification of PL in FLS cell culture media using SPE. Panel A compares PL 
classes present in nutrient media after B&D lipid extraction and B&D lipid extraction followed by 
SPE. Panel B shows PL composition in each extracted fraction after SPE. Values are presented as 
mean ± SD from three independent FLS cell preparations. PC-phosphatidylcholine, LPC-
lysophosphatidylcholine, PE-phosphatidylethanolamine, PI-phosphatidylinositol, SPM-
sphingomyelin, Cer-ceramide, B&D-lipid extraction according to Bligh and Dyer, SPE-solid phase 
extraction. 
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4.7 Detection of surfactant proteins in human knee joints 
4.7.1 Western blot analysis of surfactant proteins in human SF 
 In order to assess whether human SF contains surfactant proteins, Western blot 
analysis was performed. SP-A, -B, -C and -D protein expression was investigated by 
immunoblotting of SF, albumin-free SF, HA-free SF and lung lavage using specific 
antibodies (Table 2.5).  
Mouse monoclonal anti-human SP A (Dako Deutschland GmbH) revealed two 
bands. In the lung samples, one of the bands had an apparent molecular weight of 37 kDa 
(Figure 4.21). Antibody to SP-B stained only one band in the lung lavage samples with 
molecular weight of 15 kDa, with a clear lack of SP-B in SF samples. We could detect SP-
C neither in lung lavage nor in SF samples. SP-D antibody revealed one band in lavage 
lung samples with a molecular weight of 47 kDa. Bands detected by SP-A and SP-D 
antibodies in SF samples did not have the expected molecular weight. Hence, expression of 
SP-A and SP-D was further analysed using a 2D-gels system. Detected proteins were 
identified using MALDI-TOF/MS after in gel trypsynization. Expression of SP-B and SP-
C was not further investigated. 
 
Figure 4.21. Detection of SP-A, SP-B and SP-D on immunoblots. SF and lung lavage was 
prepared and separated on SDS-PAGE. Immunoblotting with specific antibodies was performed. 
For each antibody used, one representative blot out of 3-5 is shown. SF-synovial fluid, SF 1-
albumin-free synovial fluid, SF 2-hyualuronic acid-free synovial fluid, SP-A-surfactant protein A, 
SP-B-surfactant protein B, SP-D-surfactant protein D. 
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4.7.2 MALDI-TOF/MS protein identification  
Analysis of Western blots indicated, that SP-A and SP-D might be present in 
human SF. In order to confirm, whether the proteins detected by the antibodies on 
immunoblots are indeed surfactant proteins, additional two-dimensional gel electrophoresis 
was performed using the same antibodies (Figure 4.22). A second gel electrophoresis was 
performed using the same samples and conditions, and the gel was stained with Coomassie 
blue. Both gels were compared and the corresponding spots to those showing 
immunoreactivity with specific antibodies were excited. Subsequently, proteins present in 
selected spots were identified by MALDI-TOF/MS.  
As presented in Table 4.6 none of investigated spots contained surfactant proteins. 
Most of the proteins detected by immunoblots were albumins. These results confirmed 
previous findings, that human SF does not contain surfactant proteins. 
The finding obtained from Western blot analysis as well as from protein 
identification by MALDI-TOF/MS was further validated by RT-PCR analysis as described 
further in section 4.7.3.2.  
 
Figure 4.22. Detection of SP-A and SP-D on immunoblots after 2D-PAGE. SF and lung lavage 
were prepared and separated on 2D-PAGE. Immunoblotting with specific antibodies was 
performed. Picture is representative of two independent experiments. SF-synovial fluid, SP-A-
surfactant protein A, SP-D-surfactant protein D. Number #1-#9-excised spots. 
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Spot Identified protein 
1 Serum albumin, chain A-Human 
2 Serum albumin-Human 
3 Serum albumin-Human 
4 Serum albumin-Human 
5 Hypothetical protein DKFZp686M04163-Human 
6 Fibronectin 1.-Human 
7 Fibronectin 1.-Human 
8 Alpha-2-macroglobulin precursor-Human 
9 Interferon regulatory factor 5 variant 11-Human 
Table 4.6. Proteins identified with MALDI-TOF/MS from the spots excised from 2D gels 
which correspond to those spots identified by their immunoreactivity. 
 
4.7.3 Expression of surfactant proteins 
To support our previous observation and further investigate whether human SF 
does not contain surfactant proteins, semi-quantitative PCR was performed. For this 
purpose total RNA was isolated from all the tissues of synovial joint which might be a 
source for production of SF components such as cells dispersed in SF, synovial membrane, 
cartilage and from cultured FLS.   
4.7.3.1 Total RNA isolation from human cartilage 
Healthy human as well as OA cartilage has a low cell content, which is 1-2% of  the 
total cartilage mass [181]. The remaining 98-99% is composed of water and extracellular 
matrix with a high concentration of aggrecan, hence, isolation of total cartilage RNA is 
challenging. To obtain appropriate amount of good quality total RNA and to perform 
reverse transcription, three independent methods were applied. Using commercial available 
kits RNAquenous™ (Ambion Inc.) and PeqGOLD Total RNA (Peqlab Biotechnologie 
GmbH), or a modified phenol-chloroform method with use of PeqGOLD TriFast™ 
(Peqlab Biotechnologie GmbH). Concentration of isolated RNA was determined 
spectrophotometrically at 260 nm (Figure 4.23). Appropriate amount of RNA was obtained 
using the modified phenol-chloroform method of the PeqGOLD TriFast™. This RNA was 
used for further analysis. 
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Figure 4.23. Total RNA isolated from human cartilage. Total RNA was isolated from human 
OA cartilage obtained from three different patients using commercially available kits: 
RNAqueous™ and PeqGold Total RNA or a modified phenol-chloroform method using PeqGOLD 
TriFast™. The concentrations of isolated RNA were determined spectrophotometrically at 260 nm. 
4.7.3.2 Expression of surfactant protein analysed by RT-PCR 
RNA from cells dispersed in SF, cultured FLS, synovial membrane and the 
cartilage was isolated with a modified phenol-chloroform method using peqGOLD 
TriFast™. Subsequently, obtained RNA were used to perform transcription to cDNA. 
Gene expression profiles of SP-A and SP-D was analysed by RT-PCR using 2 µl of cDNA 
obtained from cells and tissue mentioned above as well as healthy lung. GAPDH serves as 
a reference gene for all samples. GAPDH mRNA was detected in all analysed samples 
(Figure 4.24). 
SP-A and SP-D mRNA was only detected in healthy lung samples which served as 
positive control. Electrophoresis revealed a single band with the expected molecular 
weight (270 bp for SP-A and 321 bp for SP-D). Analysed cells derived from the synovial 
joint tissues did not express detectable mRNA levels of SP-A or SP-D (Figure 4.24). 
Samples without cDNA template were used as a negative control. In those samples no 
product was detected. In the line with Western blot analysis, it was concluded that SP-A 
and SP-D are absent in human SF. 
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Figure 4.24. Agarose gel of SP-A and SP-D in human joint tissues, FLS and healthy lung. RT-
PCR was performed for human OA cartilage (n=3), SM (n=3), cultured FLS (n=3), cells dispersed 
in SF (n=3), and healthy lung (n=2). In negative control, where no cDNA template was added, no 
product was observed. GAPDH served as reference gene. Displayed pictures are representative of 
three independent experiments. bp-base pairs, FLS-fibroblast-like synoviocytes, GAPDH-
glyceraldehyde 3-phosphate dehydrogenase, SF-cells dispersed in synovial fluid, SM-synovial 
membrane, SP-A-surfactant protein A, SP-D-surfactant protein D.  
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5. Discussion 
Our research focus on SF components which can contribute to the boundary 
lubrication, their changes due to the development of OA and RA and possible 
physiological and pathophysiological role in normal and OA joints. Of particular interest 
for this study was the analysis of the composition of SF PL and changes in quantities of 
individual PL species present in SF from different stages of OA.  
5.1 Problems and limitations 
Healthy knee joints contain only about 0.5-4 ml of SF. Healthy SF is also very 
viscous, thus, it is difficult to aspirate SF completely from the joint. Due to ethical 
restrictions to obtain SF from healthy individuals, we used post-mortem SF from human 
cadavers for our study. Previous biochemical analysis of post-mortem SF revealed a stable 
content of calcium, chloride, urea and creatinine up to 5 days after death [182]. We 
performed similar correlations this time focusing on the concentrations of PL classes and 
main PL species. Our results show that the concentrations of PL classes and even PL 
species remained unchanged up to 5 days after death. Our data indicate that SF obtained 
during this interval can be included in our study. 
 
Extracellular microvesicles, in literature often called MPs represent a 
heterogeneous population of membrane-bound small vesicles released from the cells by 
exocytotic blebbing during cell activation or early apoptosis. MPs are thought to have a 
function in the development of many human diseases including RA, where they trigger 
FLS to produce pro-inflammatory mediators (for review see [69, 183]). It is known that 
MPs are present in SF and contain cell membranes composed out of PLs. However, the 
aim of our study was to determine only extracellular PLs which may contribute to the 
boundary lubrication in synovial joints. Therefore, MPs were separated from SF samples 
with a method described elsewhere [67]. PS is known to be the main PL present on the 
surface of MPs [69, 183-184]. Since we determined PS as the only one PL class present at 
higher concentration in the MPs fraction as compared to other fractions of SF, and as cell-, 
cell-debris and MPs-free fraction of SF contained very negligible amount of PS, it seemed 
that separation of MPs from SF was effective. 
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One of the clinical signs of OA can be the influx of water into the joint cavity due 
to effusion, resulting in increased total volume of SF of up to 20-fold, therefore, 
measurements per unit volume, are often disturbed by variable dilution of SF. In order to 
eliminate unknown dilution of SF, we were searching for a method to correct our results. 
Our results about the concentrations of β2-MG indicated that there are independent from 
the total volume of SF, thus, β2-MG is not a suitable factor to correct for any dilution of 
SF. A recently published method used urea to compensate for various dilution of SF [177-
178]. Urea is produced in the liver and is neither synthesised nor metabolised by joint 
tissues. This small molecule is transported across synovium through unrestricted diffusion, 
thus, it is a good marker of unknown dilution [185]. Since our correlation analysis of SF 
and serum concentrations of urea is in accordance with data published previously, we used 
the method described above to correct our quantitative values of PL obtained from ESI-
MS/MS analysis for any possible dilution due to effusion.  
 
Synovial membrane is a permeable, living “dialysis” membrane which excludes 
large molecules from SF while allowing smaller components to cross the synovium in both 
directions and freely equilibrate between SF and serum. It has been shown that 
concentrations of small molecules such as electrolytes, glucose, uric acid and antibiotics 
are equal in SF and serum [186]. Unfortunately, sampling of SF often occurs several days 
after effusion. It is plausible that during longer time of effusion, the concentration of urea 
equilibrate by diffusion with the concentration of the urea present in serum. Supposing that 
described equilibrium had occurred in some knee joints of patients included in the present 
study, concentrations of the urea determined in those SF samples would be overestimated. 
Subsequently, this would lead to under-calculated dilution factor, and by that fact 
quantitative values of PL classes and species should be higher in OA and RA SF then 
reported here. Analysis of PL species in individual patients revealed that in certain cases 
the determined concentrations were several fold higher after correction, and in other cases 
we did not observe any differences between corrected and non-corrected values. However, 
according to our knowledge the use of urea to compensate possible dilution of SF is up to 
date the best available method. Nevertheless, possible calculation error would not severely 
change results presented in this thesis.  
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The reproducibility of our data was confirmed by a second independent analysis 
where a different batch of samples, different time point, changed instrument settings and 
other preparation of internal standards were applied. Statistical analysis of the second 
analysis revealed decreased number of statistical significant differences as compared to the 
first one. An explanation for it can lie in a lower number of patients included in the second 
analysis. However, the trends of changes found in both analyses were mostly the same 
indicating good reproducibility. 
5.2 Boundary lubrication provided by PL 
Only few components were identified in SF as possible factors contributing to 
boundary lubrication namely lubricin, HA and SAPLs [63, 84, 187]. Various theories about 
which of them is mainly responsible for boundary lubrication provided by SF have been 
advanced. Originally, the main boundary lubricant was thought to be HA, however, further 
investigations indicated that HA has several properties inconsistent with serving as an 
active boundary lubricant [63, 81]. It has been shown, that the major function of HA is not 
lubrication per se but rather providing a high viscosity to SF. Indeed, high concentrations 
of HA makes SF very slippery, but does not provide boundary lubricating ability to SF [81-
82]. 
The question whether lubricin or SAPLs provide main boundary lubrication of SF 
is a controversial subject under intensive discussion since at least 43 years [188]. Several 
investigations demonstrated that enzymatic digestion with trypsin destroyed the ability of 
SF to lower friction on the surfaces of articular cartilage. Therefore, it was concluded that 
boundary lubrication is related to the protein present in SF, most probably, lubricin [189-
190]. Jay et al [90, 95, 191] in many of his reports support the concept that synovial 
boundary lubrication is a function of lubricin. According to the theory of boundary 
lubrication from 1936 [192], the lubricant must be reversibly bound to the surface. Since 
the surface of articular cartilage is highly hydrophobic, it was proposed that the major role 
in lubrication is assigned to SAPLs which possess hydrophilic head groups. Enzymatic 
digestion of SF with phospholipase C (PLC) resulted in an elimination of the lubricating 
ability of SF [191, 193]. However, PLC might possess trypsin-like activity, hence, may 
digest proteins as well. To further confirm that lipid component of SF is responsible for 
boundary lubrication, similar experiments were performed using highly purified PLA2. 
Enzymatic digestion of SF with PLA2 resulted also in increased friction coefficient in a 
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concentration-dependent manner [81]. It is known, that PLC and PLA2 affect mostly PC, 
however, it is not yet specified whether PC provides most of the boundary lubricating 
properties of SF. The lipid solvent, which has been shown to efficiently remove all PL 
present on the surfaces of tendon further increased the effect in a wear test [193]. This 
suggests that PL other than PC may also provide lubricating abilities. If we take all of the 
above mentioned findings into consideration, it seems that SAPLs strongly contribute to 
the boundary lubrication in synovial joints. Lubricin as a water-soluble component of SF, 
acts as the carrier for insoluble SAPLs [194], hence, lubricin digestion also results in an 
increased friction [191]. 
Although a growing number of studies have investigated the role, function and 
chemical structure of HA and lubricin [63, 80, 96, 120, 195-196], little is known about the 
composition, molecular structure and source of SAPLs present in SF. Besides free 
cholesterol, which is known to be the main lipid in most human tissues and fluids, 9 
different lipid classes were identified in SF. The major group of PL present in SF are PL 
containing choline namely PC, LPC and SPM. Several studies which focused on PL 
composition in synovial joints revealed similar results [51, 128, 187]. PC was the main PL 
class found, covering approximately half of all present PL. The second main PL class was 
SPM. PE was shown to cover about 30% of total PL [128]. However, our results differ 
from this previous finding. We determined only a small amount of PE which was 
approximately 1.5% of total PL. An explanation for the observed differences can lie in the 
source of material used, since the previous investigation [128] as well as the others [51, 
187] were performed using PLs harvested from the superficial surface of articular 
cartilage. A more recent study using MALDI-TOF/MS analysis show, that the main classes 
present in human SF are PC, LPC and SPM which corroborates with our findings [197]. 
Recently, Hills et al. [138] demonstrated that the articular surface in joint afflicted with 
OA is deficient in SAPLs. However, we determined that during development of OA, total 
PL content as well as concentrations of main PL classes are increased in SF. As an 
explanation for this discrepancy, one might put forward that again it is this different 
composition of PL within SF and PL harvested from the surfaces of articular cartilage 
[198].  
In the publication from 1953 [186] Ropes and Bauer reported that an increased 
accumulation of synovial lipids appears in those joints, where excessive tissue destruction 
occurs. There are several evidences [189, 199-200] to support this observation. It has been 
shown that SF of RA contains severely increased content of PL, whereas normal SF 
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contains small amounts of lipids. Therefore, it was concluded, that increased levels of PL 
for instance SPM, LPC and PI contribute to and may stimulate the inflammatory processes 
during development of RA [201-203]. Our results are in accordance with the previous 
reports, since we determined higher concentrations of major PL classes including PC, LPC, 
SPM and Cer in OA SF and RA SF compared to healthy SF. 
Results of our study show, that the percentage composition of PL in normal, OA 
and RA SF is comparable. In addition, the ratios of PL classes were calculated to 
investigate the relationship between PL classes. Previously published results indicated that 
the PC/LPC ratio in SF might be a good diagnostic marker for RA [142]. The ratio of 
PC/LPC was decreased in patients with RA as compared to healthy individuals [142]. In 
contrast to this previous observation [142], we found a significant increase of PC/LPC ratio 
in RA SF compared to healthy SF and OA SF. An explanation for this discrepancy can lie 
in the applied mass spectrometry technique, since in the previous study MALDI-TOF/MS, 
which is at best a semi-quantitative method, was used. The SMP/Cer ratio remained 
unchanged in all investigated group due to increased concentrations of both those classes, 
the SMP and Cer, in OA SF and RA SF as compared to healthy SF. 
In summary, total PL content and concentrations of major PL classes are increased 
in SF from late stage of OA compared to healthy SF and SF from early stage of the 
disease. Currently, the mechanisms lying behind these changes are not known. We can 
only assume the reasons for these results: 
1. SAPLs are considered to build a bio-film on the surfaces of articular cartilage [131-
132, 204]. During the development of OA, the superficial zone of articular cartilage 
is getting destructed. It might be possible, that during this process SAPLs bound to 
the surfaces of articular cartilage are released and therefore can be detected in SF in 
higher concentrations. 
2. During the development of OA an increased accumulation of fluid in synovial 
joints might occur contributing to the joint effusion. Therefore, components of SF 
might be highly diluted. The diluted amount of PLs present in OA SF might be a 
signal for FLS to produce and secrete higher amounts of PLs.  
3. It has been previously reported, that the articular cartilage at the early stage of 
degradation can increase the synthesis of extracellular matrix components, which is 
interpreted as a repair response [31]. It is tempting to speculate, that with SAPLs a 
similar process may occur. Cells responsible for the synthesis and release of SAPLs 
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increase their production to prevent cartilage from further degradation by 
increasing boundary lubrication.   
4. MPs might serve as the transport vehicles for extracellular PLs. It can be speculated 
that MPs are adsorbed to the surfaces of articular cartilage. Since OA is 
characterised by narrowing of the joint space, one might put forward that MPs 
which contain PLs, can be crushed between surfaces of articular cartilage thus, 
released PLs can be determined in SF.  
5.3 Composition of PL species  
Some studies focusing on the PL composition of cells were also addressing the 
questions about the composition and possible functions of individual PL species [197, 205-
207]. It is known, that the biophysical properties of PL species depend on the chain length 
and number of double bonds present in FA, hence, it is important to gain insight about 
molecular structure of PL species to fully understand their properties and possible 
functions. Recent developments of high sensitivity and high throughput ESI-MS/MS 
method have opened new analytical possibilities to determine molecular structure and thus, 
single individual PL species in different cell types and body fluids [164-166, 168, 170]. 
Our present knowledge concerning extracellular SAPLs stems mostly from the 
surfactant system present in the lung. Not much is known about SAPLs present in synovial 
joints, thus, questions addressing SF PL composition and functions of individual PL 
species remain unanswered. 
  Our study is the first showing the detailed composition of individual PL species 
present in SF. From 339 individual PL species being analysed, 182 could be quantitatively 
determined in SF. Although the functions of most molecular PL species are not known and 
need to be still explored, it can be postulated that all PL species, composed out of different 
head groups, FA chain length and number of double bounds, are synthesised for specific 
biological reasons. This issue would be interesting to be further investigated, since two 
studies already suggested that the friction between surfaces is decreased when a chain 
length of FA in PC is increased and that higher unsaturation of PL species further reduce 
the friction [208-209]. 
The diagnosis of early stage of OA is challenging. Moreover, it is difficult to 
distinguish between different stages of the disease. This knowledge is important, since it is 
assumed that most therapies might be effective only in early stage of OA. Our study is the 
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first demonstrating significant changes in PL composition between healthy, OA and RA 
SF. Furthermore, present results indicate, that the concentrations of individual PL species 
present in SF are impaired at different stages of OA. It is tempting to speculate that the PL 
pattern can reflect a certain stage of OA progression. Taken together, the determined 
differences could serve as a useful tool for diagnosis and prognosis of OA, even in early 
stages. With use of chemometrick techniques, a model including all PL species specifically 
changed in SF from different stages of OA can be build up. Since we found that the 
concentrations of 86 individual PL species are significantly increased in SF from late stage 
of OA as compared to SF from early OA, it can be assumed that this chemometrick model 
would prevent false diagnosis. 
  As already mentioned, PC is the prominent PL class found in SF. Studies using an 
animal model of RA [140], as well as a clinical study with OA patients [210], indicated 
that PC posses anti-inflammatory properties. Important processes which occur during 
activation and progression of OA are upregulation of inflammatory cytokines followed by 
increased enzymatic collagen degradation by MMPs. Our results demonstrate that most of 
PC molecular species were present in higher concentrations in OA and RA SF as compared 
to normal SF. It can be speculated that increased production of PC is the response of joint 
tissue to elevated amounts of pro-inflammatory mediators. 
  Most studies investigating PC as possible boundary lubricant were investigating the 
effect of saturated form of PC, known as DPPC. DPPC provides most of the surfactant 
activities in the lung [211], thus, it was originally thought to be the SF constituent mainly 
responsible for boundary lubrication. Previously, it has been shown that PC is present in 
SF mostly in the saturated form [212]. However, the effect of DPPC on decreasing friction 
was negligible [213]. Only very high concentrations of DPPC resulted in effective 
boundary lubrication [214-216]. In our present study a higher percentage of 
polyunsaturated PC species was determined. These results taken together with the evidence 
from recent publications, where only 8%-11% of DPPC was found on the surface of 
articular cartilage [129, 217], point on polyunsaturated PC species as those responsible for 
boundary lubrication. In addition, unsaturated PC species possess better lubrication 
properties than those provided by DPPC [129].  
  Plasmalogens probably do not provide lubricating abilities to SF, nevertheless, this 
is an interesting group to be studied, since numerous PLPE species were found in SF from 
all investigated patients groups. PLPE possess extraordinary antioxidant properties (for 
review see [218]) and cells deficient in plasmalogens are more susceptible to free radicals 
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[219]. In our study all individual species of PLPE were found to be increased in RA and 
OA SF compared to normal SF. Increased presence of reactive oxidative species (ROS) 
may contribute to cartilage degeneration during OA [135, 220-221]. An explanation for the 
observed increased PLPE concentrations in OA SF can be, that PLPE prevent cartilage 
from further damages induced by ROS. Thus, an increased production of PLPE might be a 
protective response to extracellular ROS.  
Sphingolipids regulate many different cellular processes, including cellular stress 
response, cell proliferation and differentiation, apoptosis and senescence [157]. Already 
one study indicated that SPM might play a role in the development of RA, since 
sphingomyelinase pathway was described to induce apoptosis of cultured human FLS. 
However, the role of sphingolipids in synovial joints remains to be investigated. Although, 
sphingolipids do not possess boundary lubricating abilities, it is of interest to investigate 
whether their composition is impaired in OA SF from different stages of the disease and to 
assess their possible function in synovial joints.  
Collagen type II cleavage is primarily mediated by collagenases like MMP-1 and 
MMP-13, whereas aggrecan is initially degraded by several aggreacanases and MMP-3 
[33, 222]. It has been shown that Cer stimulate chondrocyte expression of MMP-1, -3 and -
13 [223] as well as trigger aggrecanase-mediated degradation of aggrecan in cartilage 
[224]. Cer are also mediators which induce production of pro-inflammatory cytokines. We 
found higher concentrations of Cer 16:0, 22:0, 23:0 and 24:0 in RA SF and SF from late 
stage of OA. Our results together with evidences from the literature as described above 
indicate that Cer could be important factors which contribute to the development of OA. 
Our findings also support the previous speculation that OA, next to RA, can be a unique 
inflammatory disease [24].  
  Several studies already suggested that the friction is decreased when a chain length 
of FA in PC is increased. The authors also concluded that unsaturation of PL species 
further reduce the friction [208-209]. Our presented results indicate that during 
development of OA the chain is elongated in PC, PE, PLPE and PI. In normal SF we found 
a higher percentage of PL species with shorter chains of FA (≤34 C atoms). Since more 
unsaturated PL species with longer FA chains were found in the late stage of OA as 
compared to other investigated PL classes, it could be speculated, that observed 
remodelling of PL species occurs contributing to decreased friction in late stage of OA.  
A recently established canine model of human OA [72-75] corroborates the results 
obtained from human. In the dog model of OA higher concentrations of most PL species 
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were also found in OA SF as compared to healthy SF. Additional comparison of PL 
composition in human, canine and equine SF, revealed that the relative distribution of PL 
molecular species as well as their quantitative values are comparable in human and canine 
SF but not in human and equine SF. Equine SF was characterised by a very low content of 
LPC, which is in agreement with data reported previously [197]. The reason why equine 
SF contains a decreased concentration of LPC remains to be investigated. 
5.4 Joint distraction to study mechanical impact on PL  
Currently no therapies are available to stop or slow down the progression of OA, 
therefore, the final therapeutic approach for OA is total joint replacement surgery. 
Recently, unloading of joints by joint distraction was proposed as a possible therapeutic 
strategy for OA, aimed to postpone joint replacement surgery [180, 225-227]. Distraction 
is a procedure in which ends of bone in the joint are separated to a certain extend for a 
certain period of time. It has been reported that joint distraction can stop or slow down the 
progression of OA in human ankle and knee joints [225, 227]. It has been shown that 
human cartilage thickened 0.9 mm/year and that the ratio of collagen type II synthesis to 
breakdown was also increased, indicating presence of newly formatted cartilage [227]. 
Taken together these results suggest that joint distraction seems to be a promising new 
structure modifying therapy for OA. 
Preliminary results from joint distraction study using the canine ‘groove’ model of 
OA indicated that, distraction treatment resulted in a significant decrease of proteoglycan 
release from cartilage and a decreased damage of collagen. Macroscopical and histological 
analyses have shown improvement of the histologically discernible integrity of articular 
cartilage [228]. Concerning previous reports as presented recently [229], it was interesting 
for us to test, whether a distraction treatment changes the PL composition in canine SF. 
Especially we wanted to know, whether mechanical factors might have any impact on PL 
synthesis and/or composition. 
The findings of our analysis indicate, that joint distraction can effect PL 
composition of OA SF. Significant increase in the concentrations of PE and PLPE was 
found in the distraction group as compared to OA group. The other PL classes remained 
unchanged. It would be tempting to speculate, that similar to the results obtained from 
human, increased production of PLPE might be a protective response to extracellular ROS, 
since increased amount of ROS may contribute to cartilage degeneration during OA. 
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However, it remains to be established whether other mechanical parameters are also able to 
modulate PL biosynthesis and/or release. 
5.5 Phospholipid synthesis and release by FLS 
The functional role of FLS, also called type B synoviocytes, is still not fully 
understood. Several studies suggested that the main function of FLS in joint is production 
and secretion of e.g. inflammatory mediators, fibronectin [230], HA [43, 47], and lubricin 
[49-50] into the joint cavity. Dobbie et al. [44-45] have shown that FLS possess LBs. This 
unique feature, which differ FLS from others types of fibroblasts, was later verified and 
confirmed using electron microscopy [51]. Based on these results, it has been 
hypothesised, that these cells are also responsible for the production and secretion of 
SAPLs. Beside published results showing the presence of LBs in FLS and assumption that 
FLS may synthesise and release SAPLs, up to day there is no experimental proof to 
substantiate the hypothesis, that FLS are indeed the source of SAPLs present in SF. 
We investigated the effect of different cell culture conditions on PL synthesis 
and/or release by FLS. Treatment with dexamethasone, which has been shown [123] to 
influence the PL secretion revealed no changes compared to blank medium. Three-
dimentional culture of FLS on BD Matrigel™ Basement Membrane Matrix Growth Factor 
Reduced, resulted in a slight increase in total PL concentration. Reliable measurement of 
extracellular PL in nutrient media is challenging. Obtained values from the analysed 
samples were close to the limit of quantification, hence, these findings were not sufficient 
to be a proof for PL synthesis and/or release by FLS. The potential weakness of our 
experiments is signal suppression, so that ESI-MS/MS is not sensitive enough to detect PL 
present in cell culture media at the low, depressed concentrations. Therefore, this issue of 
signal suppression has still to be solved.  
Although, our preliminary results are unsatisfactory, this is a good basis to elucidate 
this problem in the future. From the discovery point of view it would be of interest to 
investigate how the biosynthesis and release of SAPLs from FLS are regulated. Monitoring 
of de novo synthesised individual PL species and their possible remodelling could enhance 
our knowledge and understanding of PL metabolic pathways. Additional treatment with 
cytokines, growth factors and drugs could answer the questions how PL biosynthesis might 
be regulated in vivo. 
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5.6 Surfactant proteins in human SF 
Surfactant proteins next to SAPLs play intrinsic function in the surfactant system of 
the lung. Differences in content of surfactant proteins trigger severely lung disorders for 
instance, idiopathic pulmonary fibrosis [231], pneumonitis or [232] pulmonary sarcoidosis 
[233]. Moreover, serum surfactant proteins levels can be a good biomarker for those 
diseases. Since the surfactant system in the joint might be similar to the one found in the 
lung, it is tempting to infer that surfactant proteins may be also present in SF where they 
might play similar functions like in the lung.  
Previously, surfactant proteins were thought to be present only in the lung. 
However, Kankavi et al. [104, 106-108] over the past 15 years provided some evidence 
that SP-A and SP-D are present also in several non-pulmonary sites of the body. Kankavi 
et al. determined these proteins in human skin, human organ of Corti, human Eustachian 
tube, human spermatozoa, human kidney and also in vagina, cervix, uterus, oviduct and 
ovaries of mares and prepuce, smegma, testis, prostate and vesicular glands of stallions 
[104, 106-108]. 
There are only few publications which provide valuable evidence for the presence 
of SP-A and SP-D in the synovial joints [109-111, 234]. Only Kankavi successfully 
detected SP-A and SP-D in human and equine SF using immunoblotting method [109-
110]. To test the previously published results, three different antibodies for SP-A, 
including the one used by Kankavi (PE-10, Dako Deutschland GmbH), the same method of 
SF preparation and the same Western blot conditions as applied by Kankavi, were used in 
this study. Used antibodies revealed the bands, however, none of which had the expected 
molecular weight. Furthermore, two-dimensional separations of proteins followed by 
MALDI-TOF/MS protein identification revealed that spots stained by used antibodies do 
not contain surfactant proteins. These results are in contradiction to the data published by 
Kankavi. The explanation for these observed differences in results may be that (a) the used 
antibodies are not only specific for SP-A and SP-D, (b) Western blot alone is an 
insufficient method to confirm presence of proteins in SF, and (c) SF does not contain 
surfactant proteins. Other published studies using ELISA method reported, that SP-A [111] 
and SP-D [234] are present in human SF. Moreover, authors suggested that the level of 
surfactant proteins is decreased in SF obtained from rheumatoid arthritic patients. 
Nevertheless, specific and unspecific binding of antibody measured by ELISA results in 
absorbance. Since no additional experiment testing specificity of used antibodies is 
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provided, measured absorbance is not reliable proof for presence of surfactant proteins in 
SF. 
The joint cavity is a closed structure and SF is an ultrafiltrate of blood with 
additives produced by the surrounding tissues. Since it is known that FLS possess LBs, 
Dobbie et al. [45, 101] and Schwarz and Hills [51] implicated, that those cells are 
responsible for the synthesis of surfactant proteins. To further confirm or contradict our 
first observations that SF does not contain surfactant protein, mRNA expression of sp-a 
and sp-d was determined. Our findings from Western blot analysis were confirmed on the 
gene level using RT-PCR method. Expression of sp-a and sp-d was not detectable in cells 
derived from synovial joint tissues including cultured FLS, not further identified cells 
suspended in SF and chondrocytes from human cartilage. 
To summarise, one- and two-dimensional separations of proteins in SF followed by 
Western blot detection with antibodies and MALDI-TOF/MS protein identification and 
additionally, SP-A and SP-D mRNA expression analysis by RT-PCR, indicate that 
surfactant proteins are not present in human SF. Altogether our findings suggest, that SP-A 
and SP-D do not participate in boundary lubrication system in synovial joints as it was 
previously suggested [109-110]. According to our knowledge, this is the first study 
determines the absence of SP-A and SP-D in SF by using immunoblotting techniques 
followed by confirmation with mass spectrometry. Moreover, it is also the first study 
investigating mRNA expression of sp-a and sp-d in cells derived from synovial tissues. 
5.7 Summary, conclusions and future perspectives 
Summary and conclusions  
 
1. The current study identified 9 different lipid classes present in SF with PC being the 
main PL class present. Moreover, PC was, in contrast to the lung, present mostly in 
the polyunsaturated form. 
 
2. Total PL content was determined in higher concentrations in SF from late stage of 
OA compared to healthy SF and SF from early stage of OA. Moreover, most of the 
main PL classes were present in higher concentrations in SF from late stage of OA 
compared to other investigated groups. These findings indicate that increased PLs 
content is involved in the pathogenesis of OA.   
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3. One hundred eighty two molecular PL species were determined to be present in 
human SF. Based on our knowledge, this study is the first report showing the 
detailed composition of PL species in SF. Although functions of most molecular PL 
species are not known and still need to be explored, it can be postulated that all PL 
species, even though they differ with respect to the head group, FA chain length 
and number of double bounds, are synthesised for specific biological reasons. 
 
4. Significant changes in concentrations of 86 individual PL species were found 
between healthy, OA and RA SF. More interestingly, significant differences in PL 
composition were observed at different stages of OA. Therefore, it can be 
concluded that specific PL pattern reflect a stage of the disease progression. These 
results may help to develop the chemometrick model which can serve as a useful 
tool for diagnosis and prognosis of OA.  
 
5. Analysis of canine healthy and OA SF revealed slight differences between those 
two groups but also demonstrated similar trends to the results obtained from 
humans, where most of PL classes were present in higher concentrations in OA SF 
when compared to healthy SF. Moreover, we found that relative PL distribution is 
similar in human and dogs with comparable concentrations of PL classes and PL 
species. These results obtained with a dog model of OA confirm our observation 
that an altered PLs content, remodeling and/or metabolism seems to be involved in 
the pathogenesis of OA. 
   
6. The findings of our analysis indicate that joint distraction can effect PL 
composition of OA SF. Significant increase in the concentrations of PE and PLPE, 
which can serve as protective agent against extracellular ROS contributing to 
cartilage degeneration during OA, was found in the distraction group as compared 
to OA group. The other PL classes remained unchanged. Therefore, it can be 
conclude that mechanical factors might have an impact on PL synthesis and/or 
composition. 
 
Discussion 
103 
 
7. Our preliminary results from cultured FLS indicate that these cells might be a 
source of PL being present in SF. However, detected concentrations of PL present 
in cell culture media were very low. The potential weakness of our experiments is 
signal suppression, so that ESI-MS/MS is not sensitive enough to detect PL present 
in cell culture media at the low, depressed concentrations. Therefore, this has to be 
further elucidated by the additional experiments to solve the problem with signal 
suppression. 
 
8. We used several different methods to confirm the hypothesis that surfactant 
proteins are present in human SF. Nevertheless, we could not provide any evidence 
to substantiate this hypothesis. Hence, we can only conclude that surfactant proteins 
are absent in human SF and do not play any role in boundary lubrication of joints. 
 
Future perspective 
 
Diagnosis of early stage of OA is challenging. Moreover, it is difficult to 
distinguish between stages of the disease. This knowledge is important, since it is assumed 
that therapies might be effective only during the early stage of OA. Our results may help to 
develop the chemometrick model which can further serve as a useful tool for diagnosis and 
prognosis of OA.  
 
Preliminary results from cultured FLS indicate that FLS can be a source of PL 
present in SF. It would be very interesting to investigate whether and how biosynthesis and 
release of SAPL from FLS are regulated. Monitoring of de novo synthesised individual PL 
species and their possible remodelling could enhance our knowledge and understanding of 
PL metabolic pathways thus, providing novel targets to treat OA. 
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6. Appendix 
Table 6.1. P-values for ratios of PL class in SF as compared between joints with different 
health status. 
Ratio 
OA early vs. 
Healthy  
OA late vs. 
Healthy 
RA vs.  
Healthy 
OA early vs. 
OA late 
OA early vs. 
RA 
OA late vs.  
RA 
PC/LPC NS NS *↑ *↓ ***↓ ***↓ 
PC/PE *↑ **↑ **↑ NS NS NS 
PC/PS **↑ ***↑ *↑ **↑ **↑ *↑ 
PE/PS **↑ **↑ NS *↑ **↑ NS 
PLPE/PE NS NS NS NS *↑ *↑ 
SPM/Cer NS NS NS NS NS NS 
Statistical analysis was performed by the non-parametric Kruskal-Wallis test followed by the false 
discovery rate (FDR) correction. Subsequently, paired Wilcoxon signed-rank test was applied to 
identify significant changes between each groups. P-values of less than 0.05 were considered 
statistically significant with: *0.01<p≤0.05; **0.001<p≤0.01; ***p<0.001; NS-not significant. 
↑:increase ↓:decrease. Data are presented as the graphs in Figure 4.6. Cer-ceramides, LPC-
lysophosphatidylcholine, OA-osteoarthritis, PC-phosphatidylcholine, PE-
phosphatidylethanolamine, PLPE-PE-based plasmalogen, PS-phosphatidylserine, RA-rheumatoid 
arthritis, SPM-sphingomyelin.  
 
Table 6.2. Summary of statistically significant changes of the concentrations of individual PL 
species as dependent on the health status of joints – second independent ESI/MS-MS analysis. 
 
PL-specie 
OA early vs. 
Healthy  
OA late vs. 
Healthy 
OA early vs. 
OA late 
Phosphatidylcholine (PC) 
   
PCO 30:0 NS↓ NS↓ NS↑ 
PC 32:0 * ↑ ** ↑ NS 
PCO 32:0 ** ↑ ** ↑ NS 
PC 32:1 NS   * ↑ NS 
PCO 32:1 NS NS↑ NS 
PC 32:2 * ↑ ** ↑ NS 
PC 34:0 *** ↑ ** ↑ NS↓ 
PCO 34:0 ** ↑ *** ↑ NS 
PC 34:1 NS↑ ** ↑ NS↓ 
PCO 34:1 ** ↑ ** ↑ NS↓ 
PC 34:2 * ↑ *** ↑ NS↓ 
PCO 34:2 NS↑ * ↑ NS↓ 
PC 34:3 ** ↑ *** ↑ NS↓ 
PC 36:0 * ↑ ** ↑ NS↓ 
PC 36:1 * ↑ ** ↑ NS↓ 
PCO 36:1 ** ↑ *** ↑ NS↓ 
PC 36:2 * ↑ *** ↑ NS↓ 
PCO 36:2 ** ↑ *** ↑ NS↓ 
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Table 6.2. Continuation.  
PL-specie 
OA early vs. 
Healthy  
OA late vs. 
Healthy 
OA early vs. 
OA late 
Phosphatidylcholine (PC) 
   
PC 36:3 ** ↑ *** ↑ NS↓ 
PC 36:4 ** ↑ *** ↑ NS↓ 
PCO 36:4 * ↑ *** ↑ NS↓ 
PC 36:5 ** ↑ *** ↑ NS↓ 
PCO 36:5 ** ↑ *** ↑ NS↑ 
PC 38:1 NS↑ * ↑ NS↑ 
PC 38:2 NS↑ ** ↑ NS↓ 
PC 38:3 * ↑ *** ↑ NS↓ 
PC 38:4 * ↑ *** ↑ NS↓ 
PC 38:5 ** ↑ *** ↑ NS↓ 
PC 38:6 ** ↑ *** ↑ NS↓ 
PC 40:4 * ↑ ** ↑ NS↓ 
PC 40:5 * ↑ *** ↑ NS↓ 
PC 40:6 * ↑ *** ↑ NS↓ 
Lysophosphatidylcholine (LPC) 
   
LPC 15:0 ** ↑ ** ↑ NS↓ 
LPC 16:0 ** ↑ *** ↑ NS↑ 
LPC 16:1 NS↑ NS↑ NS↑ 
LPC 18:0 *** ↑ *** ↑ NS↑ 
LPC 18:1 * ↑ * ↑ NS↑ 
LPC 18:2 ** ↑ NS ** ↑ 
LPC 18:3 ** ↑ NS ** ↑ 
LPC 20:0 * ↑ NS↑ NS 
LPC 20:3 *** ↑ ** ↑ NS 
LPC 20:4 * ↑ * ↑ NS 
LPC 20:5 * ↑ ** ↑ NS 
LPC 22:0 NS NS NS 
LPC 22:4 NS NS NS 
LPC 22:5 * ↑ ** ↑ NS 
LPC 22:6 ** ↑ ** ↑ NS 
Phosphatidylethanolamine (PE) 
   
PE 32:2 NS * ↓ NS 
PE 34:0 NS NS NS 
PE 34:1 NS NS↑ NS↓ 
PE 34:2 NS↑ NS↑ NS↓ 
PE 36:1 NS NS↑ NS↓ 
PE 36:2 NS↑ * ↑ NS↓ 
PE 36:3 NS↑ NS↑ NS 
PE 36:4 NS↑ * ↑ NS↓ 
PE 36:5 NS NS↑ NS 
PE 38:1 NS↑ NS↑ NS↑ 
PE 38:3 NS↑ NS↑ NS↓ 
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Table 6.2. Continuation.  
PL-specie 
OA early vs. 
Healthy  
OA late vs. 
Healthy 
OA early vs. 
OA late 
Phosphatidylethanolamine (PE 
   
PE 38:4 NS↑ * ↑ NS↓ 
PE 38:5 NS↑ NS↑ NS↓ 
PE 38:6 NS↑ ** ↑ NS↓ 
PE O 38:7 NS NS↓ NS↑ 
PE O 40:3 NS NS NS 
PE 40:5 NS↓ NS↑ NS↓ 
PE 40:6 NS↑ ** ↑ NS↓ 
PE 42:5 NS NS NS 
PE 42:7 NS NS NS 
PE-based plasmalogen (PLPE) 
   
PLPE 16:0/16:0 NS NS NS 
PLPE 16:0/16:1 NS NS NS 
PLPE 16:0/18:0 NS NS NS 
PLPE 16:0/18:1 NS NS↑ NS 
PLPE 16:0/18:2 NS NS↑ NS↓ 
PLPE 16:0/18:3 NS NS NS 
PLPE 16:0/20:3 NS NS↓ NS 
PLPE 16:0/20:4 NS↑ NS↑ NS↓ 
PLPE 16:0/20:5 NS NS↑ NS↑ 
PLPE 16:0/22:3 NS NS NS 
PLPE 16:0/22:5 NS↑ NS↑ NS↑ 
PLPE 16:0/22:6 NS↑ ** ↑ NS↓ 
PLPE 18:0/16:0 NS NS NS 
PLPE 18:0/16:1 NS NS NS 
PLPE 18:0/18:0 NS NS NS 
PLPE 18:0/18:1 NS NS↑ NS↑ 
PLPE 18:0/18:2 NS↑ NS↑ NS↓ 
PLPE 18:0/18:3 NS NS NS 
PLPE 18:0/20:3 NS NS↓ NS↓ 
PLPE 18:0/20:4 * ↑ * ↑ NS↓ 
PLPE 18:0/20:5 NS↑ NS↑ NS↑ 
PLPE 18:0/22:3 NS NS NS 
PLPE 18:0/22:5 NS↑ NS↑ NS↑ 
PLPE 18:0/22:6 NS↑ NS↑ NS↑ 
PLPE 18:1/16:0 NS NS NS 
PLPE 18:1/16:1 NS NS NS 
PLPE 18:1/18:0 NS NS NS 
PLPE 18:1/18:1 NS NS↓ NS 
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Table 6.2. Continuation.  
PL-specie 
OA early vs. 
Healthy  
OA late vs. 
Healthy 
OA early vs. 
OA late 
PE-based plasmalogen (PLPE) 
   
PLPE 18:1/18:2 NS NS↑ NS↑ 
PLPE 18:1/18:3 NS NS NS 
PLPE 18:1/20:3 NS NS NS 
PLPE 18:1/20:4 NS↑ NS↑ NS↓ 
PLPE 18:1/20:5 NS NS↓ NS 
PLPE 18:1/22:3 NS NS NS 
PLPE 18:1/22:4 NS NS NS 
PLPE 18:1/22:5 NS NS NS 
PLPE 18:1/22:6 NS↑ NS↑ NS↑ 
Phosphatidylglycerol (PG) 
   
PG 32:0 NS NS NS 
PG 34:1 NS NS NS 
PG 36:2 NS NS NS 
Phosphatidylinositol (PI) 
   
PI 36:1 NS * ↑ NS 
PI 36:4 * ↑ * ↑ NS 
PI 38:3 * ↑ ** ↑ NS 
PI 38:4 * ↑ ** ↑ NS 
PI 38:5 * ↑ NS NS 
PI 40:4 NS ** ↑ NS 
Phosphatidylserine (PS) 
   
PS 36:1 NS NS NS 
PS 36:2 NS NS NS 
Sphingomyelin (SPM) 
   
SPM 14:0 * ↑ *** ↑ NS↓ 
SPM 15:0 * ↑ *** ↑ NS↓ 
SPM 16:0 NS↑ ** ↑ NS↓ 
SPM dih 16:0 NS↑ * ↑ NS↓ 
SPM –OH 16:0 * ↑ ** ↑ NS 
SPM 16:1 * ↑ ** ↑ NS 
SPM –OH 16:1 * ↑ ** ↑ NS 
SPM 18:0 * ↑ ** ↑ NS 
SPM dih 18:0 - * ↑ NS 
SPM 18:1 * ↑ ** ↑ NS 
SPM 20:0 NS↑ NS↑ NS↓ 
SPM 20:1 * ↑ ** ↑ NS↓ 
SPM 22:0 * ↑ *** ↑ NS↑ 
SPM 22:1 * ↑ *** ↑ NS↓ 
SPM 22:2 NS * ↑ NS↓ 
SPM 24:0 * ↑ ** ↑ NS↑ 
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Table 6.2. Continuation.  
PL-specie 
OA early vs. 
Healthy  
OA late vs. 
Healthy 
OA early vs. 
OA late 
Sphingomyelin (SPM) 
   
SPM 24:1 NS↑ ** ↑ NS↓ 
SPM 24:2 NS↑ * ↑ NS↓ 
SPM 24:3 NS NS↑ NS 
Ceramide (Cer) 
   
Cer 16:0 NS * ↑ NS↓ 
GluCer 16:0 NS NS↑ NS↓ 
Cer 22:0 * ↑ ** ↑ NS↓ 
Cer 23:0 ** ↑ *** ↑ NS↓ 
Cer 24:0 ** ↑ *** ↑ NS↓ 
Cer 24:1 NS ** ↑ NS↓ 
GluCer 24:1  NS NS↑ NS↓ 
 
PC species were analysed by ESI-MS/MS in 6 healthy SF, 10 OA SF from early stage, 11 OA SF 
from late stage and 2 RA SF. Statistical analysis was performed by the non-parametric Kruskal-
Wallis test followed by the false discovery rate (FDR) correction. Subsequently, paired Wilcoxon 
signed-rank test was applied to identify significant changes between each groups. P-values of less 
than 0.05 were considered statistically significant with: *0.01<p≤0.05; **0.001<p≤0.01; 
***p<0.001; NS-not significant. ↑:increase ↓:decrease. When statistical significance was found in 
the first analysis, and not in the second, box is marked with grey background and arrows indicate 
observed trend. Boxes marked with bold line indicate that observed trend is opposite to those found 
in the first analysis. Data from RA SF are not shown due to only three patients available for second 
analysis. PC-phosphatidylcholine, PC O-ether phosphatidylcholine, LPC-lysophosphatidylcholine, 
PE- phosphatidylethanolamine, PLPE-phosphatidylethanolamine-based plasmalogen, PG-
phosphatidylglycerol, PI-phosphatidylinositol, PS-phosphatidylserine, SPM-sphingomyelin, Cer-
ceramide, GluCer-glucosylceramide, OA-osteoarthritis, , RA-rheumatoid arthritis. 
 
Table 6.3. P-values for FA chain length according to the number of C-atoms in a chosen PL 
class.  
Number of C-atoms 
OA early 
vs. Healthy  
OA late vs. 
Healthy 
RA vs.  
Healthy 
OA early 
vs. OA late 
OA early 
vs. RA 
OA late vs. 
RA 
Phosphatidylcholine (PC) 
   
   
PC 30 NS **↓ ***↓ *↑ ***↑ NS 
PC 32 NS **↓ ***↓ *↑ ***↑ NS 
PC 34 NS NS NS NS NS NS 
PC 36 **↑ **↑ ***↑ NS *↓ NS 
PC 38 *↑ *↑ NS NS *↑ NS 
PC 40 NS NS NS NS NS NS 
Phosphatidylcholine Ether 
(PCO)    
   
PC O 30 *↓ ***↓ ***↓ NS ***↑ **↑ 
PC O 32 *↓ *↓ *↓ NS NS NS 
PC O 34 **↓ **↓ ***↓ NS NS NS 
PC O 36 ***↑ ***↑ ***↑ *↓ *↓ NS 
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Table 6.3. Continuation.  
Number of C-atoms 
OA early 
vs. Healthy  
OA late vs. 
Healthy 
RA vs.  
Healthy 
OA early 
vs. OA late 
OA early 
vs. RA 
OA late vs. 
RA 
PC + PCO 
   
   
PC + PCO 30 *↓ **↓ ***↓ *↑ ***↑ NS 
PC + PCO 32 NS **↓ ***↓ *↑ ***↑ NS 
PC + PCO 34 **↓ NS NS NS NS NS 
PC + PCO 36 **↑ **↑ ***↑ NS *↓ NS 
PC + PCO 38 *↑ **↑ NS NS NS NS 
PC + PCO 40 NS NS NS NS NS NS 
Phosphatidylethanolamine 
(PE) 
   
   
PE 32 *↓ **↑ ***↓ NS ***↑ ***↑ 
PE 34 NS **↑ ***↑ NS ***↓ ***↓ 
PE 36 *↑ ***↑ ***↑ NS **↓ ***↓ 
PE 38 NS ***↑ ***↑ NS ***↓ *↓ 
PE 40 *↓ ***↓ ***↓ NS ***↑ ***↑ 
PE-based plasmalogen 
(PLPE) 
   
   
PLPE 32 ***↓ NS **↓ ***↑ NS NS 
PLPE 34 ***↓ NS *↓ NS **↑ NS 
PLPE 36 *↓ ***↓ *↓ NS NS NS 
PLPE 38 ***↑ *↑ **↑ NS **↓ NS 
PLPE 40 NS NS NS NS NS NS 
Phosphatidylinositol (PI) 
   
   
PI 32 NS ***↓ NS NS NS NS 
PI 34 NS NS NS NS NS NS 
PI 36 *↓ ***↓ NS NS NS NS 
PI 38 **↑ ***↑ NS NS NS NS 
PI 40 NS NS NS NS NS NS 
Statistical analysis was performed by the non-parametric Kruskal-Wallis test followed by the false 
discovery rate (FDR) correction. Subsequently, paired Wilcoxon signed-rank test was applied to 
identify significant changes between each groups. P-values of less than 0.05 were considered 
statistically significant with: *0.01<p≤0.05; **0.001<p≤0.01; ***p<0.001; NS-not significant. 
↑:increase ↓:decrease. OA-osteoarthritis, PC-phosphatidylcholine, PC O-ether phosphatidylcholine, 
PE-phosphatidylethanolamine, PLPE-phosphatidylethanolamine-based plasmalogen, RA-
rheumatoid arthritis. 
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Table 6.4. P-values for PL classes in SF of various mammalian species. 
 
Human vs. 
Dogs 
Human vs. 
Horses 
Horses vs. 
Dogs 
Phosphatidylcholine Ether 
(PCO) NS **↑ NS 
Phosphatidylcholine (PC) NS NS *↓ 
Lysophosphatidylcholine (LPC) **↑ ***↑ ***↓ 
Phosphatidylethanolamine (PE) NS ***↑ ***↓ 
PE-based plasmalogen (PLPE) NS ***↑ ***↓ 
Phosphatidylglycerol (PG) *↑ **↑ NS 
Phosphatidylinositol (PI) NA  NA NA 
Phosphatidylserine (PS) NS NS *↑ 
Sphingomyelin (SPM) NS ***↑ NS 
Ceramide (Cer) NS ***↑ ***↓ 
The different PL classes were quantified by ESI-MS/MS in healthy human SF (n=9), healthy 
canine SF (n=20) and healthy equine SF (n=14). Statistical analysis was performed by the non-
parametric Kruskal-Wallis test followed by the false discovery rate (FDR) correction. 
Subsequently, paired Wilcoxon signed-rank test was applied to identify significant changes 
between each groups. P-values of less than 0.05 were considered statistically significant with: 
*0.01<p≤0.05; **0.001<p≤0.01; ***p<0.001. Data are presented as the graphs in Figure 4.17. NA-
not analysed.  
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